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Abstract 
This work describes the development of applications of chiral-at-metal iridium(III)- and rhodium(III) Lewis 
acid catalysts. Based on the reversible coordination to their metal center and enolization upon coordination, 
chiral Lewis acids are capable to facilitate various α-functionalizations of 2-acyl imidazoles. In the first part, 
the visible-light driven enantioselective α-alkylation with α-cyanoalkyl bromides is presented. By merging 
photoredox catalysis with chiral Lewis acid catalysis, the α-cyanoalkylated 2-acyl imidazoles could be 
obtained with excellent enantiocontrol. This is the first example that such chiral metal enolate complexes 
react with branched carbon-centered radicals. In the second part, the results of the development of the 
asymmetric α-benzoyloxylation are presented. While the chiral rhodium Lewis acid complex demonstrated 
excellent catalytic activity to facilitate the reaction, the enantioselectivity remains to be improved. In the 
third part, results of the direct coupling of electron-rich arenes with the α-position of 2-acyl imidazoles are 
presented. The Lewis acid catalysts were found to promote the α-bromination of 2-acyl imidazoles with 2-
bromo-1,3-dicarbonyl compounds and a subsequent Friedel-Crafts alkylation with electron rich arenes 
yielding the coupling products. Because it appears that the latter step proceeds predominantly through a 
planar cationic intermediate, which results in low enantioselectivity, the investigations are focused on the 
racemic variants and arene scope under the optimized reaction conditions is presented. 
Die vorliegende Arbeit beschreibt die Anwendungsentwicklung von Iridium(III)- und Rhodium(III)-Lewis-
Säure-Katalysatoren mit metallzentrierter Chiralität. 2-Acylimidazole lassen sich durch die reversible 
Koordination an die Metallzentren und Enolisierung an den α-Positionen funktionalisieren. Der erste Teil 
behandelt die durch sichtbares Licht vermittelte, asymmetrische α-Alkylierung von 2-Acylimidazolen mit α-
Cyanoalkylbromiden. Die Photoredox-Katalyse ermöglicht die Generierung der Cyanoalkylradikale, welche 
sich dann an die chiralen Rhodium-Enolat-Komplexe mit exzellenter Enantio-selektivität addieren. Diese 
Synthese ist das erste Beispiel dafür, dass solche Metall-Enolat-Komplexe mit am Kohlenstoff verzweigten 
Radikalen reagieren. Der zweite Teil behandelt die Entwicklung der α-Benzoyloxylierung von 2-
Acylimidazolen. Der Rhodium-Lewis-Säure-Komplex zeigt ausgezeichnete katalytische Aktivität, die 
Enantioselektivität der Reaktion ist allerdings in der Zukunft noch zu verbessern. Der dritte Teil behandelt 
die direkte Kupplungsreaktion von elektronenreichen Arenen mit 2-Acylimidazolen. Die Lewis-Säure-
Komplexe katalysieren zuerst die α-Brominierung mit 2-Brom-1,3-dicarbonyl-Verbindungen und die 
Kupplungsreaktion verläuft dann über die bromierten Zwischenprodukte über die Friedel-Crafts-
Alkylierung. Da der Alkylierungsschritt vermutlich über eine planare kationische Zwischenstufe verläuft und 
deshalb keine Stereokontrolle erreicht wird, werden die verschiedene Arene nur in der racemischen Reaktion 
untersucht.  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Chapter 1. Introduction
Chapter 1. Introduction 
1.1. Asymmetric Synthesis of Chiral-at-Metal Octahedral Complexes 
The word “chirality” originates from the Greek word for hand “χειρ (kheir)” and refers to the handedness of 
an object.[1] Today it’s defined by IUPAC as: “The geometric property of a rigid object (or spatial 
arrangement of points or atoms) of being non-superimposable on its mirror image; If the object is 
superimposable on its mirror image the object is described as being achiral.”[2] In case of chiral objects, 
each of both non-superimposable mirror images is called enantiomer. A classic example are human’s hands 
where left and right hands are non-superimposable mirror images of each other. In chemistry, a chiral 
molecule can not be superposed onto its mirror image. Well-known examples for enantiomers in chemistry 
are molecules with a tetrahedral carbon atom bearing four different substituents (Figure 1) and the theoretical 
support for this idea was proposed by Le Bel and van’t Hoff nearly 150 years ago.[3,4] 
  
Figure 1: Human hands and a molecule with a tetrahedral carbon atom bearing four different substituents. 
Since Pasteur’s discovery of molecular chirality in 1848,[5] chemists have been intrigued by chiral molecules 
because most biomolecules are chiral and exist in only one enantiomeric form, such as the natural amino 
acids, which are building blocks for proteins. On the other hand, DNA is based on chiral deoxyriboses. For 
this reason, an organism reacts to both enantiomers of a chiral molecule in a different fashion as this chiral 
molecule interacts with chiral biomolecules.[6] Great efforts have been spent in developing enantioselective 
transformations in order to obtain enantioenriched compounds.[7,8] Among different strategies to obtain 
enantioenriched or enantiopure molecules, such as the resolution of a racemic mixture or by using 
enantiopure precursor from nature’s chiral pool, asymmetric catalysis is considered to be an efficient, 
elegant, and economical, in which a only catalytic amount of chiral reagent is added and induces an 
enantioselective transformation.[9] The achievements in this area have been honored by awarding the Nobel 
Prize in chemistry to Knowles, Noyori, and Sharpless in 2001 for their contributions.[10-13]  
In organometallic chemistry, metal complexes with chiral ligands are highly investigated because of their 
applicability as chiral catalysts in organic synthesis.[14] Chiral complexes with metal-located stereocenter 
remain much less explored, although the first example has already been reported by Alfred Werner in 1911. 
By applying Le Bel’s and van’t Hoff’s stereochemical idea to hexacoordinated metal complexes, Alfred 
Werner predicted that some of these compounds could exist as enantiomers.[15] His prediction was soon 
proved by the successfully resolution of the two enantiomers of [Co(en)2(NH3)X]2+ 1 (X = Cl, Br, en = 
%1
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ethylene diamine) with (+)-3-bromo-camphor-9-sulphonate (2) as chiral anion in 1911 (Figure 2), which 
demonstrated for the first time that the spatial arrangement of achiral ligands around a metal center can also 
lead to a chiral compound.[16] 
 
Figure 2: Structures of both enantiomers of the chiral cation 1; The resolution was achieved by Alfred 
Werner with the chiral anion (+)-2.[16] 
Since Werner’s discovery, various strategies have been developed to obtain enantioenriched metal complexes 
with achiral ligands, for examples through spontaneous resolution,[17] resolution through high performance 
liquid chromatography (HPLC) with a chiral stationary phase,[18] and through asymmetric catalysis.[19,20] 
Compared to other strategies, asymmetric catalysis is highly attractive due to its efficiency and has received 
a lot of attention, especially in the last decade. In order to establish chirality on the metal center, it is 
necessary to employ enantiopure chiral auxiliaries, whose absolute configurations are predetermined, thus 
diastereomers with different physicochemical properties are formed which can be separated from each other 
through different techniques. One class of such chiral auxiliaries are chiral ions. Because many complexes 
exist as salts, exchange of achiral counterions against chiral counterions enables the formation of 
diastereomeric salts. Common ions for this purpose are tris[tetrachlorobenzene-1,2-bis(olato)] phosphate(V) 
(TRISPHAT, 3),[21,22] derivatives of tartrates 4 and 10-camphorsulfonate 5,[23] and enantiopure ammonium 
salts from natural amines[18] (Figure 3). On the other hand, chiral chelating ligands are also used as 
auxiliaries to transfer chiral information onto the metal centers. However, it is important to note that in many 
cases the chiral chelating ligands stay attached to the metal centers and the complexes exist as diastereomers, 
therefore these complexes do not belong to the category “chiral-at-metal complexes”. 
%  
Figure 3: Structures of commonly used enantiopure anions to resolve chiral cationic metal complexes.[21-23] 
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In the past years, the Meggers group has made significant contributions to the asymmetric synthesis of 
octahedral chiral-at-metal complexes.[24-26] Initially, the Meggers group was dedicated to employ kinetically 
inert transition metal complexes (Ru, Ir, Rh, Re, Os) in biological systems, especially as enzyme inhibitors.
[27-33] Because a chiral environment is formed at the active site of enzymes, it is reasonable to expect that the 
potency of one enantiomer should differ from the other one. Indeed, during the development of ruthenium-
based kinase inhibitors, the Meggers group synthesized complex 6 as a racemic mixture and separated its 
enantiomers by chiral HPLC (Figure 4). Subsequent studies revealed that Λ-6 is a much more potent 
inhibitor for the PAK1 kinase than inhibitor Δ-6.[34] Such chirality-potency correlation has been observed in 
several other studies as well.[35,36] 
 
Figure 4: Structures of chiral ruthenium-based kinase inhibitors Λ-6 and Δ-6, Λ-6 is a significantly more 
potent inhibitor than Δ-6 for the PAK1 kinase.[34] 
Inspired by these observations, the Meggers group started to develop tools for the asymmetric synthesis of 
octahedral chiral-at-metal complexes. In this regards, significant progress was achieved in 2009.[37] Initially, 
commercially available ruthenium(II) dimer 7 is treated with chiral oxazoline (S)-8. Resulting complex (S)-9 
contains a metal-located stereocenter and is obtained as a mixture of diastereomers.[38] The benzene ligand is 
then substituted by three acetonitrile ligands in the presence of ultraviolet (UV) light to form ruthenium(II) 
complex (S)-10 containing no metal-located stereocenter. All of the three acetonitrile ligands and the chloride 
ligand can now be cleaved off and substituted for other ligands (Scheme 1). 
%  
Scheme 1: Introduction of the chiral auxiliary and the formation of the octahedral structure.[37] 
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The key step to obtain a metal-located stereocenter is the substitution of acetonitrile and chloride ligands 
with two bidentate ligands [e.g. dtbbpy (11) and dmbpy (12)], which undergo chiral-auxiliary-controlled 
diastereoselective coordination to form complex Λ-(S)-13 with high diastereomeric purity (99.6:0.4 dr, 
Scheme 2). 
%  
Scheme 2: Formation of a metal-located stereocenter by diastereoselective coordination.[37] 
After formation of the metal-located stereocenter, chiral auxiliary (S)-8 could be substituted by acetonitrile 
ligands under acidic conditions with retention of configuration of the metal-located stereocenter. Then, 
complex Λ-14 reacts with 2,2’-bipyridine (bpy, 15) to yield complex Λ-16 with high enantiomeric purity 
(Scheme 3a). A direct transformation of Λ-(S)-13 to Λ-16 is operable as well (Scheme 3b). 
%  
Scheme 3: Substitution of chiral oxazoline (S)-8 by 2,2’-bipyridine (15) under retention of configuration.[37] 
In a subsequent publication, the performances of several chiral oxazolines with different substituents at their 
5-position (instead of i-Pr) were investigated. This allowed to expand the scope of the achiral ligands, which 
led to the first general strategy for the asymmetric synthesis of ruthenium polypyridyl complexes with high 
enantiopurity.[39] In addition, several other compounds have been identified to be suitable chiral auxiliaries 
for this class of complexes, such as chiral binaphthyl 17,[40] sulfinamide 18,[41] L-proline (19),[42] sulfinyl-
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phenols 20 and 21 (Figure 5).[43,44] Hence, not only carbon-centered chirality but also sulfur-centered and 
axial chirality could be exploited to create octahedral complexes with metal-located stereocenter. 
%  
Figure 5: Auxiliaries with axial or sulfur-centered chirality to create octahedral complexes with metal-located 
stereocenter.[40-44] 
Instead of diastereoselective coordination, other strategies have been found operable as well. For example, 
starting with racemic cis-[Ru(bpy)3Cl2] (22), a dynamic resolution occurs upon coordination of (R)-18 to 
form single diastereomer Λ-(S)-23, whose configuration is thermodynamically favored (Scheme 4).[41] A 
similar mechanism has been observed in the case of proline (19).[42]  
%  
Scheme 4: Dynamic resolution upon coordination of chiral auxiliary (R)-18.[41] 
Furthermore, a method for the achiral precursor trans-[Ru(bpy)2(CH3CN)2](CF3SO3)2 (24·2OTf) has been 
developed. Chiral auxiliary (R)-20 is able to induce trans-cis isomerization under thermodynamic control to 
form Δ-(R)-25 selectively. Remarkably, with only 20 mol% of auxiliary (R)-21, chiral-at-metal complex Δ-26 
could still be obtained with 78% ee (Scheme 5).[44] 
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Scheme 5: Preparation of chiral-at-metal ruthenium complexes through isomerization under thermodynamic 
control.[44] 
The Meggers group has also made significant contributions to the preparation of chiral iridium(III) and 
rhodium(III) complexes. Compared to the asymmetric synthesis of ruthenium(II) polypyridyl complexes, the 
preparations of chiral iridium and rhodium complexes rely on di-µ-chloro-bridged dimers as precursor, which 
exist as racemic mixtures of ΛΛ- and ΔΔ-isomers. Splitting of these dimers and introduction of enantiopure 
auxiliary ligands results in pairs of diastereomers. Resolutions of these diastereomers can be achieved 
through different techniques. For instance, Marchi and co-worker reported that Λ-(R)-28 and Δ-(R)-28, which 
both contain fluorinated phenol oxazoline (S)-27 as chiral auxiliary, are separable by conventional flash 
column chromatography on silica gel (Scheme 6).[45] 
 
Scheme 6: Preparation of iridium complex 28 with metal-located stereocenter. Separation of diastereomers is 
achieved through column chromatography on silica gel.[45] 
The Meggers group has investigated the performance of more phenol oxazolines (S)-29-31 and phenol 
thiazoline (S)-32 and not only managed to resolve iridium complexes based on 2-phenylpyridine derivatives 
but also based on 2-phenylbenzothiazole as cyclometalating ligands. Similar to the preparation of chiral-at-
metal ruthenium(II) complexes, the chiral auxiliary could be substituted after the resolutions under acidic 
conditions so that octahedral iridium(III) complexes with metal-centered chirality, such as Λ-34, could be 
obtained with excellent yield and ee (Scheme 7).[46] 
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Scheme 7: Structures of further chiral auxiliaries and procedure to prepare chiral-at-metal cyclometalated 
iridium(III) complexes.[46] 
The chiral auxiliary strategy could be applied to rhodium complexes but only few examples have been 
reported so far. For instance, rhodium dimer complexes 35 and 36 were found to be suitable precursors to 
prepare the respective enantioenriched rhodium complex (Figure 6).[47,48] 
%  
Figure 6: Structure of rhodium dimer complex 35 and 36.[47,48] 
In the case of rhodium dimer complex 35, proline (19) has been employed as chiral auxiliary. Instead by 
column chromatography, the resolution of the Λ- and Δ-isomers is achieved through diastereoselective 
precipitation in a well-defined solvent system, where one diastereomer is obtained as precipitates (for 
example, rhodium complex Λ-L-37 is obtained when L-proline (19) is employed), while the other remains in 
solution and is subsequently discarded (Scheme 8).[47]  
%  
Scheme 8:  Preparation of rhodium(III) complex 37 with metal-located stereocenter. Separation of 
diastereomers is achieved through diastereoselective precipitation.[47]  
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In the case of rhodium dimer complex 36, phenol oxazoline (S)-38 has been employed as chiral auxiliary and 
both Λ-and Δ-isomers of 39 can be isolated at the same time by flash column chromatography on silica gel 
(Scheme 9).[48] 
 
Scheme 9:  Preparation of rhodium(III) complex 39 with metal-located stereocenter. Separation of 
diastereomers is achieved through column chromatography on silica gel.[47] 
Both proline (19) and (S)-38 can be substituted under acidic conditions, which allows the introduction of 
further achiral ligands, such as acetonitrile or 2,2’-bipyridine (15).  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1.2. Applications of Chiral-at-Metal Octahedral Complexes in Asymmetric Catalysis 
Having established strategies for the asymmetric synthesis of octahedral complexes with exclusive metal-
centered chirality,[26,48,49] the Meggers group wondered whether such complexes could be utilized as chiral 
catalysts, so that the metal-centered stereoinforamtion would be utilized to enantioselectively generate chiral 
tetrahedral carbon atoms (Scheme 10). 
%  
Scheme 10: Chirality transfer between organic small molecules and octahedral metal complexes. 
As mentioned, the preparation of enantioenriched organic compounds through asymmetric catalysis has been 
one of the central topics in organic chemistry in the past decades. To achieve this goal, many different classes 
of compounds have been investigated to serve as chiral catalysts, such as transition metal complexes with 
chiral ligands, small organic molecules as organocatalysts, and even enzymes. In contrast, octahedral 
complexes with exclusive metal-centered chirality remained largely unexplored, in part due to lack of 
preparation methods. One of the earliest examples has been reported by Gladysz and co-workers in 2008.[51] 
First, the solubility of the chiral-at-metal cationic complex Δ-[Co(en)3]3+ (40) in the organic solvent is 
increased by a borate (BArF) counterion (Figure 7). 
%  
Figure 7: Structures of the chiral cobalt complex Δ-40 and the borate BArF.[51] 
Complex Δ-40·3BArF·14H2O has been found to catalyze the Michael addition between 2-cylcopenten-1-one 
(41) and dimethyl malonate (42) giving the product (R)-43 in 78% yield and with only 33% ee (Scheme 11). 
The authors proposed that cation Δ-40 facilitates the reaction via a second coordinationsphere mechanism. 
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However, the authors also assume that the lack of a predominant well-defined transition state leads to poor 
asymmetric induction.[51] 
%  
Scheme 11: Chiral-at-metal complex Δ-40 catalyzes the Michael-addition between 41 and 42.[51] 
As can be seen from Scheme 11 and compound Δ-40, the main challenge is it to translate the catalyst’s 
metal-located stereoinformation to the products through effective interactions between both. To address this 
issue, the Meggers group reported highly sophisticated iridium complex Λ-44 to catalyze the hydrogen 
transfer reaction of nitroalkene 45 with Hantzsch ester 46.[52] By installing 5-amino-3-(2-pyridyl)-1H-
pyrazole as the catalytically active ligand, complex Λ-44 carries a double hydrogen bond donor functionality 
(both NH groups), which enables the catalyst to fixate and activate nitroalkene 45 at the same time. The 
hydroxyl group (OH) on the benzoxazole ligand is responsible for activation of Hantzsch ester 46 by 
hydrogen bonding as a hydrogen acceptor and directs the attack from only one prochiral face. The 3,5-
dimethylphenyl substituents on the cyclometalated ligands increase the stereoselectivity by blocking the 
other prochiral face, from which the undesired reaction occurs and further accelerate the reaction by 
stabilizing the hydrogen bond adduct between catalyst Λ-44 and nitroalkene 45 (Scheme 12).  
%  
Scheme 12: Chiral-at-metal iridium(III) complex Λ-44 as bifunctional catalyst for the asymmetric hydrogen 
transfer reaction between nitroalkene 45 and Hantzsch ester 46.[52] 
The aforementioned mechanistic aspects have been proved through various techniques and have led to the 
discovery of even more powerful catalyst Λ-48.[53] Compared to Λ-44, C2-symmetrical catalyst Λ-48 bears a 
bispyrazole ligand and therefore there are two catalytic sites per complex. The hydroxyl groups on Λ-44 are 
replaced by carboxamide groups, which are better hydrogen bond acceptors and the 2,6-dimethylphenyl 
substituents provide stronger steric hindrance than the 3,5-dimethylphenyl substituents. These modifications 
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have led to excellent catalytic activity, which has allowed catalyst loading as low as 0.005 mol% to still give 
the products with over 90% yield and ee (Scheme 13). 
%  
Scheme 13: C2-symmetrical chiral iridium(III) complex Λ-48 catalyzed enantioselective hydrogen transfer 
reaction between nitroalkene 45 and Hantzsch ester 46.[53] 
Based on these results, the Meggers group has moreover developed complexes Λ-49,[54] Λ-50,[55] and Λ-51[56] 
as very powerful bifunctional catalysts by introduction of different well-tuned ligands. In case of Λ-49 and 
Λ-50, deprotonation of the pyridyl pyrazole ligands leads to basic nitrogen atoms, which enables the 
complexes to serve as Brønsted base catalysts and to promote enantioselective sulfa-Michael additions and 
aza-Henry reactions with high efficiency (Scheme 14).  
%  
Scheme 14: Chiral iridium(III) complexes as Brønsted base catalysts for asymmetric Michael-addition sand 
aza-Henry reactions.[54-55] 
   
Installation of a ligand with a secondary amine functionality led to the discovery of enamine/hydrogen-
bonding catalyst Λ-51, which catalyzes the asymmetric α-amination of aldehydes (58) with azo-
dicarboxylates.[56] Subsequent reduction and cyclization afford configurationally stable and enantioenriched 
oxazolidinones (R)-59 with excellent yields and selectivities (Scheme 15).  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Scheme 15: Chiral iridium complex Λ-51 serves as an enamine/hydrogen-bonding catalyst.[56] 
Compared to organocatalysts, which are based on similar binding and activation modes, such as hydrogen 
bonding, proton transfer, and enamine formation, chiral octahedral metal complexes 44 and 48-51 have 
proved to be excellent templates for catalyst design and are able to achieve high enantioselectivity at 
remarkably low catalyst loadings. The good performances of these complexes come from their structural 
rigidity and globular complexity, which not only provide entropic advantages but also enable the fine tuning 
of catalyst optimization, so that the catalytically active functional groups can work in a cooperative manner. 
In all previous examples (Schemes 12-15), only the metal center’s chirality is utilized and the actual 
catalysis takes place at catalytically active ligands, so in all these examples the metal solely serves as a 
structural element. Subsequently, the Meggers group has developed C2-symmetric chiral iridium complex 60 
(IrO), whose both labile acetonitrile ligands can be substituted by α,β-unsaturated 2-acyl imidazole 61aa to 
afford Λ-62aa (according to 1H-NMR analysis),[57] indicating that complex IrO might be able to function as 
Lewis acid and activate imidazole substrate 61aa by increasing its reactivity towards nucleophilic attack 
(Scheme 16). 
%  
Scheme 16: Substitution of the labile acetonitrile ligands of Λ-60 by α,β-unsaturated 2-acyl imidazole 61.[57] 
Indeed, in the presence of only 1 mol% Λ-IrO, Friedel-Crafts alkylation of 1H-indole with 61aa proceeds 
smoothly to afford product (S)-63 in 97% yield and 96% ee. The excellent enantioselectivity of the reaction 
demonstrates the configurational stability of the catalyst, while both benzoxazole-attached tert-butyl groups 
ensure excellent stereoinduction (Scheme 17).[57]  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Scheme 17: Iridium(III) Lewis acid with metal-centered chirality catalyzes the asymmetric Friedel-Crafts-
alkylation between α,β-unsaturated 2-acyl imidazole 61aa and 1H-indole.[57] 
Further research resulted in the discovery of iridium(III) complex 64 (IrS), which has been found to catalyze 
a wide range of reactions such as Friedel-Crafts alkylations, Michael additions, and cycloadditions to give 
products with complex structures in high stereoselectivity (Scheme 18).[58]  
%  
Scheme 18: Chiral-at-metal iridium(III) Lewis acid IrS catalyzes an asymmetric Friedel-Crafts alkylation, 
Michael additions, and cycloadditions.[58] 
The same design principles could be applied to rhodium complexes. As described in chapter 1.1, enantio-
enriched rhodium complexes 70 (RhO)[59] and 71 (RhS)[60] can be easily synthesized from their 
corresponding auxiliary complexes 36 and 39 respectively (Figure 8).  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Figure 8: Structures of the chiral-at-metal iridium(III)- and rhodium(III) Lewis acid complexes. 
During the evaluation of their catalytic activity as Lewis acids, both rhodium(III) catalysts RhO and RhS 
proved to be often advantageous over their iridium(III) derivatives. Taking the Michael addition between 
imidazole substrate 61aa and Meldrum’s acid (72) as example: The reactions with iridium catalysts Λ-IrO 
and Λ-IrS afforded (S)-73 with 81% ee and 91% ee respectively (Table 1, entries 1 and 2), while product 
(R)-73 could be obtained with 95% ee in the presence of 2 mol% Δ-RhO (entry 3). The superiority of RhO 
and RhS over IrO and IrS is more obvious when the catalyst loadings are reduced to 1 mol%. Compared to 
the dramatically lowered enantioselectivities when Δ-IrO and Δ-RhO are employed at such low loadings 
(entries 4 and 5), Λ-RhS manages to maintain >90% ee for (S)-73 (entry 6). Due to a significantly enhanced 
reaction rates in case of the rhodium catalysts, the enantioselectivity could also be improved by simple 
reaction temperature reduction (entry 7). 
Table 1: Chiral-at-metal Lewis acid catalyzed Michael addition between 72 and 61aa. 
%  
N
X
N
X
M
Λ                                                                                 Δ
t-Bu
t-Bu
N
N
CH3
CH3
+
PF6−
N
X
N
X
M
t-Bu
t-Bu
N
N
H3C
H3C
+
PF6−
M = Ir, X = O: 60 (IrO)
M = Ir, X = S: 64 (IrS)
M = Rh, X = O: 70 (RhO)
M = Rh, X = S: 71 (RhS)
σ
O
N
N
O O
OO
+
O
N
N O
O
O
O
Catalyst
61aa 72 73
THF, T,  t
Entry Catalyst T t Product
1 Λ-IrO (2 mol%) rt 6 h (S)-73, 93% yield, 81% ee[58]
2 Λ-IrS (2 mol%) rt 6 h (S)-73, 94% yield, 91% ee[58]
3 Δ-RhO (2 mol%) rt 6 h (R)-73, 96% yield, 95% ee[58]
4 Δ-IrO (1 mol%) rt 16 h (R)-73, 99% yield, 68% ee[59]
5 Δ-RhO (1 mol%) rt 16 h (R)-73, 99% yield, 85% ee[59]
6 Λ-RhS (1 mol%) rt 16 h (S)-73, 99% yield, 93% ee[60]
7 Δ-RhO (1 mol%) 5 ºC 16 h (R)-73, 97% yield, 94% ee[59]
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In addition to electrophile activation, the iridium and rhodium Lewis acids have also demonstrated their 
ability to activate nucleophiles by catalyzing an asymmetric α-amination of 2-acyl imidazoles.[59] Upon 
coordination of 74aa to the metal center, the acidity of the α-proton increases and therefore an enolization is 
possible in the protic solvent iso-propanol. The metal enolate then attacks dibenzyl azodicarboxylate (75) to 
afford the amination product (R)-76 with good selectivity. Again, the rhodium catalyst RhO furnishes the 
product with higher ee and furthermore at a lower catalyst loading than catalyst IrO (Scheme 19). 
%  
Scheme 19: Lewis acid catalyzed asymmetric α-amination of 2-acyl imidazoles with chiral-at-metal-
rhodium(III) and iridium(III) complexes.[59] 
To prove this mechanistic proposal, iridium enolate complex 77aa was crystallized and studied by X-ray 
diffraction analysis. As illustrated in Figure 9, 2-acyl imidazole 74aa coordinates to the iridium center in a 
bidentate fashion and the nucleophilicity of the α-position is increased through enolization. The tert-butyl 
groups provide steric hindrance and the chirality of the metal center determines which of both enantiomers of 
76 is predominantly obtained. 
                                 %  
Figure 9: Crystal structure of iridium enolate complex 77aa.[59] 
In summary, the Meggers group has employed octahedral chiral-at-metal complexes in asymmetric catalysis 
by installing functional groups on the ligands in order to mimic binding and activating modes of the well-
established organocatalysts. Due to their rigid nature and structural complexity, such complexes are able to 
achieve remarkably high levels of asymmetric induction at very low catalyst loadings. In order to fully grasp 
the potential of such chiral-at-metal catalysts, complexes with labile ligands and yet stable configurations 
have been developed to activate both electrophiles and nucleophiles. Recently, the Lewis acid catalysts have 
been successfully employed in visible-light driven reactions, in which the metal center provides chirality, 
catalytic activity, and photoredox property simultaneously, which is discussed in detail in the subsequent 
section.  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1.3. Visible-Light Driven Asymmetric Photocatalysis 
As early as 1912, the idea of photochemistry was proposed by Giacomo Ciamician. He envisioned that 
mankind would one day be able to utilize sunlight as a direct indefinite source of energy for chemical 
process, just like plants absorb sunlight and convert carbon dioxide and water to glucose and oxygen.[61] 
Thinking along these lines, industrial syntheses could be carried out in an environmentally friendly manner 
and no more rely on fossil fuels, which not only create pollutions but could be completely exhausted as well. 
Despite recent progress of photochemistry in organic synthesis,[62,63] chemistry companies have only slowly 
adopted this approach for fine chemicals production. One fundamental limitation in photochemistry is that 
most organic molecules absorb light only in the UV region, which is not abundant in the solar spectrum. And 
to perform photochemical reactions, special photoreactors are often required to generate high-energy UV 
radiation, which raises safety and cost concerns. Furthermore, UV photons have energy in the energy range 
of C,C-bonds. While activating substrates and promoting desired transformations, UV radiation can therefore 
easily lead to non-productive side-reactions, especially when complex structure or sensitive functional 
groups are present in the substrate. 
One strategy to circumvent these problems is it to employ photocatalysts that are able to absorb visible light 
and form excited states to initiate chemical transformations.[64,65] Thanks to the great efforts devoted to the 
development of photovoltaic cells, organic light emitting devices (OLED), water splitting, and carbon 
dioxide reduction using visible light, the photochemical properties of various inorganic compounds[66,67] and 
organometallic complexes[68-70] have been well studied. Among these photoactive species, polypyridyl 
ruthenium(II)[71,72] and cyclometalated iridium(III)[73,74] complexes are especially attractive due to their 
straightforward preparations, long lifetime of their excited states, ability to luminescence emission, redox 
properties, and their structural and chemical stability.  
Taking [Ru(bpy)3]2+ (26) as an example, it exhibits broad, strong absorbance in the visible spectrum (λmax = 
452 nm). Upon irradiation with visible light, the complex is raised to excited states and then rapidly undergo 
radiationless deactivation and intersystem crossing (ISC) to the lowest excited state - the first triplet metal-
to-ligand-charge-transfer excited state (3MLCT1). As return of the triplet excited state to the singlet ground 
state is spin-forbidden, the lifetime of this triplet excited state can be as long as 1.1 µs in acetonitrile solution 
at room temperature.[75] Compared to the ground state, excited *[Ru(bpy)3]2+ is both easier to oxidize and 
easier to reduce. In the presence of an oxidant, photoexcited complex *[Ru(bpy)3]2+ can be oxidized 
(oxidative quenching) through a single electron transfer (SET) to generate [Ru(bpy)3]3+, which itself is also a 
strong oxidant (Scheme 20, path a). Analogously, reduced species [Ru(bpy)3]+ can also be formed depending 
on the reaction conditions (Scheme 20, path b). Therefore, various chemical reactions can be initiated by 
generating these redox-active species. Finally, *[Ru(bpy)3]2+ can be deactivated through sensitized energy 
transfer, in which the excited complex transfers its triplet energy to an acceptor (A) so that the acceptor is 
raised to triplet excited state (Scheme 20, path c).[76] This process is of high interest because triplet energy 
transfer triggered reactions with organic UV-absorbing photosensitizers have been well established, replacing 
UV-light by visible light is highly desired in this area.[77]  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Scheme 20: Major deactivation pathways of *[Ru(bpy)3]2+, potentials are given with respect to saturated 
calomel electrode (SCE).[76-77] 
One of the earliest examples where a visible light absorbing photocatalyst was employed to promote an 
organic reaction was reported by Cano-Yelo and Deronzier in 1984. They reported about a photocatalytic 
Pschorr reaction to synthesize substituted phenanthrenes.[78] The authors proposed that diazonium salt 78 is 
reduced by excited *[Ru(bpy)3]2+ through a SET and the subsequent release of nitrogen produces aryl radical 
79, which undergoes intramolecular cyclization. Radical 81 is then oxidized by [Ru(bpy)3]3+ to form cation 
81 and the deprotonation affords phenanthrene 82 (Scheme 21). 
%  
Scheme 21: Photocatalytic Pschorr reaction with visible light and its proposed mechanism.[78]  
Although several studies dealing with photocatalysis with visible light have been published following Cano-
Yelo and Deronzier’s initial report,[79-82] it was not until recent years that the utilization of visible light has 
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truly gained a lot of attentions from the organic chemists. In 2001, Krische and co-workers reported a cobalt 
catalyzed intramolecular [2+2]-cycloaddition of tethered bis(enone) 83.[83] The authors proposed that the 
reaction proceeds via anionic radical intermediate 84, which is formed through single electron reduction by 
cobalt complex 86 (Table 2, entry 1). In order to prove this mechanistic proposal, Krische employed different 
techniques to achieve this single electron reduction by other means, for example chrysene radical anion 87 
(entry 2) or cathodic reduction (entry 3) and still managed to obtain cyclobutane 85.[84,85] Yoon and co-
workers successfully combined the photoredox abilities of [Ru(bpy)3]2+ and Krische's radical [2+2]-
cycloaddition, in which photocatalysis is responsible for the reduction of bis(enones) (entry 4).[86] 
Table 2: Intramolecular [2+2]-cycloaddition of tethered bis(enone) 83 via radical anion intermediate.[83-86] 
 
After proving the necessity of each component of the reaction, Yoon and co-workers proposed that the 
photoexcited ruthenium complex is deactivated through reductive quenching by i-Pr2NEt to generate 
stronger reductant [Ru(bpy)3]+, which transfers an electron to activated bis(enone) (83.Li+). The lithium ion 
acts as a Lewis acid to facilitate the reduction and the tetrafluoroborate increases the solubility of 
[Ru(bpy)3]2+ (Scheme 22).  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Scheme 22: Proposed mechanism of the photocatalytic intramolecular [2+2]-cycloaddition of tethered 
bis(enone) 83 with visible light.[86] 
Among all the methods developed for this particular intramolecular [2+2]-cycloaddition, photoredox 
catalysis is clearly superior to the others in terms of catalyst loading, yield, and selectivity. Furthermore, 
Yoon and co-workers developed an intermolecular version of this reaction (vide infra) and demonstrated that 
the reaction can be performed on a gram scale using sunlight instead of light bulb as irradiation source 
without compromising the yields and diastereomeric ratios of the products.[87] 
Triggered by pioneering works from Yoon, MacMillan,[88] Stephenson,[89] and many others, photocatalysis 
has experienced a real boom over the last decade. The ability of visible-light-absorbing chromophores of 
single electron transfers at excited states can not only be applied to established radical transformations but 
can also be exploited to develop new unique transformations. In addition, further metal complexes such as 
[Ru(bpz)3]2+ (88), [Ir(ppy)2(dtbbpy)]+ (89), [Ir{dF(CF3)ppy}2(dtbbpy)]+ (90) and fac-[Ir(ppy)3] (91) have 
been discovered as catalysts, which have different redox properties (Figure 10).[90-95] 
 
 Figure 10: Common photoredox catalysts with visible light, potentials are presented with respect to 
saturated calomel electrode (SCE).[90-95]  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As mentioned above, photocatalysis can ben an efficient tool to develop economic and ecologic processes. 
Therefore, it is no surprise that there is large interest in enantioselective photocatalytic reactions. A number 
of reactions have been reported to achieve this goal in the past few years.[96,97] In general, most of these 
reactions fall into three categories: (1) By employing substrate-activating chiral co-catalysts, the photo-
catalysis-generated reactive radicals or ions are captured under stereocontrol; (2) By interacting with chiral 
co-catalysts, the substrate’s photophysical properties are altered and hence the subsequent photocatalyzed 
reactions proceed enantioselectively; (3) By employing chiral photocatalysts, which provide photoactivation 
and stereocontrol at the same time. 
The first of these three approaches is also the most widely adopted approach. As one of the earliest examples 
for photocatalysis with visible light, the MacMillan group successfully combined chiral imidazolidinone 
organocatalyst 92 and photoredox catalysis in order to perform asymmetric α-alkylation of aldehydes. A 
number of electron-deficient alkyl halides have been found to be suitable and these include bromo malonate 
93, phenacyl bromides 94,[88] α-cyanoalkyl bromides 95,[98] benzyl bromides 96,[99] trifluoromethyl- and 
perfluoroalkyl iodides 97.[100] In these reactions, alkyl halides are reduced through photoredox catalysis to 
radical anions, which rapidly decompose to halides and carbon-centered radicals 100. C,C-bond formation 
and the chiral induction are achieved through addition of electron-deficient radicals 100 to the electron-rich 
double bond of chiral enamine 99, which is generated from aldehyde 58 and chiral imidazolidione 92. After 
oxidation and hydrolysis α-amino radical 101 is converted to enantioenriched alkylated product 98. 
Meanwhile, 92 is released to initiate the next catalytic cycle (Scheme 23). 
 
Scheme 23: Merger of photoredox catalysis with asymmetric enamine catalysis by MacMillan.[88,98-100]  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Depending on the reaction partners, different photocatalysts can be employed for these reactions. In case of 
[Ru(bpy)3]Cl2 and [Ir(ppy)2(dtbbpy)]PF6 as photocatalysts, it is supposed that photoexcited complexes are 
first deactivated by a sacrificial amount of enamine 99 to afford the reactive reductants [Ru(bpy)3]+ and 
[Ir(ppy)2(dtbbpy)], which then transfer an electron to the alkyl halides 93-97 to initiate the first catalytic 
cycle and are reproduced by oxidizing the α-amino radical 101 from excited state (Scheme 24a). On the other 
hand, when neutral photocatalyst fac-[Ir(ppy)3] is employed as photocatalyst, no sacrificial amount of 
enamine 99 is required to initiate the reaction. Because fac-[Ir(ppy)3] should be able to reduce the alkyl 
halides directly from excited state (E1/2 (V/*III) = -1.73 V) (Scheme 24b). 
%  
Scheme 24: Photoredox catalytic cycles of MacMillan’s asymmetric α-alkylation of aldehydes.[88,98-100] 
MacMillan’s success has prompted the search for other enantioselective catalytic reactions using this dual 
catalysis strategy. Zeitler and Ferroud identified eosin Y (102) and rose bengal (103) as suitable organic 
photosensitizers, which allow it to perform MacMillan’s asymmetric alkylation of aldehydes under metal-
free conditions (Figure 11).[101,102] 
%  
Figure 11: Structures of organic photosensitizes eosin Y (102) and rose bengel (103).[101,102] 
Inspired by MacMillan’s catalysis design principle, Luo and co-workers reported an enantioselective 
alkylation of β-ketocarbonyls 104 with phenacyl bromides 94 by employing chiral primary amine 105 and 
achiral [Ru(bpy)3]Cl2 as catalysts. Chiral primary amine 105 activates β-ketocarbonyls 104 by forming 
enamines 106 and electron-deficient radicals 107 are generated through photoredox catalysis. The products 
108 could be obtained in modest to excellent yields with high ee (Scheme 25).[103]  
[Ru(bpy)3]2+
[Ir(ppy)2(dtbbpy)]+
[Ru(bpy)3]+
[Ir(ppy)2(dtbbpy)]
*[Ru(bpy)3]2+
*[Ir(ppy)2(dtbbpy)]+
visible
light
fac-[Ir(ppy)3]
fac-[Ir(ppy)3]+*fac-[Ir(ppy)3]
visible
light
e(a) (b)
e
e
e
O OHO
Br Br
BrBr
CO2H
O ONaO
I I
II
CO2HCl
Cl
Cl
Cl
102 103
%21
Chapter 1. Introduction
 
Scheme 25: Chiral primary amine (enamine catalyst) and achiral ruthenium complex catalyzed asymmetric 
alkylation of β-ketocarbonyls.[103] 
Photoredox catalysis is also able to produce ionic electrophiles: Oxidation of N-aryl-tetrahydroisoquinolines 
109 to iminium ions 110 via photoredox catalysis has been reported by Stephenson, which can be denoted as 
visible-light driven aza-Henry reaction with nitroalkanes 112 as nucloephiles.[104] Based on this report, the 
addition of other nucleophiles such as cyanide anion,[105] enol silane 113,[106] and indoles 114[107] have been 
subsequently reported as well (Scheme 26). 
%  
Scheme 26: Visible-light driven photooxidation of 109 and subsequent trapping of iminium ion 110 with 
various nucleophiles.[104-107]  
To fully explore the potential of 109 in enantioselective photoredox catalysis, several groups have attempted 
to combine chiral, nucleophile-activating catalysts with photooxidation of 109 but have faced significant 
issues. In some cases, the chiral nucleophiles have to be introduced after the photooxidation is completely 
finished in order to achieve satisfactory enantioselectivities. Therefore, such reactions are actually the 
combination of two consecutive reactions in one pot instead of merging catalysis.[108-110] The Rovis group 
reported the first successful example of an asymmetric photoredox reaction with tetrahydroisoquinoline 109 
and chiral N-heterocyclic carbene (NHC) catalyst 115. Aldehydes (58) first react with NHC catalyst 115 to 
Breslow intermediates 117 and then with photocatalytically generated iminium ions 110 to products 116, 
which are obtained with modest to very good enantioselectivities (Scheme 27).[111] 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Scheme 27: Combination of photoredox catalysis with chiral NHC catalysis.[111] 
Chiral copper catalysis has been successfully combined with visible-light driven oxidation of tetra-
hydroisoquinolines 109. An asymmetric cross-dehydrogenative-coupling reaction with alkynes (118) was 
developed, in which the copper salt and chiral ligand 119 are responsible for alkyne activation and chiral 
induction (Scheme 28).[112] 
 
Scheme 28: Combination of photoredox catalysis with chiral copper catalysis.[112] 
Chiral Lewis acids are also capable of activating nucleophiles to react with electron-deficient radicals and 
ions, which are produced through photocatalysis. In this context, Liu and co-workers first reported the 
photoreduction of aryl azides 122.[113] After being reduced to anion radical, molecular nitrogen is released 
and subsequent protonation results in the nitrogen-centered radical 123, which undergoes hydride radical 
abstraction to produce the aniline 124 (Scheme 29).  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%  
Scheme 29: Visible-light driven photoreduction of aryl azides to anilines.[113] 
Similarly, Gryko and co-workers have employed α-diazoacetates 125 to produce carbon-centered electron-
deficient radicals 128 under photoredox conditions. Radical 128 reacts with enamine 127 to afford racemic 
α-alkylated aldehydes 126 (Scheme 30).[114] 
 
Scheme 30: Visible-light driven racemic α-alkylation of aldehydes with α-diazoacetate.[114] 
Thinking along these lines, Meggers envisioned that radicals 123 and 128 could enantioselectively add to 
electron-rich double bond of chiral metal enolate complexes. Indeed, with chiral-at-metal Lewis acid Λ/Δ-
RhS, enantioselective α-alkylation and α-amination of 2-acyl imidazoles 74 could be achieved to afford 
alkylation or amination products 129 with excellent enantioselectivities (Scheme 31).[115]  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Scheme 31: Visible-light driven asymmetric α-alkylation and α-amination of 2-acyl imidazoles.[115] 
Apart from nucleophile activation through enolization, Lewis acids can enhance the electrophilicity of 
carbonyl compounds upon coordination as well, such as α,β-unsaturated carbonyl compounds, which allows 
them to be attacked by nucleophilic radicals. However, many established reactions in this category are 
performed with triethylborane and a stoichiometric amount of tributyltin hydride as radical initiator and 
hydrogen source, the first being highly flammable and the second highly toxic.[116] Visible-light driven 
photocatalysis is an approach to produce nucleophilic radicals which avoids these disadvantages.  
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Scheme 32: Chiral Lewis acid catalyzed radical addition to α,β-unsaturated carbonyl compounds.[121]  
O
N
N
R2
R1
74 122 or 125
O
N
N
R2
R1
X R3
129, 40−99%
93−99% ee
[Ru(bpy)3](PF6)2 (2.5 mol%)
Λ/Δ-RhS (4 mol%)
 Na2HPO4 (20 mol%)
21 W CFL
acetone/DMSO/H2O, rt
+
Chiral
Lewis acid
catalysis
Photoredox
catalysis
N O
R2N
R1
[RhS]
130
+
123 or 128
X R3N2
X R
X R3N2 = Ar N3
CO2R4
N2
122 125
N
O O
N
R1
MeMeEt
+ N
O O
N
MeMeEt
R1
N
R2
Ar
134, 83−96%
85−96% ee
133 (20 mol%)
Sc(OTf)3 (15 mol%)
Bu4N+Cl− (30 mol%)
[Ru(bpy)3]Cl2 (2 mol%)
N
O O
N
R1
MeMeEt
[Sc]
+
131
23 W CFL, CH3CN, rt
Chiral
Lewis acid 
catalysis
131.[Sc]
Ar N
R2
TMS
Ar N
R2
132
Photoredox
catalysis
(1) − e−
(2) − TMS+
135
NO
N N
O
i-Bu i-Bu133
%25
Chapter 1. Introduction
Photoinitiated oxidation of α-silylamines 132 to produce nucleophilic α-amino radicals 135 has been known 
for a long time[117] and racemic addition of them to electron-deficient alkenes has been demonstrated by 
several groups recently.[118-120] Yoon employed scandium(III) trifluoromethanesulfonate (OTf) and PyBOX 
ligand 133 as a chiral Lewis acid to achieve an enantioselective conjugate addition reaction of α-amino 
radicals 135, which are generated through photoredox catalysis (Scheme 32).[121] 
Meggers’ chiral-at-metal Lewis acid catalyst RhS has proven to be a superior catalyst for this type of 
reaction.[122] With organic photosensitizer 136, alkyl radicals 140 are produced from organotrifluoroborate 
precursor 137 and add to N-acyl pyrazoles 55b or 2-acyl imidazoles 61, which are activated by chiral Lewis 
acid catalyst Λ-RhS. Compared to Yoon’s catalytic system, Λ-RhS acts as a highly efficient catalyst and 
furnishes products 138 with excellent ee at even lower catalyst loading (4 mol%, Scheme 33). 
%  
Scheme 33: Visible-light driven asymmetric conjugate addition of alkyl radicals to alkenes.[122] 
The second approach to achieve visible-light driven enantioselective catalysis is to employ chiral co-catalysts 
to alter the substrates’ photophysical properties such as redox potentials and triplet energy, so that they 
become capable of getting activated by photocatalysts and the following stereogenic steps occur under 
stereocontrol. A representative example has been published by Yoon and co-workers, they were able to 
design an intermolecular and enantioselective version of their aforementioned radical [2+2]-cycloaddition 
reaction (see Table 2). As mentioned, Lewis acid LiBF4 enables single electron reduction of enones by 
[Ru(bpy)3]+. Therefore, a chiral Lewis acid should in principle provide stereocontrol, in case cyclization is 
much faster than substrate dissociation. Yoon and co-workers found out that combining Eu(OTf)3 with chiral 
peptide ligand 143 gives diastereomer trans-145 whereas slightly different ligand 144 gives the opposite 
diastereomer cis-145 (Scheme 34).[123]  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%  
Scheme 34: Chiral Lewis acid catalyzed asymmetric radical intermolecular [2+2]-cycloaddition.[123] 
This strategy has been successfully applied to an intermolecular radical [3+2]-cycloaddition as well.[124] 
Similar to the radical [2+2]-cycloaddition, chiral Lewis acid 148 facilitates single electron reduction of 
substrate 146 under photoredox conditions, the reduced substrate undergoes first a reversible ring-opening 
and then a cycloaddition with alkene 147 to yield cyclopentane product 149 with up to 99% ee (Scheme 35). 
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Scheme 35: Chiral Lewis acid catalyzed asymmetric intermolecular radical [3+2]-cycloaddition.[124]  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Yoon and co-workers have also employed a chiral Lewis acid to enable an enantioselective [2+2]-
cycloaddition through triplet energy transfer (see Scheme 20, path c).[125] One of the requirements for triplet 
energy transfer is that the sensitizer's triplet energy state is higher in energy than the one of the acceptor.[126] 
2’-Hydroxychalcones 154 and [Ru(bpy)3]2+ have triplet energy (ET) of 54 kcal/mol and 46 kcal/mol 
respectively. Therefore, direct triplet energy transfer from excited photocatalyst *[Ru(bpy)3]2+ to 154 is not 
possible. However, the triplet energy of 154 is lowered to 33 kcal/mol upon coordinating to Sc(OTf)3. In 
combination with chiral PyBOX ligand 156, 2’-hydroxychalcones 154 and dienes 155 are transformed to 
cyclobutanes 157 with excellent ee, in which only activated substrate 154.[Sc] is able to receive triplet 
energy from photoexcited catalyst *[Ru(bpy)3]2+ (Scheme 36). This mechanistic suggestion was proved with 
several experiments and more importantly, an SET-pathway could be ruled out for the reaction as no 
cyclobutane product 157 could be obtained, neither in the presence of an oxidant nor in the presence of a 
reductant. 
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Scheme 36: Chiral Lewis acid catalyzed [2+2]-cycloaddition through triplet energy transfer.[125] 
The third approach is to employ a chiral photosensitizer as single catalyst to promote enantioselective 
transformations. The first attempt to adopt this approach was reported in 1993 by Ohkubo and co-workers, 
they employed chiral photocatalyst Δ-[Ru(menbpy)3]2+ (158) and oxidant cobalt(III) acetylacetonate 
[Co(acac)3] to catalyze the oxidative dimerization of 2-naphthol (159) (Scheme 37).[127] However, product 
160 was obtained with only 16% ee presumably due to the lack of strong covalent or non-covalent bonds 
between chiral catalyst Δ-158 and substrate 159 apart from weak van-der-Waals interactions. Furthermore, it 
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is not clear whether the enantioselectivity of the resulting product derives from the chiral ligand sphere or the 
metal-centered chirality of catalyst Δ-158. Finally, the racemization of catalyst Δ-158 under the reaction 
conditions (25 ºC, 16 h, λ > 400 nm from a 500 W xenon lamp) should also be taken into consideration. 
Nonetheless, this example points out the challenge to design a single chiral catalyst which is at the same time 
the photocatalyst. Because in “classic” photochemistry, the photocatalyst’s exclusive task is it to generate 
radicals whereas another catalyst or catalytic system is responsible for stereocontrol. 
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Scheme 37: Oxidative dimerization of 2-naphthol with a chiral photosensitizer and visible light.[127] 
Bach and co-workers were able to obtain more promising results with catalyst 162, in which they fused an 
organic photosensitizer to a chiral spirocyclic pyrrolizidine. The photosensitizing element, a benzophenone 
derivative, provides photocatalytic activity and steric hindrance. The lactam functionality of catalyst 162 
recognizes and fixates substrate 161 in the catalyst’s chiral environment through hydrogen bonding. In this 
chiral environment an intramolecular radical cyclization takes place, which affords product 163 with modest 
70% ee at 30 mol% catalyst loading. A drawback of this reaction is that it requires UV-irradiation (λ > 300 
nm) instead of visible light (λ = 380-750 nm) (Scheme 38).[128]  
 
Scheme 38: Chiral spirocyclic pyrrolizidine catalyzed enantioselective intramolecular cyclization.[128] 
Bach and co-workers continued to work on this system and could significantly improve it: First, they 
replaced the flexible benzophenone moiety by a xanthone moiety, which serves in catalyst 164 as a triplet 
photosensitizer and catalyzes the intramolecular [2+2]-cycloaddition of 166 via a triplet energy transfer 
mechanism. Although UV-light (λ = 366 nm) is still required, higher yield and enantioselectivity could be 
obtained.[129,130] Finally, a visible light version (λ = 400-700 nm) of this reaction could be established by 
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employing thioxanthone catalyst 165 (Scheme 39).[131] The overall insights gained from this work have led to 
successful developments of several other asymmetric intra- and intermolecular [2+2]-cycloaddition reactions 
of quinolones and pyridones derivatives.[132-134] 
 
Scheme 39: Chiral spirocyclic pyrrolizidine catalyzed enantioselective [2+2]-cycloaddition.[129-131] 
Although Bach’s system poses a new concept in asymmetric photocatalysis, its limited substrate scope and 
the tedious catalyst synthesis remain significant drawbacks of this system. A more elegant strategy has been 
realized by Meggers and co-workers with chiral-at-metal iridium(III) Lewis acids. Meggers and co-workers 
reasoned that the metal centers of the chiral Lewis acids IrO and IrS could provide chirality, Lewis acidity, 
and photoredox functionality at the same time. Inspired by the excellent results that addition of electron-
deficient radicals to chiral electron-rich double bonds has achieved (see Scheme 23 and 25), the radical α-
alkylation of 2-acyl imidazoles 74 with phenacyl bromides 94 and substituted benzyl bromides 96 was 
chosen as a model reaction. In the presence of only 2 mol% chiral catalyst Λ-IrS and the weak base 
Na2HPO4, irradiation with visible light affords 170 with excellent results (>99% yield and 99% ee). As there 
is no reductant present in the system, bromides 94 and 96 are presumably reduced by a photoexcited 
iridium(III) species through an oxidative quenching cycle (see Scheme 20, path a and Scheme 24b). From all 
the presumably formed iridium species, it is most probable that iridium enolate complex 171 functions not 
only as the nucleophilic intermediate to capture the electrophilic radicals 100, but also as the actual 
photosensitizer. As 171 is a neutral species, it probably transfers an electron more readily to bromides 94 and 
96. Several mechanistic experiments have confirmed these mechanistic suggestions (Scheme 40).[135]  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Scheme 40: Chiral-at-metal iridium catalyzed enantioselective α-alkylation of 2-acyl imidazoles with and 
phenacyl bromides 94 and substituted benzyl bromides 96.[135]  
Meggers and co-workers have found that other electron-deficient halides as alkylation reagents are suitable 
for this photocatalytic system: By utilizing perfluoroalkyl iodides 97 (RF-I) and trichloromethyl bromide, 
asymmetric α-perfluoroalkylation[136] and α-trichloromethylation[137] of 2-acyl imidazoles 74 could be 
established. Moreover, they discovered that 2-acyl pyridines, apart from 2-acyl imidazoles, are suitable 
substrates as well (Scheme 41). 
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Scheme 41: Chiral-at-metal iridium catalyzed asymmetric α-perfluoroalkylation and α-trichloro-methylation 
of 2-acyl imidazoles and 2-acyl pyridines with visible light.[136,137] 
The Meggers group further demonstrated the versatility of their chiral iridium catalysts with an asymmetric 
α-alkylation of 2-acyl imidazoles with α-silylamines via a net oxidative pathway. Similar to an afore-
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mentioned study from Yoon and co-workers (see Scheme 32),[121] α-silylamines 132 are first photo-
catalytically oxidized to the according radical cations which then fragments into α-amino radicals 135 and 
trimethylsilyl cations. However, instead of adding to electron-deficient double bonds, α-amino radicals 135 
are further oxidized to iminium ions 177. Combining the photoredox property and the enolate chemistry of 
catalyst Λ-IrO, alkylation products 176 are obtained with excellent ee in the presence of air. According to 
photo-luminescence quenching and other control experiments, it is supposed that the reaction is initiated by 
cationic iridium species 178 (Scheme 42).[138] 
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Scheme 42: Asymmetric photocatalysis with chiral-at-metal iridium complexes by a net oxidative 
mechanism.[138] 
Furthermore, chiral-at-metal iridium complex Λ-IrS is able to catalyze the enantioselective radical-radical 
cross-coupling reaction between trifluoromethyl ketones 179-180 and diarylamines 181.[139] Electron-rich α-
amino radical 184 forms by reducing the photoexcited iridium-substrate complex to an electro-neutral 
species, which can be interpreted as an electron-deficient iridium-coordinated ketyl radical 183. The C,C-
bond is then formed by radical-radical cross-coupling to give 2-amino alcohols 182 enantioselectively 
(Scheme 43).  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Scheme 43: Asymmetric photocatalysis with chiral-at-metal iridium complexes by a radical-radical cross-
coupling mechanism.[139] 
Apart from the three aforementioned general approaches, Bach’s and Melchiorre’s groups have disclosed 
other interesting concepts to perform enantioselective photocatalysis: The Bach group successfully employed 
chiral Lewis acid catalysts to facilitate the enantioselective intramolecular [2+2]-cycloaddition of enones, in 
which the coordination by the catalyst leads to a bathochromic shift of the substrate so that the catalyst-
substrate-complex is selectively photoexcited resulting in enantioselective formation of the products.[140-142] 
Melchiorre and co-workers utilized chiral amines to activate carbonyl compounds by enamine formation, 
which are able to form electron donor-acceptor (EDA) complexes with electron-deficient alkyl halides. In 
case of the formed EDA complexes exhibit significant light absorption within the visible range, irradiation 
with visible light results in excitation of the EDA complexes which then reduce the alkyl halides to initiate 
the reactions.[143-146] Despite the success of Bach and Melchiorre, these concepts greatly depend on the 
photophysical properties of the reaction partners and therefore they do not serve as a general approach for the 
development of visible-light driven asymmetric catalysis.
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Chapter 2. Aim of this Work 
As mentioned in the first chapter of this thesis, Meggers’ transition metal complexes with metal-centered 
chirality have well proven their applicability as versatile chiral catalysts.[147,148] These complexes effectively 
catalyze a wide range of reactions and their applications in asymmetric photocatalysis are especially 
impressive. 
The aim of this work was to further explore the potential of these chiral Lewis acid catalysts in enantio-
selective transformations, particularly in photocatalysis. Because the visible-light driven asymmetric α-
alkylation reactions of 2-acyl imidazoles via enolate intermediates are closely related to the catalytic system 
developed by the MacMillan group (trapping photocatalytically generated electron-deficient radicals with 
electron-rich chiral enolates and enamines, see Schemes 23 and 40), it is reasonable to suppose that electron-
deficient alkyl halides 93-97 (see Schemes 23) should also be proper alkylation reagents for reactions 
catalyzed by the chiral-at-metal Lewis acid catalysts. Inspired by MacMillan’s results and previous results 
from the Meggers group, one aim of this work was it to investigate the reactivity of bromo malonates 93 and 
α-cyanoalkyl bromides 95 towards 2-acyl imidazoles 74 with a chiral-at-metal iridium complex as 
photocatalyst (Scheme 44). 
"  
Scheme 44: Aim of this work. 
Another aim of this work was it to develop further radical precursors apart from alkyl halides 93-97, which 
generate electron-deficient radicals photocatalytically and then react with chiral iridium or rhodium enolate 
complexes.
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Chapter 3. Results and Discussions 
3.1. Combining Photoredox Catalysis with Chiral-Rhodium(III)-Complex Directed Lewis Acid  
       Catalysis: Asymmetric α-Alkylation of 2-Acyl Imidazoles with α-Cyanoalkyl Bromides  
3.1.1. Introduction 
After the chiral iridium Lewis acids IrO and IrS had been successfully applied in a series of enantioselective 
α-alkylation reactions by utilizing iridium’s photoredox property, Lewis acidity, and chirality at the same 
time (see Schemes 40 and 41),[135-137] we wondered whether α-cyanoalkyl bromides 95 are suitable alkylation 
reagents for this system as well. The introduction of the nitrile group renders the resulting products highly 
valuable as building blocks for organic synthesis, because the nitrile group can be conveniently transformed 
into various functional groups, such as carboxylic acids, amides, amines, and others.[149] To demonstrate the 
value of introduction of a nitrile group, MacMillan and co-workers described an efficient total synthesis of 
(-)-bursehernin (188) based on their enantioselective α-cyanoalkylation of aldehydes.[98] As illustrated in 
Scheme 45, aldehyde 58a reacts with bromoacetonitrile (95a) under photocatalysis conditions to afford chiral 
α-alkylated product 185 with 94% ee. Reduction of the aldehyde group and hydrolysis of the nitrile group 
result in lactone 186 in 86% yield. Lactone 186 is then enolized by lithium diisopropylamide (LDA) and 
reacts with benzyl bromide 187 in the presence of hexamethylphosphoramide (HMPA). This alkylation step 
proceeds diastereoselectively and (-)-bursehernin (188) is obtained without any loss of ee (Scheme 45). 
"  
Scheme 45: Total synthesis of (-)-bursehernin with enantioselective α-alkylation of aldehyde 58a with 
bromoacenitrile (95a) as key step.  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In order to develop synthetically useful transformations with our chiral-at-metal Lewis acid catalysts, we 
decided to investigate the reactivity of α-cyanoalkyl bromides 95 in the visible-light driven enantioselective 
α-alkylation reactions of 2-acyl imidazoles.  
3.1.2. Preliminary Results 
Initially, 2-acyl imidazole substrate 74aa and bromoacetonitrile (95a) were chosen as standard substrates. 
The reaction was performed in the presence of Λ-IrS (2 mol%) and Na2HPO4 in a mixture of methanol and 
tetrahydrofuran (THF) (v/v, 4:1), which had been identified in previous studies as well-suited reaction 
conditions.[135] To our delight, irradiation with two 13-Watt compact fluorescent lamps (CFL) at room 
temperature for 24 h afforded product (R)-189aaa[150] in 24% yield with 58% ee. The conversion of the 
reaction was calculated to be 31% based on re-isolation of starting material 74aa (Table 3, entry 1). 
Switching catalyst from Λ-IrS to Λ-IrO resulted in higher conversion, better yield, and improved 
enantioselectivity (Table 3, entry 2). 
Table 3: Results of the catalyst optimization. 
"  
In a previously reported visible-light driven asymmetric α-amination of 2-acyl imidazoles with ODN-
carbamates 190 (ODN=2,4-dinitrophenylsulfonyloxy), Δ-RhO was found to be a suitable catalyst for this 
reaction.[151] Mechanistic studies suggest that neutral rhodium(III) enolate complex 192 absorbs photons and 
then transfers an electron to 190, which then fragments to 2,4-dinitrophenylsulfonate and electron-deficient 
aminyl radical 193 (Scheme 46). Inspired by this work, the α-alkylation of 2-acyl imidazole 74aa with 
bromoacetonitrile (95a) was performed with chiral rhodium catalyst Λ-RhO. While a significant 
improvement of the enantioselectivity (74% ee) for (R)-189aaa was observed, only 24% of the starting 
material 74aa was consumed resulting in low yield (21% yield, Table 3, entry 3). In consideration of the 
promising enantioselectivity with Λ-RhO, we decided to further optimize the reaction conditions with this 
catalyst.  
Br CN
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"  
Scheme 46: Chiral rhodium(III) Lewis acid catalyzed asymmetric α-amination of 2-acyl imidazoles.[151] 
3.1.3. Optimization of the Reaction Conditions - Single Catalyst 
The optimization efforts began with the evaluation of various solvents. By removing THF from the solvent 
system, higher conversion and yield were obtained, albeit with decreased ee (38% conv., 29% yield, 60% ee, 
Table 4, entry 2). Replacement of methanol by N-methyl-2-pyrrolidone (NMP), dimethylacetamide (DMA), 
acetonitrile, and THF led to no or very low conversion (entries 3-6). However, it was encouraging to 
discover that acetonitrile as solvent afforded product (R)-189aaa with higher ee than THF (54% and 46% ee, 
entries 5 and 6). Therefore, it seemed probable that replacement of THF by CH3CN in a combination with 
methanol could lead to an improved ee. Indeed, when the reaction was carried out in CH3OH/CH3CN 4:1, a 
slight improvement of ee was observed, but the yield remained unsatisfactory (28% yield, 77% ee, entry 7). 
Table 4: Results of solvent optimizations. 
"  
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Previous studies from our lab had revealed that the choice of the base can be crucial in certain cases,
[135-137,150] Use of NaHCO3 or sodium acetate (NaOAc) led to lower yield and ee (40% and 15% ee, Table 5, 
entries 2 and 3). Cs2CO3 greatly enhanced the rate of the reaction but the reaction proceeded with almost no 
enantioselectivity (70% yield, 5% ee, entry 4), presumably because 2-acyl imidazole substrate 74aa is 
deprotonated without coordination to the rhodium center, which leads to a racemic background reactions. 
Moreover, strong bases can facilitate racemization of enantioenriched product (R)-189aaa by enolization as 
well. As inorganic bases had not given promising results, organic 2,6-lutidine was employed but also failed 
to improve the results (30% conv., 12% yield, 31% ee, entry 5).  
Table 5: Results of base optimizations. 
"  
As illustrated in Scheme 47, addition of α-cyanoalkyl radical 194 to rhodium enolate complex 192 results in 
ketyl radical 195. The oxidation of 195 to rhodium-product-complex 196 is generally achieved either by 
catalyst turnover (192+ → 192) or by chain propagation (95 → 194), both of which are crucial for radical 
production. We suggest that the inefficient production of 194 might be responsible for the low conversion. 
"  
Scheme 47: Conversion of ketyl radical 195 to rhodium-product-complex 196 through catalyst turnover or 
chain propagation, both processes are crucial for production of α-cyanoalkyl radical 194. 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Stephenson addressed the issue of catalyst-turnover by adding trialkylamine which serves as reducing agents 
to regenerate the photocatalyst (Scheme 48),[152] which inspired us to use two equivalents of i-Pr2NEt instead 
of non-reducing bases. While conversion and yield indeed improved (53% conv., 44% yield), product 
(R)-189aaa was obtained with only 35% ee (Table 5, entry 6). It is worth noting that no conversion of 74aa 
was observed in the absence of base, which indicates that the formation of the rhodium enolate complex 192 
is crucial for the reaction (entry 7). 
"  
Scheme 48: Stephenson’s photochemical reduction of alkyl and aryl iodides, the catalysis benefits from 
employing a trialkylamine.[152] 
3.1.4. Optimization of the Reaction Conditions - Dual Catalysis Strategy 
Having only limited success with the single catalyst system, we decided to test a dual catalysis system, in 
which the chiral-at-metal Lewis acid catalyst activates 2-acyl imidazole substrates 74 by facilitating 
enolization whereas generation of α-cyanoalkyl radicals 194 is achieved by a separate photocatalyst. We 
started with Λ-RhO as Lewis acid catalyst and fac-[Ir(ppy)3] as photocatalyst due to its strong ability to 
donate an electron in its excited state among the common photoredox catalysts (see Figure 10 for 
comparison). To our delight, full conversion of 74aa was achieved and product (R)-189aaa was obtained in 
85% yield with 58% ee after 24 h irradiation (Table 6, entry 1). By repeating this reaction, we found that the 
reaction was actually finished after 17 h and (R)-189aaa was isolated with both higher yield and ee (92% 
yield, 64% ee, entry 2), which indicates that racemization of (R)-189aaa occurred under the reaction 
conditions. To address this issue, the methyl group on the imidazolyl moiety was substituted by more bulky 
groups to prevent racemization of the alkylated product. The enantioselectivity of the reaction was improved 
by employing N-phenyl substrate 74ba but a prolonged reaction duration was required in order to achieve 
complete conversion of the starting material (36 h, 72% yield, 70% ee, entry 3), which is disadvantageous as 
a long reaction time apparently favors racemization. Therefore, we decided to accelerate the reaction by 
increasing the amount of bromoacetonitrile (95a) to 6 equivalents and the required reaction time was 
successfully shortened to 12 h to afford (R)-189baa in 88% yield with 72% ee (entry 4). A brief solvent 
screening was conducted with the main goal to completely dissolve the photoredox catalyst fac-[Ir(ppy)3]. 
By increasing the amount of acetonitrile of the binary solvent system the reaction was slowed down and gave 
a slightly better enantioselectivity (24 h, 58% yield, 74% ee, entry 5). Replacing acetonitrile with dichloro-
methane partially increased the solubility of fac-[Ir(ppy)3] and the yield but the ee remained basically 
unchanged (71% yield, 73% ee, entry 6). A major improvement was observed when the steric hindrance was 
further increased by employing 74ca as substrate (81% yield and 80% ee, entry 7). Compared to fac-
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[Ir(ppy)3], soluble complex [Ir(ppy)2(dtbbpy)]PF6 (89.PF6) proved to be a better photoredox catalyst for the 
reaction giving product (R)-189caa with 84% ee (entry 8). Finally, a sufficiently satisfactory result was 
achieved by switching the catalyst from Λ-RhO to Λ-RhS. Surprisingly, product (R)-189caa was obtained 
with this catalyst in 99% yield and 94% ee after only 1.5 h photolysis (entry 9). Furthermore, the amount of 
bromoacetonitrile (95a) could be reduced to 3 equivalents without adverse effects on yield and ee of the 
product (entry 10). 
Table 6: Reaction optimization with the dual catalysis approach. 
"  
3.1.5. Evaluation of the Substrate Scope 
With optimized reaction conditions in hand, we now evaluated the substrate scope of the reaction. Several 2-
acyl imidazoles 74cb-f were synthesized using a literature-known procedure[136,151] and to test the reactivity 
of branched α-cyanoalkyl bromides rac-2-bromo-3,3-diethoxypropanenitrile (95b) was synthesized 
according to MacMillan’s procedure.[98] Because the synthesis of RhO is easier than the synthesis of RhS, 
racemic references were synthesized with rac-RhO and 6 equivalents of 95a. After 24 h photolysis, racemic 
references rac-189cba-cfa were obtained in modest to very good yield. In most cases the starting materials 
were not completely consumed (Table 7, entry 1-4). The results of substrate scope evaluation revealed that 
electron-donating substituents on the phenyl ring are well-tolerated. Excellent results were achieved with 
74cb giving product (S)-189cba in >99% yield with 95% ee (entry 1). However, electron-withdrawing 
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1 Λ-RhO fac-[Ir(ppy)3] Me 3 CH3OH/CH3CN 4:1 24 h 85% yield, 58% ee
2 Λ-RhO fac-[Ir(ppy)3] Me 3 CH3OH/CH3CN 4:1 17 h 92% yield, 64% ee
3 Λ-RhO fac-[Ir(ppy)3] Ph 3 CH3OH/CH3CN 4:1 36 h 72% yield, 70% ee
4 Λ-RhO fac-[Ir(ppy)3] Ph 6 CH3OH/CH3CN 4:1 12 h 88% yield, 72% ee
5 Λ-RhO fac-[Ir(ppy)3] Ph 6 CH3OH/CH3CN 1:1 24 h 58% yield, 74% ee
6 Λ-RhO fac-[Ir(ppy)3] Ph 6 CH3OH/CH2Cl2 1:1 24 h 71% yield, 73% ee
7 Λ-RhO fac-[Ir(ppy)3] o-tolyl 6 CH3OH/CH2Cl2 1:1 24 h 81% yield, 80% ee
8 Λ-RhO [Ir(ppy)2(dtbbpy)]PF6 o-tolyl 6 CH3OH/CH2Cl2 1:1 24 h 81% yield, 84% ee
9 Λ-RhS [Ir(ppy)2(dtbbpy)]PF6 o-tolyl 6 CH3OH/CH2Cl2 1:1 1.5 h 99% yield, 94% ee
10 Λ-RhS [Ir(ppy)2(dtbbpy)]PF6 o-tolyl 3 CH3OH/CH2Cl2 1:1 5 h 99% yield, 94% ee
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substituents gave lower enantioselectivities (entries 2-4) and in the case of 74cd,  product (S)-189cda was 
obtained almost as a racemic mixture (entry 3). To our delight, 2-acyl imidazole with alkyl moiety 74cf 
worked well in the system to give (S)-189cfa with very high ee (92% yield, 96% ee, entry 5). 
Table 7: Evaluation of the substrate scope: 2-acyl imidazoles 
!  
[a] With 6 eq. 95a; [b] With 3 eq. 95a; [c] Incomplete conversion. 
The reaction with branched α-cyanoalkyl bromide 95b was conducted with standard substrate 74ca. Similar 
to the reactions above (see Table 7), the reaction was first performed with rac-RhO as catalyst. Product 
rac-189cab was obtained in 81% yield as a mixture of diastereomers, which were resolved by silica gel flash 
column chromatography (Scheme 49) and both analytically characterized. 
"  
 Scheme 49: Reaction with branched α-cyanoalkyl bromide 95b and catalyst rac-RhO. 
With the necessary analytical data in hand, the reaction was now performed with Δ-RhS. The diastereomeric 
ratio of (S)-189cab was determined as 2.5:1 by 1H-NMR analysis of the crude reaction mixture (see 
experimental section, p.107, the configuration of the β-position was not determined). After purification, 
(S)-189cab was isolated in quantitative yield and both diastereomers were obtained with 98% ee in the 
presence of only 3 equivalents 95b after 15 h (Scheme 50).  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"  
Scheme 50: Evaluation of the substrate scope: a branched α-cyanoalkyl bromide. 
3.1.6. Mechanistic Investigations 
First, alkylated product 189cca resulted from the reaction with 74cc and Δ-RhS (Table 7, entry 2) was 
crystallized and characterized by X-ray diffraction. The absolute configuration of the chiral center is assigned 
to be S, which supports the mechanistic proposal that the reaction proceeds via a rhodium enolate complex 
197 (Scheme 51). 
          "  
Scheme 51: Crystal structure of (S)-189cca and mechanistic proposal. 
Several experiments were performed to gain more insights into the mechanism of the reaction. As mentioned, 
after only 1.5 h photolysis under optimized reaction conditions, product (R)-189caa was obtained in 99% 
yield with 94% ee (Table 8, entry 1). Within the same span of time, reactions both in the absence of light and 
in the presence of air failed to afford detectable amounts of desired product (R)-189caa according to 1H-
NMR analysis of the crude reaction mixtures (entries 2 and 4, see experimental section, Figure 17 and 18, p.
109-110). However, (R)-189caa could be obtained after a prolonged reaction time with 4% and 60% ee 
respectively (entries 3 and 5). Similarly, the absence of [Ir(ppy)2(dtbbpy)]PF6 resulted in no detectable 
conversion of 74ca after 1.5 h photolysis (entry 6) while (R)-189caa was obtained in 97% yield with 79% ee 
after 24 h photolysis (entry 7). Finally, (R)-189caa was formed in the absence of Lewis acid catalyst (31% 
yield, entry 8).  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Table 8: Results of experiments to investigate the reaction’s mechanism. 
"  
The fact that there is some reaction in the absence of light and in the presence of air, indicates the existence 
of a non-radical background reaction, for example an SN2-type nucleophilic substitution reaction, in which 
the rhodium enolate complex attacks bromoacetonitrile (95a) directly, but apparently at a much slower rate. 
Due to its relatively strong basicity, i-Pr2NEt is able to promote the enolization of 2-acyl imidazoles 74 
without the assistance of RhS, which then react with 95a in a racemic background reaction. Indeed, when 
74ca was mixed with 2 equivalents i-Pr2NEt in CD2Cl2/CD3OD (v/v 1:1) no signal for the methylene group 
of 74ca was observed by 1H-NMR (see experimental section, Figure 19-21, p.111-112). Hence, there might 
be racemic and enantioselective variants for the assumed SN2-pathway (Scheme 52). The racemic variant of 
the SN2-pathway might significantly contribute to the lower ee of 189, especially in case of the reactions 
which were carried out in the absence of light (see Table 8, entries 2 and 3). As a radical pathway can be 
ruled out in the absence of light, the fact that (R)-189caa was obtained with only 4% ee suggests that the 
rhodium enolate complex 197 is highly reactive towards α-cyanoalkyl radicals 194 but not towards α-
cyanoalkyl bromides 95. 
"  
Scheme 52: Assumed non-radical SN2-pathways to form alkylated product 189. 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As can be seen in Table 8, the radical pathway seems to be not completely suppressed by atmospheric 
oxygen, as (R)-189caa was obtained in 23% yield with 60% ee (entry 5). A literature search[90] revealed that 
air or oxygen is commonly employed either as oxidant to convert the reduced photoredox catalyst to its 
ground state or as oxidative quencher. In consideration of the cationic nature of the photocatalyst 
[Ir(ppy)2(dtbbpy)]+ and the presence of excessive reductive quencher i-Pr2NEt in the reaction mixture, it is 
reasonable to assume that the photocatalyst is first reduced from its excited state. The reduced photocatalyst 
could then be converted to the ground state either by transferring an electron to α-cyanoalkyl bromides 95 or 
by getting oxidized by air. Both pathways are competitive to each other and the latter one inhibits the 
production of α-cyanoalkyl radicals 194 to a certain degree, which might be crucial for the enantioselectivity 
of the reaction (Scheme 53). Therefore, (R)-189caa was presumably obtained with a lower but still 
significantly higher ee than the product from the dark reaction (compare with entries 3 and 5). 
"  
Scheme 53: Possible mechanism of regeneration of photocatalyst:. 
Similarly, the absence of [Ir(ppy)2(dtbbpy)]PF6 resulted in basically no conversion of 74ca after 1.5 h 
photolysis (Table 8, entry 6) while (R)-189caa was obtained in 97% yield with 79% ee after prolonged 
reaction time (entry 7), which indicates that the rhodium enolate complex 197 can also absorb photons and 
then reduce α-cyanoalkyl bromides 95 to initiate the reaction (compare with Scheme 46). At last, because 
RhS is not required for the enolization of 74ca, rac-189caa was formed in the absence of Lewis acid catalyst 
(31% yield, entry 8) presumably through the aforementioned non-radical SN2-pathway (see Scheme 52). The 
low yield demonstrates the low reactivity of ammonium enolates 198 towards α-cyanoalkyl radicals 194. 
In another study from the Meggers group, RhS is also employed as chiral Lewis acid to activate 2-acyl 
imidazoles 74 through enolization to react with alkyl and aminyl radicals which were generated by 
photoreduction of azides 122 and α-diazoacetates 125 (see Scheme 31).[115] Given the similarity of these two 
reactions to our current study, the mechanistic investigations of these two reactions might provide further 
useful informations. First, the authors performed reactions with various Lewis acid catalysts such as 
Sc(OTf)3, FeCl3, and Cu(OAc)2 and none of them was capable of catalyzing the reaction, which shows the 
unique reactivity of rhodium enolate complex 197 towards radical addition. Next, the authors performed 
Stern-Volmer quenching experiments with photocatalyst [Ru(bpy)3]2+ and they discovered that the excited 
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photoredox catalyst is reduced by rhodium enolate complex 197 to initiate the reaction and at the same time 
generates α-carbonyl radical 199 (Scheme 54).  
"  
Scheme 54: Rhodium enolate complex 197 acts as reductive quencher and is oxidized by the excited 
photoredox catalyst to produce α-carbonyl radical 199.[115] 
α-Carbonyl radical 199 could be captured either by silyl enol ether 200 or by oxygen to afford alkylated 
product 201 or oxygenation product 202 (Scheme 55). In the current study, oxygenation product 202 was not 
observed in the presence of air (Table 8, entry 4 and 5), which indicates that the excited photocatalyst 
*[Ir(ppy)2(dtbbpy)]+ is probably not deactivated by rhodium enolate complex 197 and this is consistent with 
the proposal that i-Pr2NEt acts as both base and reductive quencher. 
"  
Scheme 55: α-Carbonyl radical 199 is captured by silyl enol ether 186 and oxygen.[115]  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With these informations in hand, a mechanistic picture for the asymmetric α-alkylation of 2-acyl imidazoles 
with α-cyanoalkyl bromides can be drawn: In consideration of the basicity and the amount of i-Pr2NEt in the 
reaction mixture, we propose that substrate 74 is deprotonated directly without coordination to RhS. The 
resulting ammonium enolate 198 then substitutes the acetonitrile ligands to form rhodium enolate complex 
197. On the other hand, the reaction is triggered by photoexcitation of [Ir(ppy)2(dtbbpy)]PF6. The excited 
photocatalyst is then deactivated by the second equivalent i-Pr2NEt through reductive quenching to afford 
strong reductant [Ir]II, which transfers an electron to electron-deficient α-cyanoalkyl bromide 95. In the 
course of the fragmentation of reduced 95, α-cyanoalkyl radical 194 is formed and reacts with rhodium 
enolate complex 197 under stereocontrol. The resulting rhodium ketyl radical 203 is then readily oxidized to 
rhodium product complex 204 either by the excited photocatalyst (pathway A) or α-cyanoalkyl bromide 95 
(pathway B). The latter pathway is known as chain propagation. Finally, product 189 is released and a second 
equivalent ammonium enolate 198 coordinates to the rhodium center to initiate the next catalytic cycle 
(Scheme 56). In the previous studies utilizing chiral-at-metal Lewis acid catalysts to activate substrates 
through enolization, it is common to employ weak bases in order to ensure that substrate enolization only 
occurs upon coordination. In the current study, it appears that rhodium enolate complex 197 so preferentially 
reacts with electrophilic radicals that possible racemic pathways (non-radical SN2 pathway and radical 
addition to ammonium enolate 198) are effectively suppressed, which ultimately results in a high level of 
enantioselectivity. 
"  
Scheme 56: Proposed mechanism for the visible-light driven enantioselective α-alkylation of 2-acyl 
imidazoles with α-cyanoalkyl bromides.  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With additional mechanistic experiments, the proposed mechanism from Scheme 56 could be further 
confirmed. For instance, Stern-Volmer quenching experiments with [Ir(ppy)2(dtbbpy)]+ could determine 
whether i-Pr2NEt indeed serves as reductive quencher instead of rhodium enolate complex 197. In addition, 
experiments could be performed to capture α-cyanoalkyl radical 194 to confirm that the reaction proceeds 
via a radical pathway.  
3.1.7. Conclusion and Future Perspectives 
An asymmetric α-alkylation of 2-acyl imidazoles with α-cyanoalkyl bromides has been successfully 
established by combining photoredox catalysis with Lewis acid catalysis with chiral-at-metal octahedral 
rhodium(III) complexes. Under optimized conditions the products could be obtained with up to >99% yield 
and 98% ee (Scheme 57). 
"  
Scheme 57: α-Alkylation of 2-acyl imidazoles with α-cyanoalkyl bromides under optimized reaction 
conditions. 
The substrate scope seems to be somewhat limited as imidazole substrates with electron-withdrawing aryl 
groups result in lower ee of the products presumably due to product racemization (see Table 7). However, 
branched α-cyanoalkyl bromide 95b could be employed as alkylation reagent to afford the corresponding 
products with excellent ee (see Scheme 50). To the best of our knowledge, this is the first example where the 
chiral-at-metal iridium(III) or rhodium(III) enolate complexes react with secondary carbon-centered radicals. 
Future efforts might be spent on mechanistic investigations as mentioned above. In case this project is 
continued, the evaluation of various branched α-cyanoalkyl bromides and imidazole substrates with alkyl 
functionalization are highly promising (see Table 7, entry 5 and Scheme 50) and should therefore have a high 
priority.  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3.2. Enantioselective α-Benzoyloxylation of 2-Acyl Imidazoles Catalyzed by Chiral-at-Metal Rhodium 
       Lewis Acid 
3.2.1. Introduction 
The enantioselective α-oxygenation of carbonyl compounds has been intensely investigated due to the 
importance of the resulting products in organic synthesis. However, most catalytic strategies rely on pre-
formed enolates, either (silyl) enol ethers, or ketene acetals.[153,154] Recently, chiral amine catalysts have been 
used to facilitate direct asymmetric α-oxygenation reactions by activating aldehydes and ketones through 
enamine formation. Several groups have successfully employed nitrosobenzene (205) as electrophile to 
achieve an asymmetric α-aminoxylation of carbonyl compounds.[155-160] Despite good yields and enantio-
selectivities, the high reactivity of nitrosobenzene (205) often led to inseparable bis-aminoxylation products 
or in some cases only to modest N,O-selectivity (Scheme 58). To address these issues, several-fold excess of 
carbonyl compounds or a slow addition of nitrosobenzene (205) is required, which limits the practical value 
of this strategy. 
"  
 Scheme 58: Direct α-aminoxylation of aldehydes and ketones with nitrosobenzene catalyzed by chiral 
amines.[155-160] 
On the other hand, benzoyl peroxide (211, BPO) seems to be a good alternative oxygen source to achieve 
this asymmetric α-oxygenation because it is inexpensive, readily available, and easy to handle. Indeed, chiral 
imidazolidinone 92b,[162] pyrrolidine 213,[161] and silylated prolinol 124[163] have been reported to facilitate 
the enantioselective α-benzoyloxylation of aldehydes with BPO (211). After subsequent in situ reduction, 
enantioenriched β-benzoyl alcohol 212 could be obtained with excellent ee (Scheme 59).  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"  
Scheme 59: Direct α-benzoyloxylation of aldehydes through chiral enamine catalysis.[161-163] 
In terms of ketones, the List group discovered that chiral primary amine 215 promotes the asymmetric α-
benzoyloxylation of cyclic ketones 208.[164] Trichloroacetic acid is employed as co-catalyst in order to 
enhance the electrophilicity of BPO (211) and substoichiometric amounts of 2,6-di-tert-butyl-4-methyl-
phenol (BHT) are added to suppress an undesired radical process, which would otherwise result in side 
reactions and lower yields (Scheme 60). 
"  
Scheme 60: Direct α-benzoyloxylation of cyclic ketones by chiral enamine catalysis.[164] 
Despite the success of enamine catalysis, significant limitations of it should be addressed in the future. For 
instance, the substrate scope is limited, only aldehydes with alkyl, benzyl, and allyl moieties have been 
successfully employed, and the yields of the products remain to be improved. In the case of ketones, the 
reaction requires anhydrous BPO (211) instead of the more common hydrate to ensure satisfactory yields, 
which raises safety and cost concerns. Furthermore, to the best of our knowledge, a direct enantioselective α-
benzoyloxylation of acyclic ketones has not been developed yet. 
Recently, BPO (211) has been used in photoredox reactions as well. In a visible-light driven direct benzoyl-
oxylation of electron-rich arenes,[165] BPO (211) accepts an electron from photoexcited *[Ru(bpy)3]2+ and 
undergoes fragmentation to produce a benzoyl radical, which is an electrophilic radical and reacts with 
electron-rich arenes 217 to afford product 218 (Scheme 61).  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"  
Scheme 61: Visible light triggered direct benzoyloxylation of electron-rich arenes.[165] 
We became curious whether chiral-at-metal Lewis acid catalysts could catalyze the asymmetric α-
benzoyloxylation of 2-acyl imidazoles via either a polar or a radical pathway to address the limitations of the 
existing methods for the α-benzoyloxylation of carbonyl compounds. 
3.2.2. Preliminary Results 
We started our investigation by adopting the photoredox conditions[165] and 2-acyl imidazole 74ag was 
chosen as model substrate. To our delight, in the presence of 1.5 equivalents BPO (211), 3 equivalents 
NaHCO3, 2 mol% [Ru(bpy)3]Cl2·6H2O, and 3 mol% rac-RhO, imidazole substrate 74ag was converted to 
219ag in 72% yield after only 2 h photolysis with visible light. A control experiment revealed that visible 
light is not necessary for the reaction, which indicates that the reaction most likely proceeds via a polar 
pathway (similar to enamine catalysis, see Scheme 59 and 60). The reaction was repeated in the absence of 
visible light and photocatalyst and enantioenriched product 219ag was obtained in 96% yield with 40% ee 
(Scheme 62). It is worth noting that the absolute configuration of the enantioenriched product was not 
determined due to the relatively low selectivity. 
"  
Scheme 62: Preliminary results of the α-benzoyloxylation of 2-acyl imidazoles with BPO.  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3.2.3. Optimization of the Reaction Conditions 
First, various solvents were screened. It is worth noting that substrate 74ag was smoothly converted to 
product 219ag and that side products are basically not formed, which allows to monitor the reactions directly 
by HPLC-analysis. While CH2Cl2 and CH3NO2 did not provide any improvement (40% ee and 20% ee, Table 
9, entry 2 and 3), the absence of NaHCO3 led to an improved enantioselectivity (47% ee and 52% ee in THF, 
entry 4 and 5).  
Table 9: Solvent evaluation in the presence of NaHCO3. 
"  
[a] Reaction was performed in the absence of NaHCO3. 
Hence, further solvents were screened in the absence of base. Among all evaluated solvents, toluene and 1,2-
dimethoxyethane (DME) afforded the best results and reactions in these solvents were finished after 1.5 h to 
give product 219ag with 56% ee (Table 10, entry 3 and 7). Finally, a control experiment was performed in 
acetonitrile without the catalyst. According to HPLC analysis of the crude reaction mixture no product was 
formed, which indicates that catalyst RhO drastically accelerated the reaction. 
Table 10: Solvent evaluation in the absence of base. 
"  
O OMe
N
N
74ag
+
Λ-RhO (3 mol%), NaHCO3 (3 eq.)
In the absence of light
Solvent, rt, t
O OMe
N
N OBz
211, 1.5 eq. 219ag
BPO
Entry Solvent t Result
1 CH3CN 1.5 h 40% ee
2 CH2Cl2 12 h 40% ee
3 CH3NO2 12 h 20% ee
4 THF 12 h 47% ee
5[a] THF 2.5 h 52% ee
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N
N
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+
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O OMe
N
N OBz
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BPO
Entry Solvent t Results
1 THF 2.5 h 52 % ee
2 1,4-dioxane 1.5 h 53 % ee
3 toluene 1.5 h 56 % ee
4[a] CHCl3 1.5 h 48 % ee
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[a] Incomplete conversion; [b] Side products were observed; [c] In the absence of catalyst. 
Next, we screened different catalysts and variated the molar ratio of the reactants. Excess of imidazole 
substrate 74ag failed to improve the results in terms of both reaction rate and enantioselectivity (Table 11, 
entry 1; compare with Table 9, entry 5), while iridium catalysts significantly lowered the ee of the product 
(entry 2 and 3). 
Table 11: Influence of molar ratio and catalysts. 
 "  
[a] Incomplete conversion 
Sticking to RhO as catalyst and toluene or DME as solvent, we went on evaluating the influences of 
concentration, temperature, and different additives on the reaction. Lower temperature and lower 
concentration of substrate 74ag resulted in a slower reaction rate while little or no improvement of product’s 
ee was observed (56% ee and 58% ee, Table 12, entries 2 and 3). To accelerate the reaction, 10 mol% of 
tifluoroacetic acid (TFA) were added with the intention to enhance the electrophilicity of BPO (211). 
However, substrate 74ag still was not fully consumed and the ee of 219ag was decreased (54% ee, entry 4). 
Radical scavengers hydroxyquinone (HQ) and BHT were also not able to improve product’s ee (52% and 
56% ee, entries 5 and 6).  
5 acetone 3 h 45 % ee
6[a,b] DMSO 3 h 45 % ee
7 DME 1.5 h 56 % ee
8 EtOH 1.5 h 44 % ee
9 i-PrOH 1.5 h 51 % ee
10[c] CH3CN 1.5 h no conversion
Entry Solvent t Results
O OMe
N
N
74ag, 3 eq.
+
Catalyst (3 mol%)
In the absence of light
THF, rt, t
O OMe
N
N OBz
211, 1 eq. 219ag
BPO
Entry Catalyst t Result
1 Λ-RhO 3 h 52% ee
2[a] Λ-IrO 20 h 25% ee
3[a] Λ-IrS 20 h 27% ee
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Table 12: Optimization of reaction conditions. 
"  
[a] Incomplete conversion.  
Significant improvement was achieved with substrate 74aa, as product 219aa was obtained in promising 
85% yield with 72% ee. Replacement of the imidazolyl moiety’s methyl group by iso-propyl led to further 
improvement of the enantioselectivity to 79% ee (Scheme 63). 
"  
Scheme 63: Influence of the substrate, lacking methoxy group and N-iso-propyl group led to improved ee. 
By increasing the catalyst loading to 6 mol%, product 219da was formed with 82% ee after 1.5 h according 
to HPLC analysis of the crude reaction mixture. However, when 205da was isolated after a total reaction 
time of 22 h the ee of the isolated product was found to be only 52%, which indicates racemization of the 
product under the applied reaction conditions (Scheme 64). 
"  
Scheme 64: Indication for product racemization under the applied reaction conditions.  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Being aware that α-aryl substituted 2-acyl imidazoles are especially prone to undesired enolization and thus 
racemization, we now switched over to an alkyl substituted 2-acyl imidazole 74dh. However, no conversion 
of substrate 74dh was observed under identical reaction conditions after 24 h (Scheme 65). 
"  
Scheme 65: Reaction with the imidazole substrate 74dh. 
In consideration that in the absence of base 74dh might not be enolized. At the same time, the low 
electrophilicity of BPO (211) might prevent conversion, the reaction was now performed in the presence of 
1.1 equivalents of various bases or acids. Among all tested additives, which included Na2HPO4, NaOAc, 
Na2CO3, K2HPO4, K2CO3, Cs2CO3, i-Pr2NEt, i-Pr2NH, Et3N, n-Bu3N, 2,6-lutidine, and benzoic acid 
(PhCO2H), trifluoroacetic acid (TFA), p-toluenesulfonic acid mono hydrate (p-TsOH.H2O), trifluoromethane-
sulfonic acid (TfOH), only both bases Na2CO3 and i-Pr2NH were able to promote the reaction to afford 
product 219dh in 26% and 29% yield after 24 h. It is worth noting that imidazole substrate 74dh was not 
fully consumed in both reactions, which also proceeded with unsatisfactory enantioselectivities (Scheme 66). 
"  
Scheme 66: Reaction with substrate 74dh in the presence of i-Pr2NH and Na2CO3. 
In an alternative approach, the reaction was performed under the photoredox conditions and it seems that the 
benzoyl radical prefers to react with the imidazolyl ring instead of with the enolate’s double bond as the 1H 
NMR analysis of the resulting product indicated intact methylene signals (Scheme 67, 1H-NMR spectrum of 
the product in the experimental section, Figure 22, p.118).  
O
MeN
N
i-Pr
74dh
+
Λ-RhO (3 mol%)
In the absence of light
DME, rt, 24 h
O
MeN
N
i-Pr
OBz
211, 1.5 eq. 219dh, no conversion
BPO
O
MeN
N
i-Pr
74dh
+
Λ-RhO (3 mol%)
i-Pr2NH (1.1 eq.)
In the absence of light
DME, rt, 17 h
O
MeN
N
i-Pr
OBz
211, 1.5 eq. 219dh, 29%
61% ee
BPO
O
MeN
N
i-Pr
74dh
+
Λ-RhO (3 mol%)
Na2CO3 (1.1 eq.)
In the absence of light
DME, rt, 17 h
O
MeN
N
i-Pr
OBz
211, 1.5 eq. 219dh, 26%
60% ee
BPO
"54
Chapter 3. Results and Discussions
"  
Scheme 67: Reaction with imidazole substrate 74dh under photoredox conditions. 
3.2.4. Conclusion and Further Perspectives 
Despite single encouraging results (97% yield and 79% ee for 219da, Scheme 64), the development of 
enantioselective α-benzoyloxylation of 2-acyl imidazoles was not successful. To address the current issues 
regarding product racemization and scope, the reaction with 2-acyl imidazole 74ca as substrate and RhS as 
catalyst should be investigated. 
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 3.3. Iridium and Rhodium Lewis Acids Promoted Direct α-Arylation of 2-Acyl Imidazoles 
3.3.1. Introduction 
Great efforts have been spent on developing strategies to achieve α-arylations of carbonyl compounds due to 
the importance of the resulting products in pharmaceutical and biological chemistry. The non-catalytic 
traditional synthesis methods mostly rely on nucleophilic aromatic substitutions between enolates and highly 
activated aryl halides and therefore the substrate scope of these methods is limited.[166] On the other hand, 
metal catalyzed cross-coupling reactions are well-established, which may follow two pathways depending on 
the coupling partners (Scheme 68). In most cases, palladium, nickel, and copper complexes are employed as 
catalysts which first undergo oxidative addition to activate aryl halides or pseudo aryl halides 222. Next, 
transmetalation with 226 and enolates 221 leads to formation of the second metal-carbon bond. Finally, 
reductive elimination affords arylation products 223 (pathway A).[167-169] The other pathway has been less 
exploited so far as it requires pre-activation of both the carbonyl and the aryl compounds. Here, the oxidative 
addition step takes place with racemic α-halo carbonyl compounds 225 and various arylmetal reagents 224 
may be used as aryl source (pathway B).[170-173] 
"  
Scheme 68: General catalytic cycles for the metal-catalyzed α-arylation of carbonyl compounds.[167-173] 
Apart from the cross-coupling reactions above, other methods have been developed as well. Chi and 
coworkers reported the α-arylation of α-functionalized ketones with non-activated indoles via oxyallyl cation 
intermediates 230.[174] The MacMillan group further expanded the substrate scope of this reaction by 
employing various N-, O-, F-nucleophiles (Scheme 69a).[175] Another method which enables the utilization of 
arenes without pre-activation is to employ α-diazo carbonyl compounds 211 as substrates. Various metal 
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catalysts have been proved to catalyze the degradation of diazo compounds effectively. The resulting 
carbenoids undergo C,H-insertions to give arylated products 233 (Scheme 69b).[176-180] 
"  
Scheme 69: α-Arylation of α-functionalized ketones and α-diazo carbonyl compounds.[174-180] 
In spite of the eligibility of the aforementioned methods, pre-activation of at least one of both reaction 
partners is always required. Ideally, a direct method for the α-arylation of carbonyl compounds would be 
desired. However, an obvious challenge is that both the α-postion of a carbonyl compound and most arenes 
are nucleophiles in nature and therefore a direct coupling requires an umpolung process. One pioneering 
example has been by MacMillan and co-workers with their SOMO catalysis (single occupied molecular 
orbital)[181] and is demonstrated in Scheme 70. In this reaction, octanal (58b) is coupled with N-Boc pyrrole 
(234) to afford enantioenriched product 235 with good result (85% yield, 84% ee). The authors propose that 
the key electrophilic intermediate is formed by removal of one electron from the nucleophilic enamine by 
ceric ammonium nitrate (CAN).  
"  
Scheme 70: Enantioselective intermolecular α-arylation of aldehydes via organo-SOMO catalysis.[181]  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Further investigations by MacMillan and co-workers have resulted in the development of an enantioselective 
intramolecular α-arylation of aldehydes, similar chemistry has been reported by the Nicolaou group a little 
earlier as well (Scheme 71).[182,183] 
 
Scheme 71: Enantioselective intramolecular α-arylation of aldehydes via organo-SOMO catalysis.[182,183] 
Direct C-3 alkylation of indoles with ketones has been developed using Ce(OAc)3 as catalyst and tert-butyl-
hydroperoxide (TBHP) as stoichiometric oxidant in the presence of β-cyclodextrin (β-CD) and water.[184] The 
authors propose that the catalyst is oxidized by TBHP to active species Ce(IV)=O, which then reacts with 
indoles 114 and ketones 237 to afford products 233 through oxidative C,H-activation (Scheme 72). This 
method is atom-economical and the catalytic system can be recycled and reused.  
"  
Scheme 72: Direct C-3 alkylation of indoles with ketones via oxidative C,H-bond activation.[184] 
An aerobic, transition-metal-free direct α-arylation of ketones 237a has been reported as well.[185] However, 
this method is only suited for substituted nitrobenzenes 238 as the C,C-bond formation relies on direct attack 
of the in situ generated enolates onto electron-deficient arenes 238, which is then followed by O2-mediated 
C-H oxidation to give products 239 in modest yields (Scheme 73).  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"  
Scheme 73: Oxidative direct α-arylation of ketones with substituted nitrobenzenes via aerobic oxidation.[185] 
3.3.2. Preliminary Results 
After the visible-light driven enantioselective α-alkylation of 2-acyl imidazoles with substituted benzyl and 
phenyl bromides had been successfully established (see Scheme 40), Haohua Huo investigated the reactions 
with diethyl bromomalonate (93a) as alkylation reagent. 
Table 13: Huo's results of the reactions with diethyl bromomalonate (93a) as alkylation reagent. 
"  
[a] Reaction was performed without 93a. 
Surprisingly, α-methoxy product 240ag was obtained as a racemic mixture (88% yield, 0% ee, Table 13, 
entry 1) instead of expected alkylated product 241. Switching to catalyst Λ-IrS resulted in 240ag with 18% 
ee (entry 2). Further experiments revealed that both diethyl bromomalonate (93a) and the methoxy 
substituent on the substrate’s phenyl ring are crucial for the formation of α-methoxy product 240, as the 
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Entry Catalyst 2-Acyl imidazole t Result
1 Λ-IrO 74ag 6 h 240ag, 88%, 0% ee
2 Λ-IrS 74ag 6 h 240ag, 67%, 18% ee
3[a] rac-IrO 74ag 22 h No conversion
4 rac-IrO 74aa 22 h No conversion
5 rac-IrO 74ba 22 h No conversion
6 rac-IrO 74da 22 h No conversion
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absence of diethyl bromomalonate (93a) or use of substrates 74aa, 74ba, and 74da resulted in no conversion 
of the imidazole substrates (entries 3-6). 
The formation of α-methoxy product 240ag is an intriguing observation because it indicates that the α-
position of the imidazole’s carbonyl group undergoes an umpolung process and is attacked by the 
nucleophilic solvent methanol. Based on previous studies from our lab where chiral-at-metal Lewis acids are 
employed in asymmetric photoredox catalysis,[135-137] we reasoned that malonyl radical 242 does not, as 
initially expected, add to the double bond of iridium enolate complex 77ag but oxidizes 77ag to afford α-
keto radical intermediate 244ag, which is further oxidized to α-keto carbocation 245, presumably by the 
oxidized photocatalyst (Scheme 74). This suggestion also provides a reasonable explanation for the 
importance of the methoxy substituent attached to imidazole substrate 74ag, which stabilizes α-keto 
carbocation 245ag. However, due to its positive charge, carbocation 245ag is very likely attacked by 
methanol without coordination to the chiral catalyst and therefore only low enantioselectivities are observed.  
$  
Scheme 74: Proposed mechanism for the formation of methoxy product 240. 
In order to achieve better results with this transformation, we decided to explore the potential of other 
nucleophiles to capture α-keto radical 244ag under stereocontrol. Among the evaluated nucleophiles, all of 
which are known to react with α-keto radicals,[90-95] only the reaction with 1H-indole (114a) yielded the 
desired product while methoxy product 240ag was obtained in 30-74% yield in the presence of 2-(trimethyl-
siloxy)furan (246), silyl enol ether 200, and 1,1-diphenylethylene (249). No conversion of imidazole 
substrate 74ag was observed in the reactions with allylsilane 246 and enamine 248 (Scheme 75).  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"  
Scheme 75: Evaluation of nucleophiles to couple with 2-acyl imidazole 74ag. 
Repetition of the experiment 1H-indole (114a) and enantiopure catalyst Λ-IrO afforded product 250aga in 
68% yield with 20% ee. Due to the commercial availability of diethyl bromomalonate (93a) we also tested 
the reaction with excess of 93a and to our delight, the desired product was obtained with slightly improved 
selectivity (28% ee, Scheme 76). It is worth to mention that it was not clear at the time whether the indole 
moiety was attached via its 2- or 3-position and the absolute configuration of the enantioenriched product 
was not determined. Although 250aga was the major product, a small amount of methoxy product 240ag was 
also formed.  
"  
Scheme 76: Investigation of the reaction with 1H-indole. 
In order to suppress formation of methoxy product 240ag, we performed a short solvent screening, which 
revealed that iso-propanol is the solvent of choice as no alkoxyl products were formed with it and a higher 
yield for 250aga could be obtained (79% conv. and 72% yield after 40 h, Scheme 77).  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"  
Scheme 77: Investigation of the reaction in iso-propanol. 
3.3.3. Mechanistic Investigations 
Before further optimization of the reaction conditions, we wanted to gain more insights into the mechanism 
of the reaction, because our initial mechanistic suggestions (see Scheme 74) was apparently not consistent 
with the aforementioned observations (see Scheme 75). First, it seems to be unlikely that in the presence of 
excess nucleophiles α-keto radical complex 244ag would be further oxidized to carbocation 245ag, which 
then reacts with methanol to give methoxy product 240ag. Second, in case of the reactions where no 
conversion of imidazole substrate 74ag was observed, malonyl radical 242 still did not react with the 
mentioned nucleophiles in Scheme 75. All of these observations indicate that α-keto radical complex 244ag 
and malonyl radical 242 are not formed as initially proposed. 
As mentioned, it was initially not clear whether the indolyl residue of product 250aga was connected to 2-
acyl imidazolyl moiety via its 2- or its 3-position. An two-dimensional NMR analysis of 250aga revealed 
that the indolyl residue is connected to the rest of the product via its 3-position as we observed a correlation 
signal between the NH proton and the adjacent proton in the 1H,1H-COSY spectrum (Figure 12). 
 
"  
Figure 12: 1H,1H-COSY spectrum of compound 250aga. 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Additional evidence for the proposed structure was provided by reactions with 2- and 3-substituted indoles. 
While imidazole substrate 74ag and 1,2-dimethyl-1H-indole (114b) were smoothly converted to α-arylated 
product 250agb in 69% yield only 54% conversion for 74ag was observed and methoxy product 240ag was 
obtained in 33% yield when the reaction was carried out with 3-methyl-1H-indole (114c) (Scheme 78). By 
proving the structure of product 250 we were able to conclude that it can not be a radical intermediate 244 
which reacts with 1H-indole (114a) as the 2-position would be the preferred coupling position in this case.
[186,187] In other words, it is unlikely that radical 244ag is formed in the course of the reaction. 
"  
Scheme 78: Reactions with 2- and 3-substituted indoles. 
Next, control experiments were performed in the absence of light and we found out that visible light was not 
necessary for the reaction as enantioenriched product 250aga was obtained after 15 h even with higher yield 
and ee (82% yield, 33% ee, Scheme 79). This experiment further confirms that the reaction does not proceed 
via a radical pathway as single electron transfer (SET) is hardly able to take place in the absence of light.  
"  
Scheme 79: Control experiment in the absence of light, the reaction gave improved yield and ee for 250aga. 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A hint about the reaction mechanism was given by the reaction with imidazole substrate 74aa lacking a 
methoxy substituent. After 20 h in the absence of light, substrate 74aa was converted to a mixture of 
arylated, methoxylated, and brominated products (Scheme 80). 
"  
Scheme 80: Reaction with imidazole substrate 74aa lacking a methoxy substituent. 
The formation and isolation of brominated product 251aa is intriguing because it might be an intermediate 
during the formation of 250aaa and 240aa. Indeed, when reaction was carried out with imidazole substrate 
74ag in iso-propanol in the absence of 1H-indole (114a), brominated product 251ag was again observed 
according to thin layer chromatography (TLC) of the reaction mixture after 48 h. By adding 1H-indole 
(114a) to the reaction mixture, brominated product 251ag disappeared after 7 h and arylated product 250aga 
was formed (Scheme 81 and see experimental section, Figure 25, p.125). A literature survey revealed that 
mono- or dibromo-1,3-dicarbonyl compounds are known as brominating agents.[188,189] 
"  
Scheme 81: Mechanism investigation by adding 1H-indole stepwise, α-brominated product is the 
intermediate for the formation of 250aga. 
With these informations in hand, a more accurate mechanism can be proposed: imidazole substrate 74ag first 
coordinates to the iridium center of catalyst IrO in a bidentate fashion and two acetonitrile molecules are 
released, which results in enhanced acidity of the α-proton and enolization in the presence of Na2HPO4. 
Iridium enolate complex 77ag then attacks the electrophilic bromine of diethyl bromomalonate (93a) and 
brominated product 251ag is presumably released before the Friedel-Crafts alkylation occurs. Non-
coordinating brominated product 251ag undergoes fragmentation to form α-keto cation 245ag, whose 
stability explains the reactivity difference between the substrates with and without methoxy substituent (74ag 
and 74aa) as the methoxy substituent is able to effectively stabilize the positive charge on 245ag. Finally, 
Friedel-Crafts alkylation between 245ag and 114a gives arylated product 250aga (Scheme 82). 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"  
Scheme 82: Mechanistic studies and proposal: iridium Lewis acid catalyzes the α-bromination of 2-acyl 
imidazole, which is followed by a Friedel-Crafts alkylation 
According to the low but still significant ee of the arylated product 250aga (33% ee, see Scheme 79), we 
suggest that although the aforementioned mechanism via α-keto cation 245ag is the dominant pathway for 
the conversion of 251ag to 250aga, an enantioselective pathway should exist as well. For instance, the 
bromination step should in principle proceed enantioselectively and a subsequent SN2-like Friedel-Crafts 
alkylation with enantioenriched bromide 251ag would then result in enantioenriched arylated product 
250aga going along with an inversion of the stereocenter of 251ag. Hence, it is important to determine the 
absolute configuration of enantioenriched product 250aga, in order to fully understand the reactions 
mechanism, which would allow to rationally develop asymmetric variant of this reaction.  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3.3.4. Optimization of the Reaction Conditions  
Having revealed that the α-keto cation 245ag is the key intermediate of the racemic pathway, we now 
focused on optimizing the reaction conditions to develop a racemic variant of the direct α-arylation of 2-acyl 
imidazoles. As mentioned, iso-propanol as solvent is able to effectively prevent the formation of the alkoxy 
product. However, in this solvent the reaction proceeded slower and did not run to completion (see Scheme 
77). Therefore, we synthesized 3,3-dibromopetane-2,4-dione (252) in the hope that it would be a stronger 
bromination reagent. Indeed, employing dibromide 252 led to complete conversion of 74ag in iso-propanol 
to give arylated product 250aga in 86% yield (Table 14, entry 1). It is worth mentioning that substrate 74aa 
required quantitative amounts of AgOTf to furnish 250aaa in 51% yield (entry 2). Notably, substrate with 
alkyl moiety 74bh could not be coupled with 1H-indole (114a) even in the presence of AgOTf and instead 
brominated product 251bh was obtained in 99% yield (entry 3). 
Table 14: Evaluation of 252 as brominating reagent with different imidazole substrates. 
"  
Catalyst RhO was tested in this reaction as well. However, replacement of IrO against RhO resulted in a 
lower yield (59% yield). Among all the tested solvents, which included CH3NO2, acetone, THF, DMF, 
toluene, chloroform, 1,4-dioxane, DMSO, diethyl ether, and DME, only reactions in THF and DMF led to 
complete conversion of 74ag to arylated product 250aga in 76% and 28% yield respectively (Scheme 83).  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In the absence of light
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R1 = Me, R2 = Ph: 74aa
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O O
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R1 = Me, R2 = p-MeO-Ph, R3 = 3-indolyl: 250aga
R1 = Ph, R2 = Me, R3 = Br: 251bh
Entry Imidazole substrate Additive Product (yield)
1 74ag none 250aga (86%)
2 74aa AgOTf (1.1 eq,) 250aaa (51%)
3 74bh AgOTf (1.1 eq,) 251bh (99%)
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"  
Scheme 83: Solvent screening with RhO as catalyst. 
Next, we evaluated the influence of different bases in THF and found out that 2,6-lutidine gave highest yield 
(89%, Table 15, entry 3), while cesium carbonate and amines gave low yields of 250aga (43% and 42%, 
entries 2, 4, and 5). 
Table 15: Results of base screening. 
"  
3.3.5. Evaluation of the Arene Scope 
We then explored the arene scope of the reaction using 2-acyl imidazole substrate 74ag. To our delight, the 
yield of 250agb was improved to 81% by using rhodium catalyst RhO compared to 69% with iridium 
catalyst IrO (see Scheme 78). Substituents on the 5- and 6- position of the indole ring are well-tolerated and 
both electron-rich and electron-deficient indoles could be coupled with 74ag to give products 250agd, 
74ag, 1 eq., 0.4 M           114a, 3 eq.                                                       250aga, i-PrOH: 59%
                                                                                                                                   THF: 76%
                                                                                                                                  DMF: 28%
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"67
Chapter 3. Results and Discussions
250age, and 250agf in good yields. Notably, apart from indoles, other electron-rich arenes such as benzenes 
and pyrroles are suitable arenes for the reaction (253 and 254) (Scheme 84). 
"  
Scheme 84: Arene scope of the direct α-arylation of 2-acyl imidazoles. 
3.3.6. Conclusion and Future Perspectives 
With the initial goal to use diethyl bromomalonate (93a) in a photocatalyzed asymmetric α-alkylation of 2-
acyl imidazoles, we developed a racemic variant of the rhodium Lewis acid catalyzed direct α-arylation of 2-
acyl imidazoles. According to our mechanistic studies, the reaction proceeds through a Lewis acid catalyzed 
bromination and a subsequent Friedel-Crafts alkylation. While electron-rich imidazole substrates (e.g. 74ag) 
could be used in the reaction without any problems, electron-neutral imidazoles (e.g. 74aa) already required 
the addition of a silver(I) salt to proceed the formation of the corresponding carbocation 245. The reaction 
does not work with alkyl substituted 2-acyl imidazole (e.g. 74bh), which only give brominated intermediate 
251 as product. 
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In order to make the method more attractive, further optimizations could be done in the future. As the 
method gives racemic product, the tert-butyl substituents on the catalyst are no longer necessary. The means 
that rhodium complexes 255 and 256 are probably able to catalyze the reaction as well, whose synthesis is 
much easier (Figure 13).  
"  
Figure 13: Rhodium complexes with less-complicated structure are probably able to catalyze the reaction as 
well. 
Second, the amounts of the bromination reagent and the arenes might be reduced by increase of reaction 
concentration and temperature. In addition, the synthetic value of this method could be demonstrated by 
performing the syntheses of the two endothelia antagonists UK-350,926 (257) and UK-349,862 (258).[190] 2-
Acyl imidazole 74ai seems to be a suitable substrate for the direct α-arylation method due to the electron-
rich nature of the phenyl substituent. Direct conversion of arylated products 250aig and 250aih to endothelia 
antagonists 257 and 258 should be feasible due to the existence of well-established procedures to remove the 
imidazolyl group and introduce other groups such as sulfonamide 259 (Scheme 85).[115,122,151,191,192] 
 
Scheme 85: Retrosynthesis of UK-350,926 and UK-349,862 based on the chiral-at-metal Lewis acid 
catalyzed direct α-arylation of 2-acyl imidazoles. 
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In conclusion, the chiral-at-metal iridium(III) and rhodium(III) Lewis acids have demonstrated their 
excellent configurational stability and their capacity to facilitate the enolization of 2-acyl imidazoles. Based 
on this, various α-functionalization methods for 2-acyl imidazoles could be developed with high efficiency in 
terms of both yield and enantioselectivity. In this thesis, the successful development of an asymmetric α-
alkylation with α-cyanoalkyl bromides and a racemic direct α-arylation have been described. In addition, an 
asymmetric α-benzoyloxylation has been developed which remains to be further improved (Scheme 86). As 
mechanistic studies of all these three reactions revealed, the nucleophilic metal enolate complexes are 
capable of reacting with various electrophiles directly without pre-activation. 
"  
Scheme 86: Chiral-at-metal iridium(III) and rhodium(III) catalyzed α-functionalization of 2-acyl imidazoles. 
Besides the future perspectives for these three processes which have been discussed beforehand, further 
efforts should be spent on expanding the substrate scope, especially on replacing imidazolyl by other readily 
accessible groups, in order to enable a more convenient substrate synthesis and product derivatization. For 
instance, N-acyl pyrazoles are promising as they have already been successfully employed in several 
reactions[122,138,193,194] and the reactivity of this class of compounds remains to be explored.   
As mentioned in Chapter 3.1.6 (p. 45), the mechanistic investigations of the asymmetric α-alkylation of 2-
acyl imidazoles 74 with azides 122 and α-diazoacetates 125 from the Meggers group[115] has provided useful 
informations to our current studies. Furthermore, it is impressive to see that it is actually rhodium enolate 
complex 197 that acts as a reductive quencher to initiate the reaction (Scheme 87a) and the resulting α-keto 
radical 199 was successfully captured by silyl enol ether 200 (Scheme 87b). 
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Scheme 87: Asymmetric α-alkylation of 2-acyl imidazoles with azides or diazoacetates and the experimental 
support for the existence of the α-keto radical.[115] 
This observation has the potential to lead to further applications of our chiral-at-metal Lewis acids in 
enantioselective photoredox catalysis with visible light. It will be intriguing to see whether compound 201 is 
formed with any selectivity in the presence of an enantiopure catalyst. From a mechanistic perspective, the 
formation of compound 201 is highly similar to MacMillan's SOMO-organocatalysis instead of the 
photoredox catalysis with chiral imidazolidinones. Although these two processes share several similarities, 
such as the radical nature, the resulting products (enantioenriched α-alkylated aldehydes), and the chiral 
imidazolidinone catalysts, the photoredox catalysis should not be considered as the visible-light version of 
the SOMO-organocatalysis. In case of photoredox catalysis, the active chiral intermediate is the enamine, 
which reacts with with electron-deficient radicals under stereocontrol, whereas the enamine gets oxidized in 
SOMO-organocatalysis to form a radical intermediate and reacts with various SOMO-philes (Figure 14). 
O
N
N
o-tolyl
Ph
rac-RhS (4 mol%)
[Ru(bpy)3](PF6)2 (2.5 mol%)
Na2HPO4 (20 mol%)
21 W CFL
acetone/DMSO/water
rt, 20 h
O
N
N
o-tolyl
Ph
+
Ph
OTMS
200 (5 eq.)
N3 C6F5
Ph
O
201, 42%74ca 122a
*PSPS
[Ru(bpy)3]2+
light
O
R2
N
N
R1
[RhS]
O
R2
N
N
R1
[RhS] +
e−
197 199
O
N
N
R2
R1
74 122 or 125
O
N
N
R2
R1
X R3
129, 40−99%
93−99% ee
[Ru(bpy)3](PF6)2 (2.5 mol%)
Λ/Δ-RhS (4 mol%)
 Na2HPO4 (20 mol%)
21 W CFL
acetone/DMSO/H2O, rt
+ X R3N2
Initiation of the reaction
(a)
(b)
"71
Chapter 4. Summary and Outlook
"  
Figure 14: Structures of the active intermediates for MacMillan’s photoredox catalysis and SOMO-
organocatalysis. 
MacMillan and co-workers noted this difference regarding intermediate in the asymmetric α-nitroalkylation 
of aldehydes via oxidative organocatalysis.[195] They discovered that depending on the reaction conditions, 
product 261 was formed with different diastereoselectivity (Table 16). 
Table 16: Asymmetric α-nitroalkylation of aldehydes via oxidative organocatalysis, diastereoselectivity 
varies from the reaction conditions.[195] 
"  
The authors suggested that the difference of the diastereoselectivity arises from whether enamine 99cc or 
nitronate 260 gets oxidized by ceric ammonium nitrate and through variation of the silyl protective group 
and reaction conditions, a selective oxidation can be achieved (Scheme 88). 
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Scheme 88: MacMillan and co-workers proposed that the diastereoselectivity of the reaction is determined 
by whether nitronate or enamine gets oxidized.[195] 
Although both SOMO-organocatalysis[181,195-198] and photoredox catalysis [88,98-100] with chiral 
imidazolidinones have been well-established, it is not until very recently that MacMillan and co-workers 
have successfully employed enamine radical cation in asymmetric photoredox catalysis,[199] where alkenes 
were employed as SOMO-philes to react with the enamine radical cation, the following hydrogen-atom 
transfer (HAT) with a thiolphenol catalyst and hydrolysis afforded enantioenriched alkylated aldehydes 262 
(Scheme 89).[199] 
"  
Scheme 89: MacMillan’s enantioselective α-alkylation of aldehydes by merging photoredox, enamine, and 
HAT-catalysis.[199] 
Due to the similarity between α-keto radical 199 of the enamine radical cation, the combination our chiral-at-
metal rhodium Lewis acid catalyst RhS and the photoredox catalyst [Ru(bpy)3]2+ could potentially disclose a 
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series of interesting enantioselective transformations according to MacMillan's SOMO-organo-catalysis and 
the aforementioned reaction (see Scheme 87b) serves as an excellent starting point for further investigations. 
One obvious challenge is that the chiral rhodium catalyst is not required for the bond formation step and α-
keto radical 264 could be captured without coordinating to the metal center (Scheme 90). However, this 
should be overcome by employing excess amounts of silyl enol ether 200. 
"  
Scheme 90: As the chiral rhodium catalyst is not required for the bond formation step and the possible 
release of α-keto radical 264 results in racemic reaction. 
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5.1. Methods and Materials 
General Methods for Syntheses: All air- and moisture sensitive reactions were carried out under nitrogen 
atmosphere. Glassware was heated to 630 ºC with a heat gun for 10 min under vacuum and refilled with 
moisture-free nitrogen prior to use. Room Temperature is defined as 20-22 ºC. Reactions with visible-light 
were performed by placing one or two 13-Watt Osram DULUXSTAR TWIST compact fluorescent lamps 
(CFL, 13W/840 E27, 850 Lumens) in front of the Schlenk-tubes. The distance between the lamps and the 
Schlenk-tubes was approximately 10 cm as shown in Figure 15. In the cases that reactions were performed in 
the absence of light, the Schlenk-tubes or flasks were wrapped up with aluminum foil, before the reactions 
were carried out. 
!  
Figure 15: Exemplary setup of the photoreactions with visible light.  
Solvents: The solvents for reactions were distilled from sodium/benzophenone (THF, Et2O) or calcium 
hydride (CH3CN, CH2Cl2, CHCl3, toluene, DMF). N-methyl-2-pyrrolidone (NMP) and methanol were dried 
over molecular sieves and stored under nitrogen atmosphere. HPLC-grade ethanol, iso-propanol, acetone and 
reagent grade N,N-dimethyl-acetamide (DMA), xylene, 1,2-dimethoxyethane, nitromethane, 1,4-dioxane, 
and dimethylsulfoxide (DMSO) were purchased and used without further purification. The solvents for 
extraction and chromatography were distilled on rotary evaporator at 40 °C prior to use.  
Materials: All reagents were purchased from commercial suppliers and used directly. The synthesized 
reagents were either employed directly or stored in sealed vessels at 4 ºC prior to use.  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Thin Layer Chromatography: Thin layer chromatography (TLC) was performed with aluminum TLC 
plates coated with silica gel (Merck DC Kieselgel 60 F254). The visualization of the compounds was achieved 
by either using a UV lamp (λ = 254 or 366 nm) or by immersing the developed plates in iodine stain or 
potassium permanganate dip.  
Column Chromatography: Column chromatography was performed with silica gel 60 M from Machery-
Nagel as stationary phase. Compressed air was used in order to build up pressure for flash column 
chromatography.  
Centrifugation: Centrifugation was performed on an Eppendorf Centrifuge 5810R. 
Nuclear Magnetic Resonance Spectroscopy: NMR spectra were recorded on Bruker DRX 500 (1H-NMR: 
500 MHz, 13C-NMR: 125 MHz) or Bruker AV 300 (1H-NMR: 300 MHz, 13C-NMR: 75.5 MHz) at room 
temperature. The chemical shifts δ are given in ppm (parts per million) relative to tetramethylsilane (TMS, δ 
= 0 ppm) and NMR standards for calibration are as follows: 1H-NMR: δ = 7.26 (CDCl3), 5.31 (CD2Cl2), 3.31 
(CD3OD), 2.50 (DMSO-d6); 13C-NMR: δ = 77.16 (CDCl3), 53.80 (CD2Cl2), 39.52 (DMSO-d6). Coupling 
constants J are calculated according to the recorded spectra in hertz (Hz). The multiplicities of the signals are 
described as s = single, d = doublet, t = triplet, q = quartet, m = multiplet and combinations thereof. 
Mass Spectrometry: High-resolution mass spectra (HRMS) were recorded on a Brusker En Apex Ultra 7.0 
TFT-MS(ESI+) instrument using ESI technique by the staffs of the department for mass spectrometry on the 
chemistry faculty, Philipps-University of Marburg.  
Chiral HPLC Analysis: Chiral HPLC analysis was carried out with Agilent 1200 HPLC system. Daicel 
Chiralpak AD-H column (internal diameter: 4.60 mm, length = 250 mm) and Daicel Chiralpak IC column 
(internal diameter: 4.60 mm, length = 250 mm) were used as stationary phase. As mobile phase, 
commercially available HPLC grade hexanes and i-PrOH were used directly. 
Single-Crystal X-Ray Diffraction Studies: X-ray data were collected with a Bruker D8 QUEST area 
Detektor. Measurement and evaluation of the data were performed by the staffs of the department for crystal 
structure analysis on the chemistry faculty, Philipps-University of Marburg. The obtained crystal structure 
was refined by Dr. Klaus Harms.  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5.2. Synthesis of Catalysts 
The catalysts were synthesized according to literature. To determine the absolute configuration and the 
enantiopurity of the catalysts, 1H-NMR spectra of the metal auxiliary complexes with literature. 
5-(tert-Butyl)-2-phenylbenzo[d]oxazole (265)[57] 
!  
2-Amino-4-(tert-butyl)phenol (1.65 g, 10.0 mmol) and benzaldehyde (1.00 mL, 10.0 mmol) were added to 
m-xylene (33 mL). After stirring for 0.5 h at 120 ºC, 4-methoxy-TEMPO (93.0 mg, 500 µmol) was added 
and reaction mixture was stirred at 120 ºC for 20 h in the presence of air. The mixture was cooled to rt and 
concentrated under vacuum, the residue was purified through flash column chromatography on silica gel (n-
hexane:EtOAc 20:1) to afford the product (2.04 g, 8.12 mmol, 81%) as white solid. 
1H-NMR (300 MHz; CDCl3): δ 8.26 (ddd, J = 5.4, 2.9, 1.4 Hz, 2H), 7.84 (dd, J = 1.9, 0.5 Hz, 1H), 
7.52-7.47 (m, 4H), 7.41 (dd, J = 8.6, 1.9 Hz, 1H), 1.41 (s, 9H, 3CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 163.2 (N=C-O), 148.9 (OCCN), 148.1 (C-t-Bu), 142.2 (OCCN), 131.3 
(CPh), 128.9 (2CPh), 127.6 (2CPh), 127.5 (CPh), 122.9 (OCCHC-t-Bu), 116.6 (NCCHC-t-Bu), 109.8 (OCCHC-
t-Bu), 35.0 (CMe3), 31.9 (3CH3); 
HRMS(ESI+) calcd. for C17H18NO (M + H)+ 252.1383, found: 252.1392. 
1-(Bromo)-4-(tert-butyl)-2-nitrobenzene (266)[58]
 
A mixture of HNO3 (1.40 mL, 65% in H2O) and H2SO4 (2.10 mL, 98%) was added dropwise to 1-bromo-4-
(tert-butyl)benzene (2.00 mL, 11.7 mmol) at 0 ºC. After warming to rt, the mixture was stirred at rt for 18 h, 
then quenched with ice, and extracted with n-hexane (3 × 20 mL). The organic layers were combined, dried 
over Na2SO4, and concentrated under vacuum to afford the product (3.02 g, 11.7 mmol, >99%) as pale 
yellow oil.  
1H-NMR (300 MHz; CDCl3): δ 7.83 (d, J = 2.3 Hz, 1H, t-BuCCHCNO2), 7.64 (d, J = 8.5 Hz, 1H, BrCCH), 
7.44 (dd, J = 8.5, 2.4 Hz, 1H, CHCHC-t-Bu), 1.34 (s, 9H, 3CH3).  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5-(tert-Butyl)-2-phenylbenzo[d]thiazole (267)[200] 
!  
1-Bromo-4-(tert-butyl)-2-nitrobenzene (3.02 g, 11.7 mmol), benzyl amine (3.20 mL, 29.3 mmol) and sulfur 
(562 mg, 17.6 mmol) were added to pyridine (2.4 mL) under nitrogen atmosphere. The mixture was stirred at 
100 ºC for 18 h, cooled to rt, and concentrated under vacuum. The residue was diluted with CH2Cl2 and then 
filtered over celite. The filtrate was concentrated under vacuum and the residue was purified through flash 
column chromatography on silica gel (n-hexane then n-hexane:EtOAc 40:1) to afford the product (2.12 g, 
7.93 mmol, 68%) as yellow solid. 
1H-NMR (300 MHz; CDCl3): δ 8.13 (dd, J = 1.9, 0.5 Hz, 1H), 8.10-8.08 (m, 2H), 7.84-7.81 (m, 1H), 
7.51-7.48 (m, 4H), 1.43 (s, 9H, 3CH3);
13C-NMR (75.5 MHz; CDCl3): δ 168.3 (N=C-S), 154.5 (SCCN), 150.3 (C-t-Bu), 133.9 (SCCN), 132.1 
(CPh), 131.0 (CPh), 129.1 (2CPh), 127.6 (2CPh), 123.6 (SCCHC-t-Bu), 121.1 (NCCHC-t-Bu), 119.8 (SCCHC-
t-Bu), 35.1 (CMe3), 31.7 (3CH3); 
HRMS(ESI+) calcd. for C17H18NS (M + H)+ 268.1154, found: 268.1157. 
Iridium(III) dimer derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (268)[57] 
!  
Iridium(III) chloride trihydrate (580 mg, 1.64 mmol) and 5-(tert-butyl)-2-phenylbenzo[d]oxazole (909 mg, 
3.62 mmol) were added to 2-ethoxyethanol (56.0 mL) and water (18.7 mL) under nitrogen atmosphere. The 
mixture was heated to 120 ºC under reflux for 24 h. After cooling to rt, the yellow precipitates were obtained 
through filtration and then washed with water and diethyl ether. The yellow solid (1.23 g, 844 µmol, >99%) 
were dried under air and used without further purification.  
1H-NMR (300 MHz; CD2Cl2): δ 8.31 (dd, J = 1.7, 0.7 Hz, 4H), 7.58-7.55 (m, 4H), 7.28-7.21 (m, 8H), 6.86 
(td, J = 7.4, 1.0 Hz, 4H), 6.65-6.59 (m, 4H), 6.07 (dd, J = 7.8, 0.3 Hz, 4H), 1.23 (s, 36H, 9CH3); 
13C-NMR (75.5 MHz; CD2Cl2): δ 177.0, 149.1, 148.1, 144.4, 139.8, 132.9, 131.6, 130.5, 125.7, 123.6, 
121.8, 115.1, 110.6, 35.3, 31.7. 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Iridium(III) dimer derived from 5-(tert-butyl)-2-phenylbenzo[d]thiazole (269)[58] 
!  
Iridium(III) chloride trihydrate (500 mg, 1.42 mmol) and 5-(tert-butyl)-2-phenylbenzo[d]thiazole (834 mg, 
3.12 mmol) were added to 2-ethoxyethanol (48.0 mL) and water (16.0 mL) under nitrogen atmosphere. The 
mixture was heated to 120 ºC under reflux for 24 h and then cooled to rt. The orange precipitates were 
obtained through filtration and then washed with water and diethyl ether. The orange solid (637 mg, 
419 µmol, 59%) were dried under air and used without further purification. 
1H-NMR (300 MHz; CD2Cl2): δ 8.88 (d, J = 1.7 Hz, 4H), 7.48 (dd, J = 7.6, 1.2 Hz, 4H), 7.43 (d, J = 8.5 Hz, 
4H), 7.29 (dd, J = 8.6, 1.8 Hz, 4H), 6.76 (td, J = 7.4, 1.0 Hz, 4H), 6.39 (td, J = 7.5, 1.1 Hz, 4H), 5.94 (d, J = 
7.8 Hz, 4H), 1.22 (s, 36H, 12CH3); 
13C-NMR (75.5 MHz; CD2Cl2): δ 179.3, 151.8, 150.3, 145.9, 142.2, 133.9, 129.2, 127.9, 125.4, 122.7, 
121.75, 121.67, 120.3, 35.6 (4CMe3), 31.8 (12CH3). 
Rhodium(III) dimer derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (35)[59] 
Rhodium(III) chloride trihydrate (419 mg, 2.00 mmol) and 5-(tert-butyl)-2-phenylbenzo[d]oxazole (1.03 g, 
4.10 mmol) were added to 2-ethoxyethanol (69.0 mL) and water (23.0 mL) under nitrogen atmosphere. The 
mixture was heated to 120 ºC under reflux for 24 h and then cooled to rt. The black precipitates were 
collected through centrifuge, washed with CH3OH and extracted with CH2Cl2. Evaporation of the solvent 
under vacuum afforded the product as pale yellow solid (746 mg, 584 µmol, 58%). 
1H-NMR (300 MHz; CD2Cl2): δ 8.39 (t, J = 1.2 Hz, 4H), 7.66 (dd, J = 7.6, 1.2 Hz, 4H), 7.22 (d, J = 1.0 Hz, 
8H), 6.97 (td, J = 7.4, 1.0 Hz, 4H), 6.77 (td, J = 7.6, 1.5 Hz, 4H), 6.13 (d, J = 7.8 Hz, 4H), 1.23 (s, 36H, 
12CH3); 
13C-NMR (75.5 MHz; CD2Cl2): δ 170.4, 170.3, 164.8, 164.3, 148.9, 147.9, 139.6, 139.5, 133.5, 131.20, 
131.18, 131.1, 125.4, 123.9, 123.0, 115.8, 110.4, 35.3 (4CMe3), 31.7 (12CH3).  
S
N
t-Bu
S
N
t-Bu
Ir
S
N
t-Bu
S
N
t-Bu
Ir
Cl
Cl
!79
O
N
t-Bu
O
N
t-Bu
Rh
O
N
t-Bu
O
N
t-Bu
Rh
Cl
Cl
Chapter 5. Experimental Section
Racemic iridium(III) Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (rac-IrO, 
60)
 
Iridium dimer 268 (500 mg, 343 mmol) and AgPF6 (191 mg, 755 mmol) were added to acetonitrile (114 mL) 
under nitrogen atmosphere. The mixture was stirred at 50 ºC for 18 h and then cooled to rt. After evaporating 
the solvent under vacuum, the residue was purified through flash column chromatography on silica gel 
(CH2Cl2:CH3CN 30:1) to afford the product as yellow solid (630 mg, 685 µmol, >99%). 
1H-NMR (300 MHz; CD2Cl2): δ 7.77 (dd, J = 1.8, 0.6 Hz, 2H), 7.69-7.60 (m, 6H), 6.92 (td, J = 7.5, 1.1 Hz, 
2H), 6.76 (td, J = 7.5, 1.5 Hz, 2H), 6.30-6.27 (m, 2H), 2.35 (s, 6H, 2CNCH3), 1.38 (s, 18H, 2C(CH)3); 
13C-NMR (75.5 MHz; CD2Cl2): δ 177.3, 151.1, 148.7, 142.0, 138.3, 132.9, 132.6, 130.0, 126.2, 125.0, 
123.6, 120.8, 112.9, 111.9, 35.6, 31.7, 3.8; 
HRMS(ESI+) calcd. for C38H38IrN4O2 (M+) 775.2621, found: 775.2659. 
Racemic rhodium(III) Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (rac-
RhO, 70)
 
Rhodium dimer  35 (128 mg, 100 µmol) and AgPF6 (55.6 mg, 220 µmol) were added to CH3CN (33.3 mL) 
under nitrogen atmosphere. The mixture was stirred at 50 ºC for 18 h and then cooled to rt. After evaporating 
the solvent under vacuum,  the residue was purified through column chromatography on silica gel (CH2Cl2 
then CH2Cl2:CH3CN 20:1) to afford the product as pale yellow solid (167 mg, 201 µmol, >99%). 
1H-NMR (300 MHz; CD2Cl2): δ 7.88 (s, 2H), 7.77-7.67 (m, 6H), 7.08 (td, J = 7.5, 1.0 Hz, 2H), 6.93 (td, J = 
7.6, 1.5 Hz, 2H), 6.39 (d, J = 7.9 Hz, 2H), 2.30 (s, 6H), 1.46 (s, 18H); 
13C-NMR (75 MHz; CD2Cl2): δ 168.8, 148.4, 146.1, 135.4, 130.73, 130.69, 129.63, 129.62, 127.9, 123.6, 
122.5, 121.9, 110.7, 109.2, 33.0, 29.1. 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Racemic rhodium(III) Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]thiazole (rac-
RhS, 71)[60]
 
Rhodium(III) chloride trihydrate (100 mg, 478 µmol) and 5-(tert-butyl)-2-phenylbenzo[d]thiazole (307 mg, 
478 µmol) were added to 2-ethoxyethanol (4.80 mL) under nitrogen atmosphere. The mixture was stirred at 
125 ºC. A dark red solution was formed after 2 h and yellow precipitates were observed after 15 h. The 
mixture was cooled to rt and filtered. The residue was washed with water, dried under air to afford orange 
solid (177 mg), which were then added to acetonitrile (41.0 mL) and AgPF6 (73.4 mg, 290 µmol). After 
stirring at 50 ºC for 18 h, the mixture was concentrated under vacuum and the residue was purified through 
flash column chromatography on silica gel (CH2Cl2 then CH2Cl2:CH3CN 20:1) to afford the product as pale 
yellow solid (50.0 mg, 58.0 µmol, 12% over 2 steps).   
1H-NMR (300 MHz; CD2Cl2): δ 8.49 (s, 2H), 8.01 (d, J = 8.6 Hz, 2H), 7.71 (dd, J = 8.6, 1.8 Hz, 2H), 7.66 
(dd, J = 7.6, 1.2 Hz, 2H), 7.03 (td, J = 7.5, 0.9 Hz, 2H), 6.83 (td, J = 7.6, 1.3 Hz, 2H), 6.20 (d, J = 7.7 Hz, 
2H), 2.17 (s, 6H), 1.45 (s, 18H); 
13C-NMR (75.5 MHz; CD2Cl2): δ 176.8, 152.9, 150.0, 140.4, 133.5, 131.3, 129.1, 126.2, 125.5, 124.5, 
122.9, 117.0, 35.6, 31.6, 3.6; 
MS(ESI+) found: 635.7626, C34H32N2RhS2 (M - 2CH3CN)+. 
Λ/Δ-(S)-Iridium auxiliary complex derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (270)[57] 
 
Iridium  dimer  268 (250 mg, 172 µmol) and (S)-2-(4-isopropyl-4,5-dihydrothiazol-2-yl)phenol (102 mg, 
429 µmol) were added to ethanol (17.2 mL) under nitrogen atmosphere. After adding triethylamine (238 µL, 
1.72 mmol), the mixture was stirred at 95 ºC for 24 h. The homogeneous solution was cooled to rt and kept at 
rt without stirring for further 24 h, during which yellow precipitates were formed. The precipitates were 
obtained through filtration and identified as complex Δ-(S)-270 (109 mg, 119 µmol, 35%) by comparing its 
1H-NMR data to literature.[57] The filtrate was concentrated under vacuum and purified through column 
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chromatography on silica gel (CH2Cl2:n-hexane 2:1) to afford complexes Δ-(S)-270 (41.0 mg, 44.9 µmol, 
13%) and Λ-(S)-265 (153 mg, 168 µmol, 49%) respectively. 
Λ-(S)-270: 
1H-NMR (300 MHz; CD2Cl2): δ 7.96 (d, J = 1.5 Hz, 1H), 7.70 (dd, J = 7.6, 0.8 Hz, 1H), 7.65-7.55 (m, 3H), 
7.52-7.47 (m, 3H), 7.44 (dd, J = 1.8, 0.5 Hz, 1H), 7.14 (ddd, J = 8.6, 6.8, 1.8 Hz, 1H), 6.97-6.82 (m, 3H), 
6.79-6.73 (m, 2H), 6.70-6.67 (m, 1H), 6.37 (dd, J = 7.6, 0.5 Hz, 1H), 6.28 (s, 1H), 4.72 (ddd, J = 9.8, 2.6, 
1.7 Hz, 1H), 3.38 (dd, J = 11.6, 9.8 Hz, 1H), 3.01 (dd, J = 11.7, 1.6 Hz, 1H), 1.45 (s, 9H), 1.19 (s, 9H), 0.23 
(d, J = 7.0 Hz, 3H), 0.15 (d, J = 7.0 Hz, 3H). 
Δ-(S)-270: 
1H-NMR (300 MHz; CD2Cl2): δ 7.96 (d, J = 1.9 Hz, 1H), 7.73-7.60 (m, 3H), 7.55-7.49 (m, 2H), 7.44 (dd, J 
= 7.1, 1.7 Hz, 2H), 7.37 (dd, J = 8.0, 1.7 Hz, 1H), 7.02 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 6.95-6.88 (m, 2H), 
6.84-6.73 (m, 3H), 6.60 (dd, J = 8.5, 0.6 Hz, 1H), 6.47-6.44 (m, 1H), 6.32-6.27 (m, 1H), 3.63 (dd, J = 8.3, 
1.6 Hz, 1H), 2.91 (dd, J = 11.3, 1.9 Hz, 1H), 2.68 (t, J = 10.6 Hz, 1H), 2.14 (dtd, J = 13.7, 6.8, 1.4 Hz, 1H), 
1.27 (s, 9H), 1.19 (s, 9H), 1.06 (d, J = 6.8 Hz, 3H), 0.05 (d, J = 7.0 Hz, 3H). 
Λ-L-Rhodium prolinate complex derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (37)[59] 
!
Sodium methoxide (16.2 mg, 300 µmol) was dissolved in CH3OH (16.0 mL) and L-proline (34.5 mg, 
300 µmol) was added in one portion. The mixture was stirred at rt under nitrogen atmosphere for 10 min and 
then rhodium dimer 35 (201 mg, 150 µmol) was added. The mixture was stirred at 50 ºC for 12 h and then 
cooled to rt. CH2Cl2 (16.0 mL) was added and the reaction mixture was stirred at rt for further 12 h. The 
solvent was removed by evaporation and the residue was taken up with CH2Cl2/Et2O (5.00 mL, v/v 1:6), the 
precipitates were obtained through centrifuge and then washed with CH2Cl2/Et2O (3 × 5.00 mL, v/v 1:6) to 
afford the product (87.2 mg, 112 µmol, 42%) as pale yellow solid.
1H-NMR (300 MHz; CD2Cl2): δ 8.09 (d, J = 1.9 Hz, 1H), 7.76 (dd, J = 7.5, 1.5 Hz, 2H), 7.72-7.69 (m, 1H), 
7.66-7.54 (m, 3H), 7.29 (d, J = 1.6 Hz, 1H), 7.02 (tdd, J = 7.4, 2.8, 1.1 Hz, 2H), 6.93-6.87 (m, 2H), 6.69 (d, 
J = 7.7 Hz, 1H), 6.42 (d, J = 7.6 Hz, 1H), 4.23-4.10 (m, 2H), 2.68 (s, 1H), 2.18-1.95 (m, 4H), 1.34 (s, 9H), 
1.37 (s, 9H). 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Λ/Δ-(S)-Rhodium auxiliary complex derived from 5-(tert-butyl)-2-phenylbenzo[d]thiazole (39)[60] 
!    !  
rac-RhS (230 mg, 267 µmol), (S)-3-fluoro-2-(4-phenyl-4,5-dihydrooxazol-2-yl)phenol (75.4 mg, 293 µmol), 
and K2CO3 (73.7 mg, 533 µmol) were added to ethanol (13.4 mL) under nitrogen atmosphere and the 
mixture was stirred at 70 ºC for 18 h. After cooling to rt, the reaction mixture was filtered over celite and the 
precipitates were washed with CH2Cl2. The filtrate was concentrated under vacuum and the residue was 
taken up with EtOH/n-hexane (30.0 mL, v/v 1:1). The precipitates were obtained through centrifuge and 
washed with EtOH/n-hexane (4 × 15.0 mL, v/v 1:1) to afford complex Λ-(S)-39 as yellow solid (120 mg, 
135 µmol, 50%). The filtrate was purified through column chromatography on silica gel (n-hexane:EtOAc 
5:1) to give complex Δ-(S)-39 complex as yellow solid (115 mg, 130 µmol, 48%). 
Λ-(S)-39: 
1H-NMR (300 MHz; CD2Cl2): δ  8.89 (d, J = 1.9 Hz, 1H), 7.96 (d, J = 1.8 Hz, 1H), 7.79 (d, J = 8.6 Hz, 1H), 
7.60 (d, J = 8.6 Hz, 2H), 7.52 (dd, J = 8.6, 1.8 Hz, 1H), 7.45 (dd, J = 8.6, 1.9 Hz, 1H), 7.41-7.38 (m, 1H), 
6.99-6.68 (m, 9H), 6.37-6.30 (m, 3H), 5.87 (d, J = 7.7 Hz, 1H), 5.79 (dd, J = 12.3, 7.3 Hz, 1H), 4.85 (d, J = 
4.7 Hz, 2H), 3.99 (d, J = 4.4 Hz, 1H), 1.44 (s, 9H), 1.27 (s, 9H). 
Δ-(S)-39: 
1H-NMR (300 MHz; CD2Cl2): δ 9.06 (s, 1H), 8.37 (s, 1H), 7.92 (dd, J = 8.5, 1.8 Hz, 1H), 7.78 (dd, J = 8.3, 
1.9 Hz, 1H), 7.59 (t, J = 8.5 Hz, 2H), 7.50 (d, J = 8.6 Hz, 1H), 7.18 (d, J = 7.6 Hz, 1H), 6.97-6.70 (m, 8H), 
6.56 (t, J = 7.4 Hz, 1H), 6.40 (t, J = 7.4 Hz, 1H), 6.26 (dd, J = 14.0, 8.4 Hz, 2H), 6.15 (d, J = 7.3 Hz, 1H), 
5.80 (t, J = 9.8 Hz, 1H), 4.32-4.27 (m, 1H), 4.07-4.00 (m, 1H), 3.92 (dd, J = 11.5, 8.3 Hz, 1H), 1.37 (s, 9H), 
1.23 (s, 9H); 
13C-NMR (75.5 MHz; CD2Cl2): δ 176.6, 167.1, 152.6, 151.3, 140.6, 138.8, 135.3, 133.5, 132.9, 132.7, 
130.1, 129.5, 128.2, 127.7, 127.4, 126.0, 125.7, 124.5, 124.4, 123.1, 122.2, 122.1, 122.0, 119.3, 118.9, 117.4, 
98.7, 98.4, 75.0, 70.3, 35.6, 35.4, 31.6, 31.5. 
Cleavage of the Chiral Auxiliary  
General procedure 1 
To the auxiliary complex (1.00 eq.) solution in acetonitrile (10.0 mM) was added trifluoroacetic acid (5.0 eq.) 
under nitrogen atmosphere. The reaction mixture was stirred at rt in the absence of light for 2 h and then 
concentrated under vacuum. The residue was taken up with CH2Cl2 and then NH4PF6 (30.0 eq.) was added. 
The mixture was stirred at rt and the anion exchange was monitored by TLC analysis. After complete 
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conversion, solvent was evaporated under vacuum and the residue was purified through flash column 
chromatography on silica gel to afford the enantiomeric pure Lewis acid catalysts. 
Λ-Iridium Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (Λ-IrO, 60)[57]
   
Iridium auxiliary complex Λ-(S)-270 (227 mg, 249 µmol) was converted to Λ-IrO (203 mg, 222 μmol, 89%) 
according to general procedure 1. The 1H-NMR data was consistent with the racemic compound. 
Λ-Iridium Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]thiazole (Λ-IrS, 64)[58]
 
Λ-(S)-Iridium auxiliary complex (217 mg, 230 µmol) was converted to Λ-IrS (215 mg, 225 μmol,  98%) 
according to general procedure 1. 
1H-NMR (300 MHz; CD2Cl2): δ 8.41 (d, J = 1.7 Hz, 2H), 8.01 (d, J = 8.6 Hz, 2H), 7.72 (dd, J = 8.6, 1.8 Hz, 
2H), 7.66 (dd, J = 7.7, 0.9 Hz, 2H), 6.95 (td, J = 7.5, 1.0 Hz, 2H), 6.73 (td, J = 7.5, 1.4 Hz, 2H), 6.17 (dd, J = 
7.7, 0.4 Hz, 2H), 2.34 (s, 6H), 1.46 (s, 18H); 
13C-NMR (75.5 MHz; CD2Cl2): δ 181.3, 153.0, 150.3, 142.7, 141.1, 132.9, 131.5, 128.7, 126.1, 125.4, 
123.6, 123.1, 121.6, 116.7, 35.6, 31.7, 4.0; 
HRMS(ESI+) calcd. for C38H38IrN4S2 (M+) 807.2160, found: 807.2184.  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Λ-Rhodium Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]oxazole (Λ-RhO, 70)[59] 
!  
Rhodium prolinate complex Λ-L-37 (146 mg, 204 µmol) and NH4PF6 (333 mg, 2.04 mmol) were added to 
acetonitrile (41.0 mL) under nitrogen atmosphere and stirred at 50 ºC in the absence of light for 18 h. After 
cooling to rt, the mixture was concentrated under vacuum and the residue was purified through flash column 
chromatography on silica gel (CH2Cl2 then CH2Cl2:CH3CN 20:1) to afford the product as pale yellow solid 
(154 mg, 175 µmol, 86%). The 1H-NMR data was consistent with the racemic compound. 
Λ-Rhodium Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]thiazole (Λ-RhS, 71)[60]
 
Rhodium auxiliary complex Λ-(S)-39 (120 mg, 135 µmol) were dissolved in acetonitrile (7.00 mL) and then 
trifluoroacetic acid (51.5 µL, 673 µmol) was added in one portion. The reaction mixture was stirred at rt for 
1 h. Excess NH4PF6 was added. The mixture was stirred at rt for further 10 min and then filtered over a silica 
pad (CH2Cl2:CH3CN 20:1). The filtrate was concentrated under vacuum and dissolved in CH2Cl2. Excess 
NH4PF6 was added again and the anion exchange was monitored by TLC-analysis. After complete 
conversion, the mixture was concentrated under vacuum and the residue was purified through flash column 
chromatography on silica gel (CH2Cl2:CH3CN 20:1) to afford the catalysts Λ-RhS (47.1 mg, 54.6 µmol, 
40%). 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Δ-Rhodium Lewis acid catalyst derived from 5-(tert-butyl)-2-phenylbenzo[d]thiazole (Δ-RhS, 71)[60] 
!  
Rhodium auxiliary complex Δ-(S)-39 (115 mg, 129 µmol) were dissolved in acetonitrile (6.50 mL) and then 
trifluoroacetic acid (49.4 µL, 645 µmol) was added in one portion. The reaction mixture was stirred at rt for 
1 h. Excess NH4PF6 was added. The mixture was stirred at rt for further 10 min and then filtered over a silica 
pad (CH2Cl2:CH3CN 20:1). The filtrate was concentrated under vacuum and dissolved in CH2Cl2. Excess 
NH4PF6 was added again and the anion exchange was monitored by TLC-analysis. After complete 
conversion, the mixture was concentrated under vacuum and the residue was purified through flash column 
chromatography on silica gel (CH2Cl2:CH3CN 20:1) to afford the catalysts Δ-RhS (62.8 mg, 72.8 µmol, 
56%). 
Iridium dimer derived from 2-phenylpyridine (271)[201] 
!  
Iridium(III) chloride trihydrate (500 mg, 1.42 mmol) and 2-phenylpyridine (446 µL, 3.12 mmol) were added 
to 2-ethoxyethanol (48.0 mL) and water (16.0 mL) under nitrogen atmosphere. The mixture was heated to 
120 ºC under reflux for 24 h and then cooled to rt. The precipitates were obtained through filtration and then 
washed with water and diethyl ether. The yellow solid (480 mg, 451 µmol, 63%) were dried under air and 
used without further purification. 
1H-NMR (300 MHz; CD2Cl2): δ 9.25 (ddd, J = 5.8, 1.5, 0.7 Hz, 4H), 7.93 (d, J = 7.8 Hz, 4H), 7.79 (ddd, J = 
8.1, 7.4, 1.6 Hz, 4H), 7.55 (dd, J = 7.8, 1.3 Hz, 4H), 6.84-6.78 (m, 8H), 6.60 (td, J = 7.5, 1.2 Hz, 4H), 5.87 
(dd, J = 7.8, 0.8 Hz, 4H); 
13C-NMR (75.5 MHz; CD2Cl2): δ 168.5, 151.9, 145.3, 144.4, 137.0, 130.8, 129.5, 124.1, 123.0, 121.8, 
119.1. 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fac-Tris(2-phenylpyridinato-C2,N)iridium(III) [fac-Ir(ppy)3] (91)[201] 
!  
Iridium dimer 271 (216 mg, 201 µmol) and 2-phenylpyridine (144 µL, 1.01 mmol) were added to 2-
ethoxyethanol (38.8 mL) under nitrogen atmosphere. After adding AgPF6 (104 mg, 403 µmol), the mixture 
was heated to 200 ºC for 24 h and then cooled to rt. Water was added and precipitates were collected through 
filtration, washed with CH3OH, diethyl ether and n-hexane. The residue was purified through flash column 
chromatography on silica gel (CH2Cl2:CH3OH 10:1) to afford the product (201 mg, 307 µmol, 76%) as 
yellow solid.  
1H-NMR (300 MHz; CD2Cl2): δ 7.91 (d, J = 8.2 Hz, 3H), 7.68-7.61 (m, 6H), 7.56 (ddd, J = 5.5, 1.6, 0.9 Hz, 
3H), 6.94-6.85 (m, 6H), 6.81-6.72 (m, 6H); 
13C-NMR (75.5 MHz; CD2Cl2): δ 166.9, 161.4, 147.6, 144.2, 137.2, 136.6, 130.1, 124.4, 122.5, 120.3, 
119.3;
HRMS(ESI+) calcd. for C33H24IrN3Na (M + Na)+ 678.1493, found: 678.1501. 
Iridium photoredox catalyst [Ir(ppy)2(dtbbpy)]PF6 (89·PF6)[202] 
!  
Iridium dimer 271 (200 mg, 187 µmol), AgPF6 (104 mg, 410 µmol), and 4,4’-di-tert-butyl-2,2’-bipyridine 
(125 mg, 466 µmol) were added to CH2Cl2 (18.7 mL) under nitrogen atmosphere. The mixture was stirred at 
rt for 4 h. After evaporating the solvent under vacuum, the residue was purified through flash column 
chromatography on silica gel (CH2Cl2:CH3CN 20:1) to afford the product as yellow solid (311 mg, 
340 µmol, 91%). 
1H-NMR (300 MHz; CD2Cl2): δ 8.28 (d, J = 1.7 Hz, 2H), 7.95 (dd, J = 7.8, 0.6 Hz, 2H), 7.90 (d, J = 5.8 Hz, 
2H), 7.79 (ddd, J = 8.2, 7.4, 1.5 Hz, 2H), 7.73 (dd, J = 7.7, 1.2 Hz, 2H), 7.51 (ddd, J = 5.8, 1.5, 0.7 Hz, 2H), 
7.43 (dd, J = 5.9, 1.9 Hz, 2H), 7.09-6.99 (m, 4H), 6.93 (td, J = 7.4, 1.4 Hz, 2H), 6.30 (dd, J = 7.6, 0.8 Hz, 
2H), 1.42 (s, 18H); 
13C-NMR (75.5 MHz; CD2Cl2): δ 168.3, 164.5, 156.0, 150.7, 149.0, 144.1, 138.5, 132.0, 131.1, 126.0, 
125.2, 123.6, 123.0, 121.3, 120.2, 36.0, 30.4; 
HRMS(ESI+) calcd. for C40H40IrN4 (M+) 769.2879. found: 769.2909.  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5.3. Synthesis of Catalysis Substrates 
1-Methyl-1H-imidazole (272a) and 1-isopropyl-1H-imidazole (272d) are commercially available and were 
employed directly, whereas 1-phenyl-1H-imidazoles (272b) and 1-(o-tolyl)-1H-imidazole (272c) were 
synthesized according to literature.[203] Weinreb-amides 273 and 2-acyl imidazoles 74 were synthesized 
according to the procedures published by our group recently.[137,138,151]   
5.3.1. Synthesis of 1H-Imidazoles 
1-Phenyl-1H-imidazole (272b) 
!  
1H-Imidazole (1.02 g, 15 mmol), phenyl iodide (897 µL, 10.0 mmol), Cu2O (143 mg. 1.00 mmol), and KOH 
(1.32 g, 20.0 mmol, 85% w/w) were added to DMSO (20.0 mL). The mixture was bubbled with argon at rt 
for 30 min. Under argon atmosphere, the degassed mixture was stirred at 130 ºC for 24 h. After cooling to rt, 
the dark blue reaction mixture was filtered over silica gel and washed with ethyl acetate. The filtrate was 
then taken up by water (100 mL) and ethyl acetate (100 mL). The aqueous layer was extracted with ethyl 
acetate (3 × 50 mL). The organic layers were combined, dried over Na2SO4, filtered, and concentrated under 
vacuum. The residue was purified through flash column chromatography on silica gel (n-hexane:EtOAc 1:2) 
to afford the product (1.20 g, 8.32 mmol, 83%) as pale yellow oil. 
1H-NMR (300 MHz; CDCl3): δ 7.89 (s, 1H, N=CHN), 7.52-7.47 (m, 2H, HPh), 7.42-7.35 (m, 3H, HPh), 
7.29-7.30 (m, 1H, CHN=C), 7.22 (s, 1H, CHNPh); 
13C-NMR (75.5 MHz; CDCl3): δ 137.4 (CHNC), 135.5 (NCHNPh), 130.4 (CHN=C), 129.8 (2CPh), 127.4 
(CPh), 121.4 (2CPh), 118.2 (CHNPh); 
HRMS(ESI+) calcd. for C9H9N2 (M + H)+ 145.0760, found: 145.0764. 
1-(o-Tolyl)-1H-imidazole (272c) 
!  
1H-Imidazole (3.06 g, 45.0 mmol), o-tolyl iodide (3.80 mL, 30.0 mmol), KOH (4.36 g, 66.0 mmol, 85% w/
w), and Cu2O (429 mg, 3.00 mmol) were added to DMSO (60.0 mL). The reaction mixture was degassed by 
being bubbled with argon for 30 min at rt. After stirring at 130 ºC for 18 h and then cooling to rt, the mixture 
was poured onto water and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were 
dried over Na2SO4 and filtered over celite. The solvent was evaporated under vacuum and the residue was 
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purified through flash column chromatography on silica gel (n-hexane:EtOAc 2:1) to afford the product 
(3.85 g, 24.3 mmol, 81%) as yellow oil. 
1H-NMR (300 MHz; CDCl3): δ 7.62 (s, 1H, N=CH-N), 7.36-7.34 (m, 3H, CH=N-CH + 2Ho-tolyl), 7.24-7.22 
(m, 2H, 2Ho-tolyl), 7.07 (s, 1H, CHN-o-tolyl), 2.19 (s, 3H, CH3). 
5.3.2. Synthesis of Weinreb-Amides 
Depending on the commercially available starting materials, Weinreb-amides 273 were synthesized through 
two different procedures. 
General Procedure 2A 
!  
N,O-Dimethylhydroxylamine hydrochloride (537 mg. 5.50 mmol) and pyridine (1.00 mL, 12.5 mmol) were 
dissolved in CH2Cl2 (10.0 mL) and cooled to 0 ºC. Acyl chloride (5.00 mmol) was added dropwise under 
nitrogen atmosphere. The solution was stirred at 0 ºC for 30 min and then at rt for 1 h. The solution was 
diluted with ethyl acetate (50.0 mL) and washed with aq. HCl (1 M, 3 × 10.0 mL), saturated aq. NaHCO3 
solution (3 × 10.0 mL), and brine (1 × 20.0 mL). The organic layer was dried over Na2SO4 and concentrated 
under vacuum. The residue was purified through flash column chromatography on silica gel (n-
hexane:EtOAc) to afford the product. 
General Procedure 2B 
!  
N,O-Dimethylhydroxylamine hydrochloride (537 mg. 5.50 mmol), carboxylic acid (5.00 mmol), and 4-
dimethylaminopyridine (61.1 mg, 500 µmol) were dissolved in CH2Cl2 (25.0 mL) and cooled to 0 ºC. 
Triethylamine (927 µL, 6.65 mmol) and ethylcarbodiimide hydrochloride (1.25 g, 6.50 mmol) were added at 
0 ºC successively. After being stirred at 0 ºC for 1 h under nitrogen atmosphere, the reaction solution was 
warmed to rt and stirred for further 16 h. The solution was diluted with ethyl acetate (50.0 mL) and washed 
with aq. HCl (1 M, 3 × 10.0 mL), saturated aq. NaHCO3 solution (3 × 10.0 mL), and brine (1 × 20.0 mL). 
The organic layer was dried over Na2SO4 and concentrated under vacuum. The residue was purified through 
flash column chromatography on silica gel (n-hexane:EtOAc) to afford the product.  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N-Methoxy-N-methyl-2-phenylacetamide (273a) 
!  
Following general procedure 2A, 2-phenylacetyl chloride (3.00 mL, 22.7 mmol) was converted to Weinreb-
amide 273a (4.04 g, 22.5 mmol, 99%).  
1H-NMR (300 MHz; CDCl3): δ 7.30-7.17 (m, 5H, 5HPh), 3.73 (s, 2H, O=CCH2), 3.54 (t, J = 1.1 Hz, 3H, 
OCH3), 3.14-3.13 (m, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 172.2 (O=C), 134.9, (O=CCH2C), 129.2 (2CPh), 128.3 (2CPh), 126.6 (CPh), 
61.1 (OCH3), 39.3 (O=CCH2), 32.1 (NCH3); 
HRMS(ESI+) calcd. for C10H13NO2Na (M + Na)+ 202.0838, found: 202.0839. 
N-Methoxy-N-methyl-2-(p-tolyl)acetamide (273b) 
!  
Following general procedure 2B, 2-(p-tolyl)acetic acid (751 mg, 5.00 mmol) was converted to Weinreb-
amide 273b (948 mg, 4.91 mmol, 98%). 
1H-NMR (300 MHz; CDCl3): δ 7.17 (d, J = 8.1 Hz, 2H, 2Hp-tolyl), 7.11 (d, J = 8.0 Hz, 2H, 2Hp-tolyl), 3.71 (s, 
2H, O=CCH2), 3.57 (s, 3H, OCH3), 3.16 (s, 3H, NCH3), 2.31 (s, 3H, CCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 172.3 (O=C), 136.0 (CCH3), 131.7 (O=CCH2C), 129.0 (4Cp-tolyl), 61.0 
(OCH3), 38.8 (O=CCH2), 32.1 (NCH3), 20.8 (CCH3); 
HRMS(ESI+) calcd. for C11H16NO2 (M + H)+ 194.1176, found: 194.1176. 
2-(4-Bromophenyl)-N-methoxy-N-methylacetamide (273c) 
!  
Following general procedure 2B, 2-(4-bromophenyl)acetic acid (1.08 g, 5.00 mmol) was converted to 
Weinreb-amide 273c (1.29 g, 5.00 mmol, >99%). 
1H-NMR (300 MHz; CDCl3): δ 7.43-7.38 (m, 2H, 2Hp-Br-Ph), 7.16-7.12 (m, 2H, 2Hp-Br-Ph), 3.69 (s, 2H, 
O=CCH2), 3.60 (s, 3H, OCH3), 3.16 (s, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 171.7 (O=C), 133.9 (CBr), 131.5 (2Cp-Br-Ph), 131.1 (2Cp-Br-Ph), 120.7 
(O=CCH2C), 61.3 (OCH3), 38.7 (O=CCH2), 32.3 (NCH3);  
HRMS(ESI+) calcd. for C10H12BrNO2Na (M + Na)+ 281.9924, found: 281.9927.  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N-Methoxy-N-methyl-2-(4-nitrophenyl)acetamide (273d) 
!  
Following general procedure 2B, 2-(4-nitrophenyl)acetic acid (906 mg, 5.00 mmol) was converted to 
Weinreb-amide 273d (1.11 g, 4.95 mmol, 99%). 
1H-NMR (300 MHz; CDCl3): δ 8.12-8.07 (m, 2H, 2Hp-nitro-Ph), 7.43-7.38 (m, 2H, 2Hp-nitro-Ph), 3.83 (s, 2H, 
O=CCH2), 3.65 (s, 3H, OCH3), 3.15 (s, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 170.6 (O=C), 146.9 (CNO2), 142.6 (O=CCH2C), 130.4 (2Cp-nitro-Ph), 123.5 
(2Cp-nitro-Ph), 61.4 (OCH3), 38.8 (O=CCH2), 32.2 (NCH3); 
HRMS(ESI+) calcd. for C10H12N2O4Na (M + Na)+ 247.0689, found: 247.0691. 
2-(2-Chlorophenyl)-N-methoxy-N-methylacetamide (273e) 
!  
Following general procedure 2B, 2-(2-chlorophenyl)acetic acid (853 mg, 5.00 mmol) was converted to 
Weinreb-amide 273e (1.06 g, 4.96 mmol, 99%). 
1H-NMR (300 MHz; CDCl3): δ 7.34-7.31 (m, 1H, Ho-Cl-Ph), 7.26-7.23 (m, 1H, Ho-Cl-Ph), 7.20-7.13 (m, 2H, 
2Ho-Cl-Ph), 3.86 (s, 2H, O=CCH2), 3.63 (t, J = 1.6 Hz, 3H, OCH3), 3.16 (t, J = 1.3 Hz, 3H, NCH3);  
13C-NMR (75.5 MHz; CDCl3): δ 171.1 (O=C), 134.2 (CCl), 133.1 (O=CCH2C), 131.3 (Co-Cl-Ph), 129.2 (Co-Cl-
Ph), 128.1 (Co-Cl-Ph), 126.6 (Co-Cl-Ph), 61.1 (OCH3), 36.8 (O=CCH2), 32.2 (NCH3); 
HRMS(ESI+) calcd. for C10H12ClNO2Na (M + Na)+ 236.0449, found: 236.0450. 
N-Methoxy-N-methylbutyramide (273f) 
!  
Following general procedure 2A, butyric chloride (522 µL, 5.00 mmol) was converted to Weinreb-amide 
273f (386 mg, 2.94 mmol, 59%). The product is volatile.
1H-NMR (300 MHz; CDCl3): δ 3.60 (t, J = 0.6 Hz, 3H, OCH3), 3.09 (s, 3H, NCH3), 2.31 (t, J = 7.5 Hz, 2H, 
O=CCH2), 1.64-1.51 (m, 2H, CH2CH3), 0.88 (td, J = 7.4, 0.7 Hz, 3H, CH2CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 174.5 (O=C), 61.1 (OCH3), 33.8 (O=CCH2), 32.2 (NCH3), 18.0 (CH2CH3), 
13.9 (CH2CH3); 
HRMS(ESI+) calcd. for C6H13NO2Na (M + Na)+ 154.0838, found: 154.0839.  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N-Methoxy-2-(4-methoxyphenyl)-N-methylacetamide (273g) 
!  
Following general procedure 2A, 2-(4-methoxyphenyl)acetyl chloride (3.00 mL, 19.6 mmol) was converted 
to Weinreb-amide 273g (3.99 g, 19.1 mmol, 97%). 
1H-NMR (300 MHz; CDCl3): δ 7.20 (d, J = 8.7 Hz, 2H, Hp-MeO-Ph), 6.84 (d, J = 8.7 Hz, 2H, Hp-MeO-Ph), 3.76 
(d, J = 1.4 Hz, 3H, CH3ON), 3.69 (s, 2H, O=CCH2), 3.59 (d, J = 1.2 Hz, 3H, CH3OC), 3.16 (d, J = 1.2 Hz, 
3H, CH3N); 
13C-NMR (75.5 MHz; CDCl3): δ 172.7 (C=O), 156.5 (COCH3), 130.3 (2Cp-MeO-Ph), 127.0 (O=CCH2C), 
114.0 (2Cp-MeO-Ph), 61.3 (CH3ON), 55.3 (CH3OC), 38.5 (O=CCH2), 32.3 (CH3N);  
HRMS(ESI+) calcd. for C11H15NO3Na (M + Na)+ 232.4953, found: 232.0948.
N-Methoxy-N-methylpropionamide (273h) 
!  
Following general procedure 2B, propionic acid (748 µL, 10.0 mmol) was converted to Weinreb-amide 273h 
(837 mg, 7.14 mmol, 71%). The product is volatile. 
1H-NMR (300 MHz; CDCl3): δ 3.68 (s, 3H, OCH3), 3.18 (s, 3H, NCH3), 2.45 (q, J = 7.5 Hz, 2H, O=CCH2), 
1.14 (t, J = 7.5 Hz, 3H, O=CCH2CH3).
5.3.3. Synthesis of 2-Acyl Imidazoles
General Procedure 3 
!  
N-Substituted 1H-imidazole 272 (1.20 eq.) was dissolved in THF (400 mM) and cooled to −78 ºC. n-Butyl-
lithium (1.20 eq., 1.60 M or 2.50 M in hexane) was added dropwise. The reaction mixture was stirred at 
−78 ºC for 30 min and then at rt for 30 min. The mixture was cooled to −78 ºC and Weinreb-amide 273 
(1.00 eq.) was added. The mixture was allowed to warm to rt and stirred for further 18 h. The reaction was 
quenched by adding acetic acid (6.00 eq.) and then diluted with ethyl acetate. The organic layer was washed 
with saturated aq. NaHCO3 solution (3×), water (3×), and brine (1×). After drying over Na2SO4, the solvent 
was removed under vacuum and the residue was purified through flash column chromatography on silica gel 
(n-hexane: EtOAc) to afford the product.  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R2 = p-Br-Ph: c
R2 = p-NO2-Ph: d
R2 = o-Cl-Ph: e
R2 = Et: f
R2 = p-CH3O-Ph: g
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1-(1-Methyl-1H-imidazol-2-yl)-2-phenylethan-1-one (74aa) 
!  
Following general procedure 3, 1H-imidazole 272a (2.16 g, 26.3 mmol) and Weinreb-amide 273a (3.93 g, 
21.9 mmol) were converted to 2-acyl imidazole 74aa (3.25 g, 16.2 mmol, 74%). 
1H-NMR (300 MHz; CDCl3): δ 7.38-7.24 (m, 5H, 5HPh), 7.22 (d, J = 1.0 Hz, 1H, CHN=C), 7.06 (d, J = 
0.5 Hz, 1H, CHNCH3), 4.47 (s, 2H, O=CCH2), 3.98 (s, 3H, CH3); 
HRMS(ESI+) calcd. for C12H13N2O (M + H)+ 201.1022, found: 201.1023. 
2-(4-Methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-one (74ag) 
!  
Following general procedure 3, 1H-imidazole 272a (706 mg, 8.60 mmol) and Weinreb-amide 273g (1.50 g, 
7.17 mmol) were converted to 2-acyl imidazole 74ag (1.33 g, 5.78 mmol, 81%). 
1H-NMR (300 MHz; CDCl3): δ 7.28-7.23 (m, 2H, 2Hp-MeO-Ph), 7.16 (d, J = 0.9 Hz, 1H, CHN=C), 7.01 (s, 
1H, CHNCH3), 6.87-6.82 (m, 2H, Hp-MeO-Ph), 4.35 (s, 2H, CH2), 3.94 (s, 3H, OCH3), 3.76 (s, 3H, NCH3);  
13C-NMR (75.5 MHz; CDCl3): δ 190.5 (C=O), 158.6 (COCH3),142.9 (N=CNCH3), 130.9 (2Cp-MeO-Ph), 129.3 
(O=CCH2C), 127.4(CHN), 126.7 (CHNCH3), 114.0 (2Cp-MeO-Ph), 55.3 (OCH3), 44.6 (O=CCH2), 36.2 
(NCH3); 
HRMS(ESI+) calcd. for C13H15N2O2 (M + H)+ 231.1128, found: 232.1134. 
2-Phenyl-1-(1-phenyl-1H-imidazol-2-yl)ethan-1-one (74ba) 
!  
Following general procedure 3, 1H-imidazole 272b (966 mg, 6.70 mmol) and Weinreb-amide 273a (1.00 g, 
5.58 mmol) were converted to 2-acyl imidazole 74ba (782 mg, 2.98 mmol, 53%).  
1H-NMR (300 MHz; CDCl3): δ 7.40-7.35 (m, 3H, 3HPh), 7.31-7.17 (m, 8H, 7HPh + CHN=C), 7.15 (d, J = 
1.0 Hz, 1H, CHNPh), 4.43 (s, 2H, O=CCH2);  
13C-NMR (75.5 MHz; CDCl3): δ 188.6 (O=C), 142.9 (N=CNPh), 138.4 (NC), 134.5 (O=CCH2C), 130.1 
(2CPh), 129.9 (CHN=C), 129.0 (2CPh), 128.8 (CHNPh), 128.5 (2CPh), 127.5 (CPh), 126.9 (CPh), 126.0 (2CPh), 
45.7 (O=CCH2); 
HRMS(ESI+) calcd. for C17H15N2O (M + H)+ 263.1179, found: 263.1181.  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2-Phenyl-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethan-1-one (74ca) 
!  
Following general procedure 3, 1H-imidazole 272c (802 mg, 5.07 mmol) and Weinreb-amide 273a (757 mg, 
4.22 mmol) were converted to 2-acyl imidazole 74ca (831 mg, 3.01 mmol, 71%). 
1H-NMR (300 MHz; CDCl3): δ 7.33 (d, J = 1.0 Hz, 1H, CHN=C), 7.3-7.17 (m, 8H, 5HPh + 3Ho-tolyl), 
7.06-7.04 (m, 2H, CHN-o-tolyl), 4.41 (q, J = 15.2 Hz, 2H, O=CCH2), 1.86 (s, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 188.4 (O=C), 143.4 (CHN=C), 137.9 (CHNC), 134.6 (CHN=C), 134.5 
(O=CCH2C), 130.8 (Co-tolyl), 130.1 (Co-tolyl), 129.98 (2CPh), 129.1 (Co-tolyl), 128.5 (2CPh), 126.9 (CH3C), 126.8 
(CPh), 126.6 (Co-tolyl), 126.3 (CHN-o-tolyl), 45.5 (O=CCH2), 17.1 (CH3); 
HRMS(ESI+) calcd. for C18H17N2O (M + H)+ 277.1335, found: 277.1338. 
2-(p-Tolyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethan-1-one (74cb) 
!  
Following general procedure 3, 1H-imidazole 272c (261 mg, 1.65 mmol) and Weinreb-amide 273b (290 mg, 
1.50 mmol) were converted to 2-acyl imidazole 74cb (291 mg, 1.00 mmol, 67%). 
1H-NMR (300 MHz; CDCl3): δ 7.34 (d, J = 0.9 Hz, 1H, CHN=C), 7.31-7.05 (m. 8H, 4Hp-tolyl + 3Ho-tolyl + 
CHN-o-tolyl), 7.01 (d, J = 7.5 Hz, 1H, Ho-tolyl), 4.41 (d, J = 15.2 Hz, 1H, O=CCH2), 4.35 (d, J = 15.2 Hz, 1H, 
O=CCH2), 2.28 (s, 3H, p-CH3-Ph), 1.89 (s, 3H, o-CH3-Ph); 
13C-NMR (75.5 MHz; CDCl3): δ 188.6 (O=C), 143.4 (CHN=C), 138.1 (CCH3), 138.0 (CHNC), 134.6 
(CHN=C), 134.3 (O=CCH2C), 130.82 (Co-tolyl), 130.76 (Cp-tolyl), 130.1 (Co-tolyl), 129.1 (Co-tolyl), 128.4 
(Cp-tolyl), 127.6 (Cp-tolyl), 127.03 (Cp-tolyl), 126.9 (NCCCH3), 126.6 (Co-tolyl), 126.4 (CHN-o-tolyl), 45.4 
(O=CCH2), 21.5 (CH3), 17.2 (NCCCH3); 
HRMS(ESI+) calcd. for C19H19N2O (M + H)+ 291.1492, found: 291.1495. 
2-(4-Bromophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethan-1-one (74cc) 
!  
Following general procedure 3, 1H-imidazole 272c (261 mg, 1.65 mmol) and Weinreb-amide 273c (387 mg, 
1.50 mmol) were converted to 2-acyl imidazole 74cc (459 mg, 1.29 mmol, 86%). 
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1H-NMR (300 MHz; CDCl3): δ 7.40-7.35 (m, 2H, 2Hp-Br-Ph), 7.34 (d, J = 1.0 Hz, 1H, CHN=C), 7.32-7.19 
(m, 3H, 3Ho-tolyl), 7.18-7.13 (m, 2H, 2Hp-Br-Ph), 7.09-7.04 (m, 2H, CHN-o-tolyl + Ho-tolyl), 4.41 (d, J = 15.3 
Hz, 1H, O=CCH2), 4.33 (d, J = 15.3 Hz, 1H, O=CCH2), 1.88 (s, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 187.8 (O=C), 143.1 (CHN=C), 137.8 (CHNC), 134.5 (CHN=C), 133.5 
(O=CCH2C), 131.7 (2Cp-Br-Ph), 131.6 (2Cp-Br-Ph), 130.8 (Co-tolyl), 130.2 (Co-tolyl), 129.2 (Co-tolyl), 127.1 (CCH3), 
126.7 (Co-tolyl), 126.3 (CHN-o-tolyl), 121.0 (CBr), 44.8 (O=CCH2), 17.2 (CH3); 
HRMS(ESI+) calcd. for C18H16BrN2O (M + H)+ 355.0441, found: 355.0445. 
2-(4-Nitrophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethan-1-one (74cd) 
!  
Following general procedure 3, 1H-imidazole 272c (261 mg, 1.65 mmol) and Weinreb-amide 273d (336 mg, 
1.50 mmol) were converted to 2-acyl imidazole 74cd (141 mg, 439 µmol, 29%).  
1H-NMR (300 MHz; CDCl3): δ 8.16-8.11 (m, 2H, 2Hp-nitro-Ph), 7.49-7.45 (m, 2H, 2Hp-nitro-Ph), 7.38 (d, J = 
1.0 Hz, 1H, CHN=C), 7.35-7.22 (m, 3H, 3Ho-tolyl), 7.14 (d, J = 1.0 Hz, 1H, CHN-o-tolyl), 7.09 (dd, J = 7.6, 
1.0 Hz, 1H, Ho-tolyl), 4.55 (q, J = 13.7 Hz, 2H, O=CCH2), 1.90 (s, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 186.8 (O=C), 147.2 (CNO2), 142.9 (CHN=C), 142.1 (O=CCH2C), 137.7 
(Co-tolyl), 134.5 (CHN=C), 130.97 (2Cp-nitro-Ph), 130.95 (Co-tolyl), 130.5 (Co-tolyl), 129.4, (Co-tolyl) 127.5 (CCH3), 
126.8 (Co-tolyl), 126.3 (CHN-o-tolyl), 123.7 (2Cp-nitro-Ph), 45.2 (O=CCH2), 17.2 (CH3); 
HRMS(ESI+) calcd. for C16H15N3O3Na (M + Na)+ 344.1006, found: 344.1009. 
2-(2-Chlorophenyl)-1-(1-(o-tolyl)-1H-imidazol-2-yl)ethan-1-one (74ce) 
!  
Following general procedure 3, 1H-imidazole 272c (261 mg, 1.65 mmol) and Weinreb-amide 273e (320 mg, 
1.50 mmol) were converted to the 2-acyl imidazole 74ce (371 mg, 1.19 mmol, 80%). 
1H-NMR (300 MHz; CDCl3): δ 7.36-7.09 (m, 10H, 4Ho-tolyl + 4Ho-Cl-Ph + 2Himidazolyl), 4.73 (d, J = 17.6 Hz, 
1H, O=CCH2), 4.54 (d, J = 17.6 Hz, 1H, O=CCH2), 1.96 (s, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 187.1 (O=C), 143.2 (CHN=C), 137.9 (CHNC), 134.8 (CCl), 134.6 
(CHN=C), 133.1 (O=CCH2C), 132.3 (Co-Cl-Ph), 130.8 (Co-tolyl), 130.1 (Co-Cl-Ph), 129.4 (Co-tolyl), 129.1 (Co-tolyl), 
128.5 (Co-Cl-Ph), 126.8 (Co-tolyl + Co-Cl-Ph), 126.7 (CH3C), 126.3 (CHN-o-tolyl), 43.7 (O=CCH2), 17.2 (CH3); 
HRMS(ESI+) calcd. for C18H16ClN2O (M + H)+ 311.0946, found: 311.0949.  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1-(1-(o-Tolyl)-1H-imidazol-2-yl)butan-1-one (74cf) 
!  
Following general procedure 3, 1H-imidazole 272c (261 mg, 1.65 mmol) and Weinreb-amide 273f (197 mg, 
1.50 mmol) were converted to 2-acyl imidazole 74cf (290 mg, 1.27 mmol, 85%). 
1H-NMR (300 MHz; CDCl3): δ 7.38-7.23 (m, 4H, CHN=C + 3Ho-tolyl), 7.12-7.09 (m, 1H, Ho-tolyl), 7.05 (d, J 
= 1.0 Hz, 1H, CHN-o-tolyl), 3.19-3.00 (m, 2H, O=CCH2), 1.96 (s, 3H, CCH3), 1.67 (dq, J = 14.7 Hz, 7.4 
Hz, 2H, CH2CH3), 0.94 (t, J = 7.4 Hz, 3H, CH2CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 191.6 (O=C), 143.7 (N=CN-o-tolyl), 138.2 (CHNC), 134.6 (CHN=C), 
130.8 (Co-tolyl), 129.7 (Co-tolyl), 129.1 (Co-tolyl), 126.7 (Co-tolyl), 126.4 (CHN-o-tolyl), 126.3 (CCH3), 41.0 
(O=CCH2), 17.6 (CH2CH3), 17.2 (CCH3), 13.9 (CH2CH3); 
HRMS(ESI+) calcd. for C14H17N2O (M + H)+ 229.1335, found: 229.1337. 
1-(1-iso-Propyl-1H-imidazol-2-yl)-2-phenylethan-1-one (74da) 
!  
Following general procedure 3, 1H-imidazole 272d (760 µL, 6.70 mmol) and Weinreb-amide 273a (1.00 g, 
5.58 mmol) were converted to 2-acyl imidazole 74da (888 mg, 3.89 mmol, 70%).
1H-NMR (300 MHz; CDCl3): δ 7.36-7.21 (m, 7H, 5HPh + 2Himidazolyl), 5.49 (dt, J = 13.4 Hz, 6.7 Hz, 1H, 
NCHMe2), 4.45 (s, 2H, O=CCH2), 1.39 (d, J = 6.7 Hz, 6H, 2CH3);  
13C-NMR (75.5 MHz; CDCl3): δ 190.3 (O=C), 142.3 (N=CN), 134.9 (CPh), 130.0 (2CPh), 129.8 (CHN=C), 
128.5 (2CPh), 126.8 (CHNi-Pr), 121.6 (CPh), 49.4 (NCHMe2), 46.1 (O=CCH2), 23.7 (2CH3); 
HRMS(ESI+) calcd. for C14H17N2O (M + H)+ 229.1335, found: 229.1345. 
1-(1-iso-Propyl-1H-imidazol-2-yl)propan-1-one (74dh) 
!  
Following general procedure 3, 1H-imidazole 272d (973 µL, 8.57 mmol) and Weinreb-amide 273h (837 mg, 
7.14 mmol) were converted to 2-acyl imidazole 74dh (899 mg, 5.41 mmol, 76%). The product is volatile. 
1H-NMR (300 MHz; CDCl3): δ 7.24 (d, J = 0.9 Hz, 1H, CHN=C), 7.15 (d, J = 0.6 Hz, 1H, CHNiPr), 5.55 
(dt, J = 13.4, 6.7 Hz, 1H, CHMe2), 3.15 (q, J = 7.4 Hz, 2H, O=CCH2), 1.43 (d, J = 6.7 Hz, 6H, CH(CH3)2), 
1.17 (t, J = 7.4 Hz, 3H, O=CCH2CH3); 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13C-NMR (75.5 MHz; CDCl3): δ 194.0 (O=C), 142.2 (N=CNi-Pr), 129.3 (CHN=C), 120.9 (CHNi-Pr), 49.3 
(NCH), 33.1 (O=CCH2), 23.7 (NCH(CH3)2), 8.3 (O=CCH2CH3). 
5.3.4. Synthesis of Other Reagents 
Both branched α-cyanoalkyl bromide 95b and dibromo-1,3-dicarbonyl compound 252 were synthesized 
according to published literature.[98,204] 
rac-2-Bromo-3,3-diethoxypropanenitrile (95b)[98] 
!  
3-Ethoxyacrylonitrile (1.00 mL, 9.72 mmol, E,Z-mixture) was dissolved in ethanol (10.0 mL) under nitrogen 
atmosphere. N-bromosuccinimid (1.73 g, 9.72 mmol) was added in 5 portions every 5 min. The mixture was 
stirred at rt for further 2 h and then filtered. The filtrate was concentrated under vacuum and then taken up 
with CH2Cl2 and water. After layer separation, the aqueous layer was extracted with CH2Cl2. The combined 
organic layers were dried over MgSO4 and concentrated under vacuum. The residue was purified through 
flash column chromatography on silica gel (n-hexane:EtOAc 25:1) to afford the product as colorless oil 
(926 mg, 4.17 mmol, 43%). 
1H-NMR (300 MHz; CDCl3): δ 4.68 (dd, J = 5.7, 0.5 Hz, 1H, CH(OEt)2), 4.29 (d, J = 5.7 Hz, 1H, 
CHCNBr), 3.84-3.57 (m, 4H, 2CH2), 1.23 (q, J = 6.9 Hz, 6H, 2CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 115.2 (CN), 101.2 (CH(OEt)2), 65.1 (OCH2CH3), 64.1 (OCH2CH3), 29.3 
(BrCCN), 14.98 (OCH2CH3), 14.96 (OCH2CH3); 
HRMS(ESI+) calcd. for C7H12BrNO2Na (M + Na)+ 243.9944, found: 243.9945.  
3,3-Dibromopentane-2,4-dione (252)[204] 
!  
Pentane-2,4-dione (1.00 mL, 9.74 mmol) and N-bromosuccinimid (4.33 g, 24.4 mmol) were dissolved in 1,2-
dichloroethane (25.0 mL) under nitrogen atmosphere. The mixture was stirred at 60 ºC for 18 h and then 
cooled to rt. The white precipitates were removed by filtration and the yellow filtrate was concentrated under 
vacuum. The residue was purified through flash column chromatography on silica gel (n-hexane:EtOAc 
25:1) to afford the product as pale yellow oil (2.04 g, 7.92 mmol, 81%). 
1H-NMR (300 MHz; CDCl3): δ 2.61 (s, 6H, 2CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 193.4 (2O=C), 68.4 (CBr2), 24.7 (2CH3).  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5.4. Asymmetric α-Alkylation of 2-Acyl Imidazoles with α-Cyanoalkyl Bromides 
As mentioned, the absolute configuration of enantioenriched product 189cca was assigned to be S through 
X-ray diffraction (see Chapter 3.1.6, p.42). According to this result and the absolute configuration of the 
catalyst, which was employed in this reaction, the absolute configurations of other enantioenriched alkylated 
products 189 can be extrapolated. 
5.4.1. Optimizations of the Reaction Conditions - Single Catalyst 
General Procedure 4 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74aa (200 µmol), base (220 µmol), and catalyst 
(4.00 µmol) under nitrogen atmosphere. Solvent (500 µL) was added and the reaction mixture was stirred at 
rt for 5 min. After adding bromoacetonitrile (41.8 µL, 600 µmol), the Schlenk-tube was sealed with a screw-
cap and reaction mixture was frozen by immersing the tube in liquid nitrogen. The frozen mixture was 
evacuated for 15 min and then warmed to rt under nitrogen atmosphere. This freeze-pump-thaw degassing 
procedure was repeated for further two cycles and the reaction mixture was stirred at rt under irradiation with 
two 13- Watt compact fluorescent lamps (CFL) for 24 h. After evaporating the solvent under vacuum, the 
residue was purified through flash column chromatography on silica gel (n-hexane:EtOAc 5:1 then 2:1) to 
afford remaining starting material 74aa and product (R)-189aaa. The conversion was calculated according to 
recovered 74aa and the enantiomeric purity was determined through HPLC analysis of (R)-189aaa on chiral 
stationary phase. 
Catalyst Screening (Table 3, p.36) 
!  
Following general procedure 4, 2-acyl imidazole substrate 74aa (40.0 mg, 200 µmol) was converted to 
(R)-189aaa with Na2HPO4 (31.2 mg, 220 µmol) as base in CH3OH/THF (500 µL, v/v 4:1) as solvent. The 
reaction with Λ-IrS (3.80 mg, 4.00 µmol) as catalyst afforded 74aa (27.7 mg, 138 µmol, 31% conv.) and 
(R)-189aaa (11.3 mg, 47.2 µmol, 24%) with 58% ee (entry 1). The reaction with Λ-IrO (3.70 mg, 4.00 µmol) 
as catalyst afforded 74aa (20.0 mg, 100 µmol, 50% conv.) and (R)-189aaa (23.6 mg, 98.6 µmol, 49%) with 
63% ee (entry 2). The reaction with Λ-RhO (3.30 mg, 4.00 µmol) as catalyst afforded 74aa (30.2 mg, 
151 µmol, 24% conv.) and (R)-189aaa (10.0 mg, 41.8 µmol, 21%) with 73% ee (entry 3). 
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(R)-4-(1-Methyl-1H-imidazol-2-yl)-4-oxo-3-phenylbutanenitrile (189aaa) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.42-7.39 (m, 2H, 2HPh), 7.33-7.20 (m, 3H, 3HPh), 7.10 (d, J = 0.7 Hz, 1H, 
CHN=C), 6.98 (s, 1H, CHNCH3), 5.47 (t, J = 7.7 Hz, 1H, O=CCH), 3.92 (s, 3H, CH3), 3.06 (dd, J = 16.7, 
7.9 Hz, 1H, CH2CN), 2.86 (dd, J = 16.7, 7.5 Hz, 1H, CH2CN); 
13C-NMR (75.5 MHz; CDCl3): δ 188.2 (O=C), 141.8 (CHN=C), 136.4 (O=CCHC), 130.0 (CHN=C), 129.1 
(2CPh), 128.3 (2CPh), 128.2 (CHNCH3), 128.0 (CPh), 118.2 (CN), 49.1 (O=CCH), 36.1 (CH3), 20.7 (CH2CN); 
HRMS(ESI+) calcd. for C14H13N3ONa (M + Na)+ 263.0980, found: 262.0953; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(major) 
= 6.7 min, tR(minor) = 11.1 min. 
Solvent Screening (Table 4, p.37) 
!  
Following general procedure 4, 2-acyl imidazole substrate 74aa (40.0 mg, 200 µmol) was converted to 
(R)-189aaa with Na2HPO4 (31.2 mg, 220 µmol) as base and Λ-RhO (3.30 mg, 4.00 µmol) as catalyst. The 
reaction in CH3OH (500 µL) afforded 74aa (25.0 mg, 125 µmol, 38% conv.) and (R)-189aaa (13.7 mg, 
57.3 µmol, 29%) with 60% ee (entry 2). No product formation was observed in N-methyl-2-pyrrolidone 
(500 µL) and dimethyl acetamide (500 µL) (entry 3 and 4). The reaction in CH3CN and THF afforded only 
traces amount of (R)-189aaa with 54% ee (entry 5) and 46% ee (entry 6) respectively. The reaction in 
CH3OH/CH3CN (500 µL, v/v 4:1) afforded (R)-189aaa (13.5 mg, 56.4 µmol, 28%) with 77% ee (entry 7). 
Base Screening (Table 5, p.38) 
!  
Following general procedure 4, 2-acyl imidazole substrate 74aa (40.0 mg, 200 µmol) was converted to 
(R)-189aaa with and Λ-RhO (3.30 mg, 4.00 µmol) as catalyst in CH3OH/CH3CN (500 µL, v/v 4:1) as 
solvent. The reactions with NaHCO3 (9.20 mg, 220 µmol) and sodium acetate (9.00 mg, 220 µmol) afforded 
(R)-189aaa only in traces of amount with 40% ee (entry 2) and 15% ee (entry 3) respectively. The reaction 
with Cs2CO3 (35.8 mg, 220 µmol) afforded (R)-189aaa (33.5 mg, 140 µmol, 70%) with 5% ee (entry 4). The 
reaction with 2,6-lutidine (25.5 µL, 220 µmol) afforded 74aa (28.1 mg, 140 µmol, 30% conv.) and 
(R)-189aaa (5.80 mg, 24.2 µmol, 12%) with 31% ee (entry 5). The reaction with i-Pr2NEt (69.2 µL, 
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400 µmol) afforded 74aa (18.8 mg, 93.9 µmol, 53% conv.) (R)-189aaa (17.4 mg, 72.7 µmol, 36%) with 31% 
ee (entry 6). The reaction in the absence of base didn’t afford any product after 24 h according to TLC 
analysis of the reaction mixture (entry 7).  
5.4.2. Optimizations of the Reaction Conditions - Dual Catalysis Strategy 
General Procedure 5 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74 (200 µmol), i-Pr2NEt (69.2 µL, 400 µmol), 
chiral Lewis acid catalyst (4.00 µmol), photoredox catalyst (4.00 µmol), and solvent (500 µL) under nitrogen 
atmosphere. The reaction mixture was stirred at rt for 5 min. After adding bromoacetonitrile, the Schlenk-
tube was sealed with a screw-cap and reaction mixture was degassed through the freeze-pump-thaw 
procedure for three cycles and stirred at rt under irradiation with two 13-Watt CFL for the given duration. 
After evaporating the solvent under vacuum, the residue was purified through column chromatography on 
silica gel (n-hexane:EtOAc 5:1 then 2:1) to afford the product. The enantiomeric purity was determined 
through HPLC analysis of the product on chiral stationary phase. 
Optimization of Dual Catalysis Strategy (Table 6, p.40) 
Entries 1-2: 
!  
Following general procedure 5, the 2-acyl imidazole substrate 74aa (40.0 mg, 200 µmol) and bromo-
acetonitrile (41.8 µL, 600 µmol) were converted to (R)-189aaa with Λ-RhO (3.30 mg, 4.00 µmol) and fac-
[Ir(ppy)3] (2.60 mg, 4.00 µmol) in CH3OH/CH3CN (500 µL, v/v 4:1). 24 h photolysis and the following 
purification yielded (R)-189aaa (40.6 mg, 170 µmol, 85%) with 58% ee (entry 1), while 17 h photolysis 
afforded (R)-189aaa (44.2 mg, 185 µmol, 92%) with 64% ee (entry 2).  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Entries 3-6: 
!  
Following general procedure 5, 2-acyl imidazole substrate 74ba (52.5 mg, 200 µmol) and bromoacetonitrile 
(41.8 µL, 600 µmol) were converted to (R)-189baa with Λ-RhO (3.30 mg, 4.00 µmol) and fac-[Ir(ppy)3] 
(2.60 mg, 4.00 µmol) in CH3OH/CH3CN (500 µL, v/v 4:1). (R)-189baa (43.5 mg, 144 µmol, 72%) was 
obtained with 70% ee after 36 h photolysis (entry 3). Increasing the amount of the bromoacetonitrile 
(83.6 µL, 1.20 mmol) yielded (R)-189baa (53.2 mg, 177 µmol, 88%) with 72% ee and the duration of the 
reaction was shortened to 12 h (entry 4). Switching the solvent system to CH3OH/CH3CN (500 µL, v/v 1:1) 
and CH3OH/CH2Cl2 (500 µL, v/v 1:1) yielded (R)-189baa (34.7 mg, 115 µmol, 58% and 42.7 mg, 142 µmol, 
71%) with 74% ee and 73% ee after 24 h photolysis respectively (entry 5 and 6). 
 (R)-4-Oxo-3-phenyl-4-(1-phenyl-1H-imidazol-2-yl)butanenitrile (189baa) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.46-7.24 (m, 9H, 8HPh + Himidazolyl), 7.18-7.14 (m, 3H, 2HPh + Himidazolyl), 
5.48 (t, J = 7.7 Hz, 1H, O=CCH), 2.98 (dd, J = 16.8, 7.7 Hz, 1H, CH2CN), 2.79 (dd, J = 16.8, 7.7 Hz, 1H, 
CH2CN); 
13C-NMR (75.5 MHz; CDCl3): δ 186.9 (O=C), 141.8 (CHN=C), 138.0 (CHNC), 136.2 (O=CCHC), 130.5 
(CHN=C), 129.3 (2CPh), 129.2 (2CPh), 129.1 (CPh), 128.4 (2CPh), 128.3 (CPh), 127.9 (CHNPh), 125.8 (2CPh), 
118.1 (CN), 49.6 (O=CCH), 20.7, (CH2CN); 
HRMS(ESI+) calcd. for C19H15N3ONa (M + Na)+ 324.1107, found: 324.1110; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(major) 
= 7.9 min, tR(minor) = 23.5 min. 
Entries 7-10: 
!  
Following general procedure 5, 2-acyl imidazole substrate 74ca (55.3 mg, 200 µmol) and bromoacetonitrile 
(83.6 µL, 1.20 mmol) were converted to (R)-189caa with Λ-RhO (3.30 mg, 4.00 µmol) and fac-[Ir(ppy)]3 
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(2.60 mg, 4.00 µmol) in CH3OH/CH2Cl2 (500 µL, v/v 1:1) after 24 h photolysis. Product (R)-189caa 
(51.2 mg, 162 µmol, 81%) was obtained with 80% ee (entry 7). Replacing fac-[Ir(ppy)]3 with 
[Ir(ppy)2(dtbbpy)]PF6 (3.70 mg, 4.00 µmol) resulted in (R)-189caa (51.3 mg, 163 µmol, 81%) with 84% ee 
(entry 8). The combination of Λ-RhS (3.80 mg, 4.00 µmol) and [Ir(ppy)2(dtbbpy)]PF6 (3.70 mg, 4.00 µmol) 
yielded (R)-189caa (62.7 mg, 199 µmol, 99%) with 94% ee after 1.5 h photolysis (entry 9). The same result 
(62.7 mg, 199 µmol, 99% yield, 94% ee) was achieved after 5 h photolysis, when the amount of acetonitrile 
(41.8 µL, 600 µmol) was reduced (entry 10).  
(R)-4-Oxo-3-phenyl-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (177caa) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.39-6.86 (m, 11H, 5HPh + 4Ho-tolyl + 2Himidazolyl), 5.46 (t, J = 7.8 Hz, 1H, 
O=CCH), 2.97 (dt, J = 16.5, 8.1 Hz, 1H, CH2CN), 2.77 (td, J = 17.4, 7.5 Hz, 1H, CH2CN), 2.04 and 1.58 (s,, 
3H, CH3), contained rotamers;  
13C-NMR (75.5 MHz; CDCl3): δ 186.9 (O=C), 142.3 (CHN=C), 137.52 and 137.50 (d, J = 2.0 Hz, CHNC), 
136.2 and 136.1 (O=CCHC), 134.9 and 134.3 (CHN=C), 130.9 and 130.8 (Co-tolyl), 130.69 and 130.64 (Co-
tolyl), 129.44 and 129.39 (Co-tolyl), 129.2 (d, J = 4.2 Hz, 2CPh), 128.41 and 128.38 (2CPh), 128.3 (CPh), 127.3 
(Co-tolyl), 126.8 and 126.7 (CCH3), 126.6 and 126.2 (CHN-o-tolyl), 118.1 (CN), 49.6 and 49.4 (O=CCH), 20.7 
and 20.4 (CH2CN), 17.3 and 16.6 (CH3), contained rotamers; 
HRMS(ESI+) calcd. for C20H17N3ONa (M + Na)+ 338.1264, found: 338.1267; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(major) 
= 6.3 min, tR(minor) = 21.3 min. 
5.4.3. Evaluation of the Substrate Scope 
General Procedure 6 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74c (200 µmol), i-Pr2NEt (69.2 µL, 400 µmol), 
[Ir(ppy)2(dtbbpy)]PF6 (3.70 mg, 4.00 µmol), and Δ-RhS (3.50 mg, 4.00 µmol) under nitrogen atmosphere. 
CH3OH/CH2Cl2 (500 µL, v/v 1:1) was added and the reaction mixture was stirred at rt for 5 min. After 
adding α-cyanoalkyl bromide 95 (600 µmol), the Schlenk-tube was sealed with a screw-cap and reaction 
mixture was degassed through the freeze-pump-thaw procedure for three cycles and stirred at rt under 
irradiation with two 13-Watt CFL for the given duration. After evaporating the solvent under vacuum, the 
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residue was purified through flash column chromatography on silica gel (n-hexane:EtOAc 5:1 then 2:1) to 
afford the product. The enantiomeric purity was determined through HPLC analysis of the product on chiral 
stationary phase. The preparations of the racemic references were carried out with 6 equivalents α-
cyanoalkyl bromide and rac-RhO as catalyst on 100 µmol scale. 
Scope of the 2-Acyl Imidazoles (Table 7, p.41) 
!  
(S)-4-Oxo-3-(p-tolyl)-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (189cba) 
!  
Following general procedure 6, 2-acyl imidazole substrate 74cb (29.0 mg, 100 µmol) and bromoacetonitrile 
(41.8 µL, 600 µmol) were converted to rac-189cba (17.9 mg, 54.3 µmol, 54%) with rac-RhO (1.70 mg, 
2.00 µmol) as catalyst after 24 h photolysis. The conversion of 74cb was incomplete. With Δ-RhS (3.50 mg, 
4.00 µmol) as catalyst, 74cb (58.1 mg, 200 µmol) and bromoacetonitrile (41.8 µL, 600 µmol) were converted 
to (S)-189cba (66.7 mg, 200 µmol, >99%, 95% ee) as pale yellow solid. The conversion of 74cb was 
complete after 12 h (entry 1). 
1H-NMR (300 MHz; CDCl3): δ 7.42-6.89 (m, 10H, 8Ho-tolyl + 2Himidazolyl), 5.43 (t, J = 7.7 Hz, 1H, O=CCH), 
2.97 (ddd, J = 16.8, 9.0, 7.9 Hz, 1H, CH2CN), 2.76 (td, J = 16.5, 7.4 Hz, 1H, CH2CN), 2.32 (d, J = 1.9 Hz, 
3H, CH3), 2.05 and 1.63 (s, 3H, NCCCH3), contained rotamers;  
13C-NMR (75.5 MHz; CDCl3): δ 187.1 (O=C), 142.4 (CHN=C), 139.0 and 138.9 (CHNC), 137.60 and 
137.55 (CCH3), 136.10 and 136.06 (O=CCHC), 134.9 and 134,4 (CHN=C), 130.97 and 130.86 (Co-tolyl), 
130.70 and 130.66 (Co-tolyl), 129.46 and 129.41 (Co-tolyl), 129.1 (4Cp-tolyl), 128.98 and 128.96 (Co-tolyl), 127.23 
and 126.68 (CHN-o-tolyl), 126.84 and 126.19 (NCCCH3), 125.51 and 125.44 (Co-tolyl), 118.2 (CN), 49.57 
and 49.44 (O=CCH), 21.5 (CH3), 20.8 and 20.6 (d, J = 20.7 Hz, CH2CN), 17.4 and 16.6 (NCCCH3), 
contained rotamer;  
HRMS(ESI+) calcd. for C21H19N3ONa (M + Na)+ 352.1420, found: 352.1424; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(minor) 
= 5.9 min, tR(major) = 26.8 min.  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(S)-3-(4-Bromophenyl)-4-oxo-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (189cca) 
!  
Following general procedure 6, 2-acyl imidazole substrate 74cc (35.5 mg, 100 µmol) and bromoacetonitrile 
(41.8 µL, 600 µmol) were converted to rac-189cca (25.3 mg, 64.2 µmol, 64%) with rac-RhO (1.70 mg, 
2.00 µmol) as catalyst after 24 h photolysis. The conversion of 74cc was incomplete. With Δ-RhS (3.50 mg, 
4.00 µmol) as catalyst, 74cc (71.0 mg, 200 µmol) and bromoacetonitrile (41.8 µL, 600 µmol) were converted 
to (S)-189caa (72.0 mg, 183 µmol, 91%, 88% ee) as white solid. The conversion of 74cc was complete after 
12 h (entry 2). 
1H-NMR (300 MHz; CDCl3): δ 7.48-7.44 (m, 2H, 2Hp-Br-Ph), 7.40-6.90 (m, 8H, 4Ho-tolyl + 2Hp-Br-Ph + 
2Himidazolyl), 5.44 (t, J = 7.8 Hz, 1H, O=CCH), 3.00-2.89 (m, 1H, CH2CN), 2.85-2.71 (m, 1H, CH2CN), 2.03 
and 1.64 (s, 3H, CH3), contained rotamers;  
13C-NMR (75.5 MHz; CDCl3): δ 186.4 (O=C), 142.0 (CHN=C), 137.43 and 137.39 (CHNC), 135.2 (CBr), 
134.8 and 134.3 (CHN=C), 132.44 and 132.39 (O=CCHC), 131.0 and 130.9 (Co-tolyl), 130.87 and 130.83 
(Co-tolyl), 130.1 (2Cp-Br-Ph), 129.55 and 129.51 (Co-tolyl), 127.6 (Co-tolyl), 126.9 and 126.8 (CCH3), 126.6 and 
126.1 (CHN-o-tolyl), 122.6 (2Cp-Br-Ph), 117.8 (CN), 48.97 and 48.83 (O=CCH), 20.6 and 20.4 (CH2CN), 17.3 
and 16.8 (CH3), contained rotamers; 
HRMS(ESI+) calcd. for C20H16BrN3ONa (M + Na)+ 416.0369, found: 416.0372; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(minor) 
= 7.7 min, tR(major) = 24.3 min. 
(S)-3-(4-nitrophenyl)-4-oxo-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (189cda) 
!  
Following general procedure 6, 2-acyl imidazole substrate 74cd (32.1 mg, 100 µmol) and bromoacetonitrile 
(41.8 µL, 600 µmol) were converted to rac-189cda (27.7 mg, 76.9 µmol, 77%) with rac-RhO (1.70 mg, 
2.00 µmol) as catalyst after 24 h photolysis. The conversion of 74cd was complete. With Δ-RhS (3.50 mg, 
4.00 µmol) as catalyst, 74cd (64.3 mg, 200 µmol) and bromoacetonitrile (41.8 µL, 600 µmol) were converted 
to (S)-189cda (58.5 mg, 162 µmol, 81%, 1% ee) as white solid. The conversion of 74cd was complete after 
24 h (entry 3). 
1H-NMR (300 MHz; CDCl3): δ 8.20 (dd, J = 8.7, 1.8 Hz, 2H, 2Hp-nitro-Ph), 7.61-7.54 (m, 2H, 2Hp-nitro-Ph), 
7.44-6.91 (m, 6H, 2Himidazolyl + 4Ho-tolyl), 5.61 (t, J = 7.7 Hz, 1H, O=CCH), 3.07-2.80 (m, 2H, CH2CN), 2.03 
and 1.65 (s, 3H, CH3), contained rotamers;  
13C-NMR (75.5 MHz; CDCl3): δ 185.3 (O=C), 147.8 (CNO2), 143.26 and 143.19 (CHN=C), 141.6 
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(O=CCHC), 137.11 and 137.10 (CHNC), 134.7 and 134.1 (CHN=C), 131.04 and 131.00 (Co-tolyl), 130.99 and 
130.88 (2Cp-nitro-Ph), 129.59 and 129.56 (Co-tolyl), 129.4 (Co-tolyl), 127.9 (Co-tolyl), 126.89 and 126.76 (CCH3), 
126.41 and 125.98 (CHN-o-tolyl), 124.31 and 124.27 (2Cp-nitro-Ph), 117.30 and 117.28 (CN), 49.13 and 49.03 
(O=CCH), 20.41 and 20.25 (CH2CN), 17.2 and 16.7 (CH3), contained rotamers; 
HRMS(ESI+) calcd. for C20H16N4O3Na (M + Na)+ 383.1115, found: 383.1118; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(minor) 
= 10.6 min, tR(major) = 41.1 min. 
(S)-3-(2-chlorophenyl)-4-oxo-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (189cea) 
!  
Following general procedure 6, 2-acyl imidazole substrate 74ce (31.1 mg, 100 µmol) and bromoacetonitrile 
(41.8 µL, 600 µmol) were converted to rac-189cea (22.1 mg, 63.3 µmol, 63%) with rac-RhO (1.70 mg, 
2.00 µmol) as catalyst after 24 h photolysis. The conversion of 74ce was incomplete. With Δ-RhS (3.50 mg, 
4.00 µmol) as catalyst, 74ce (62.2 mg, 200 µmol) and bromoacetonitrile (41.8 µL, 600 µmol) were converted 
to (S)-189cea (70.1 mg, 200 µmol, >99%, 84% ee) as pale yellow solid. The conversion of 74ce was 
complete after 12 h (entry 4). 
HRMS(ESI+) calcd. for C20H17ClN3O (M + H)+ 350.1055, found: 350.1056; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(minor) 
= 5.4 min, tR(major) = 13.0 min. 
(R)-3-(1-(o-tolyl)-1H-imidazole-2-carbonyl)pentanenitrile (189cfa) 
!  
Following general procedure 6, 2-acyl imidazole substrate 74cf (22.8 mg, 100 µmol) and bromoacetonitrile 
(41.8 µL, 600 µmol) were converted to rac-189cfa (26.7 mg, 100 µmol, >99%) with rac-RhO (1.70 mg, 
2.00 µmol) as catalyst after 24 h photolysis. The conversion of 74cf was complete. With Δ-RhS (3.50 mg, 
4.00 µmol) as catalyst, 74cf (45.7 mg, 200 µmol) and bromoacetonitrile (41.8 µL, 600 µmol) were converted 
to (S)-189cfa (49.4 mg, 185 µmol, 92%, 96% ee) as yellow oil. The conversion of 74cf was complete after 
24 h (entry 5). 
1H-NMR (300 MHz; CDCl3): δ 7.42-7.26 (m, 4H, 3Himidazolyl + HPhMe), 7.17-7.07 (m, 2H, Himidazolyl + Ho-
tolyl), 4.15 (quintet, J = 6.8 Hz, 1H, O=CCH), 2.69-2.50 (m, 2H, CH2CN), 2.00-1.73 (m, 5H, CH3 + 
CH2CH3), 0.92 (q, J = 7.7 Hz, 3H, CH2CH3); 
O
N
N
Cl
CN
O
N
N CN
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13C-NMR (75.5 MHz; CDCl3): δ 190.5 (O=C), 142.51 and 142.49 (CHN=C), 137.8 and 137.7 (CHNC), 
134.9 and 134.2 (CHN=C), 131.0 and 130.9 (Co-tolyl), 130.49 and 130.46 (Co-tolyl), 129.4 (Co-tolyl), 127.34 and 
127.30 (Co-tolyl), 126.9 and 126.75 CCH3), 126.6 and 126.2 (CHN-o-tolyl), 118.41 and 118.38 (CN), 44.8 and 
44.65 (O=CCH), 25.1 (CH2CH3), 18.16 and 18.12 (CH2CN), 17.32 and 17.15 (CH3), 10.93 and 10.86 
CH2CH3); 
HRMS(ESI+) calcd. for C16H17N3ONa (M + Na)+ 290.1264, found: 290.1266; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(minor) 
= 5.7 min, tR(major) = 6.5 min. 
Scope of the α-Cyanoalkyl bromides (Scheme 49, p.41 and Scheme 50, p.42) 
!  
(3S)-2-(Diethoxymethyl)-4-oxo-3-phenyl-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (177cab) 
!  
Following general procedure 6, 2-acyl imidazole 74ca (55.3 mg, 200 µmol) and branched α-cyanoalkyl 
bromide 95b (200 µL, 1.20 mmol) were converted to rac-189cab (67.6 mg, 81%) with rac-RhO (3.30 mg, 
4.00 µmol) as catalyst. The conversion of 74ca was incomplete after 24 h photolysis. The diastereomers of 
rac-189cab were separated from each other through flash column chromatography on silica gel (n-
hexane:EtOAc 3:1 then 1.5:1) to obtain the necessary analytical data for respective diastereomer of 189cab. 
With Δ-RhS (3.50 mg, 4.00 µmol) as catalyst, 74ca (55.3 mg, 200 µmol) and branched α-cyanoalkyl bromide 
95b (104 µL, 600 µmol) were converted to (S)-189cab (83.2 mg, 199 µmol, >99%). The conversion of 74ca 
was complete after 15 h. According to the earlier obtained analytical data and 1H-NMR spectra of the crude 
reaction mixture, the diastereomeric ratio was determined as 2.5:1 (Figure 16). The HPLC analysis on chiral 
stationary phase of the product revealed 98% ee for both diastereomers of (S)-189cab. 
1H-NMR (300 MHz; CDCl3): major diastereomer: δ 7.43-6.79 (m, 10H, 4Ho-tolyl + 5HPh + Himidazolyl), 7.03 
(d, J = 0.9 Hz, 1H, CHN-o-tolyl), 5.51 (dd, J = 11.7, 9.8 Hz, 1H, O=CCH), 4.57 (dd, J = 7.7, 5.8 Hz, 1H, 
CH(OEt)2), 3.87 (ddd, J = 9.6, 8.5, 5.8 Hz, 1H, NCCH), 3.74-3.64 (m, 2H, OCH2CH3), 3.57-3.46 (m, 2H, 
OCH2CH3), 2.05 and 1.51 (s, 3H, CH3), 1.20-1.05 (m, 6H, 2OCH2CH3), contained rotamers; minor 
diastereomer: δ 7.41-6.91 (m, 10H, 4Ho-tolyl + 5HPh + Himidazolyl), 7.04 (d, J = 0.4 Hz, 1H, CHN-o-tolyl), 
5.57 (dd, J = 10.5, 6.3 Hz, 1H, O=CCH), 4.08 (dd, J = 14.8, 3.6 Hz, 1H, CH(OEt)2), 3.80-3.69 (m, 1H, 
NCCH), 3.56-3.48 (m, 2H, OCH2CH3), 3.42-3.32 (m, 2H, OCH2CH3), 2.05 and 1.63 (s, 3H, CH3), 
1.26-1.20 (m, 3H, OCH2CH3), 1.10 (td, J = 7.0, 2.0 Hz, 3H, OCH2CH3), contained rotamers; 
O
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13C-NMR (75.5 MHz; CDCl3): δ 186.8, 186.5, 186.4, 142.53, 142.46, 142.43, 142.33, 137.70, 137.67, 
137.61, 137.55, 135.12, 135.08, 134.98, 134.66, 134.56, 134.49, 134.2, 130.92, 130.84, 130.79, 130.69, 
130.63, 130.57, 130.49, 130.41, 129.37, 129.32, 129.26, 129.13, 129.08, 129.03, 128.96, 128.2, 127.20, 
127.17, 127.11, 127.02, 126.80, 126.69, 126.63, 126.53, 126.29, 126.26, 126.1, 118.22, 118.14, 118.05, 
118.00, 100.71, 100.54, 99.7, 64.2, 63.95, 63.91, 63.70, 63.60, 63.57, 52.22, 52.06, 51.1, 50.7, 40.13, 39.94, 
39.77, 39.63, 17.41, 17.28, 16.7, 16.5, 15.19, 15.14, 15.11, 14.93, contained rotamers, mixture of both 
diasteromers;  
HRMS(ESI+) calcd. for C25H28N3O3 (M + H)+ 419.2125, found: 418.2130; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 1.0 mL/min, hexanes:i-PrOH 70:30, isocratic flow, major 
diastereomer: tR(minor) = 4.6 min, tR(major) = 6.1 min; minor diastereomer: tR(minor) = 4.0 min, 
tR(major) = 6.0 min. 
!  
Figure 16: 1H-NMR spectrum of the crude reaction mixture to determine the diastereomeric ratio of 
(S)-189cab. 
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5.4.4. Mechanistic Investigations (Table 8, p.43) 
General Procedure 7 (Reaction Conditions without Variations) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ca (55.3 mg, 200 µmol), i-Pr2NEt (69.2 µL, 400 
µmol), [Ir(ppy)2(dtbbpy)]PF6 (3.70 mg, 4.00 µmol), Λ-RhS (3.50 mg, 4.00 µmol), and CH3OH/CH2Cl2 
(500 µL, v/v 1:1) under nitrogen atmosphere. The mixture was stirred at rt for 5 min. After adding bromo-
acetonitrile (83.6 µL, 1.20 mmol), the Schlenk-tube was sealed with a screw-cap and reaction mixture was 
degassed through the freeze-pump-thaw procedure for three cycles and stirred at rt under irradiation with two 
13-Watt CFL for the given duration. After evaporating the solvent under vacuum, the residue was purified 
through flash column chromatography on silica gel (n-hexane:EtOAc 5:1 then 2:1) to afford the product. The 
enantiomeric purity was determined through HPLC analysis of the product on chiral stationary phase as 
described (see Chapter 5.4.2, p.103). 
Entries 2 and 3: 
Following general procedure 7, the reaction was performed in the absence of light. The reaction mixture was 
submitted to 1H-NMR analysis after 1.5 h and no product formation could be detected (Figure 17). The 
reaction was repeated and worked up after 48 h. The purification afforded remaining substrate 74ca 
(12.4 mg, 44.9 µmol, 78% conv.) and product (R)-189caa (45.6 mg, 145 µmol, 72%) with 4% ee. 
Entries 4 and 5:  
Following general procedure 7, the reaction was performed without being degassed. An air balloon was 
connected to the Schlenk-tube during the reaction. The reaction mixture was submitted to 1H-NMR analysis 
after 1.5 h and no product formation could be detected (Figure 18). The reaction was repeated and worked up 
after 48 h. The purification afforded remaining substrate 74ca (32.9 mg, 119 µmol, 41% conv.) and product 
(R)-189caa (14.5 mg, 46.0 µmol, 23%) with 60% ee. 
Entries 6 and 7: 
Following general procedure 7, the reaction was performed in the absence of [Ir(ppy)2(dtbbpy)]PF6. The 
reaction mixture was submitted to 1H-NMR analysis after 1.5 h and no product formation could be detected. 
The reaction was repeated and the TLC analysis of crude reaction mixture indicated a complete conversion 
of 2-acyl imidazole substrate 74ca after 24 h photolysis. The purification afforded product (R)-177caa 
(61.2 mg, 194 µmol, 97%) with 79% ee. 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Entry 8: 
Following general procedure 7, the reaction was performed in the absence of Λ-RhS and worked up after 
48 h to afford product rac-189caa (19.8 mg, 62.8 µmol) in 31% yield. 
!  
Figure 17: 1H-NMR spectrum of the crude reaction mixture from Table 8, entry 2 (p.43).  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!  
Figure 18: 1H-NMR spectrum of the crude reaction mixture from Table 8, entry 4 (p.43). 
1H-NMR Analysis of Enolization (p.43) 
!  
As reference, 2-acyl imidazole substrate 74ca was dissolved in CD2Cl2/CD3OD (v/v 1:1) at rt and submitted 
to 1H-NMR analysis (Figure 19). 2-acyl imidazole substrate 74ca (55.3 mg, 200 µmol) was dissolved in 
CD3OD/CD2Cl2 (500 µL, v/v 1:1) under nitrogen atmosphere in a Schlenk-tube. After adding i-Pr2NEt 
(69.2 µL, 400 µmol) and Na2HPO4 (56.8 mg, 400 µmol) respectively, the mixtures were degassed through 
the freeze-pump-thaw procedure for three cycles and stirred at rt for 10 min. The mixtures were submitted to 
1H-NMR analysis and the methylene signal of 74ca could be observed with Na2HPO4 (Figure 20) and 
vanished in the presence of i-Pr2NEt (Figure 21), indicating that 74ca was enolized by i-Pr2NEt in the 
absence of Lewis acid catalyst. 
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!  
Figure 19: 1H-NMR spectrum 74ca in CD2Cl2/CD3OD. 
!  
Figure 20: 1H-NMR spectrum of 74ca and Na2HPO4 in CD2Cl2/CD3OD. 
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!  
Figure 21: 1H-NMR spectrum of 74ca and i-Pr2NEt in CD3OD/CD2Cl2. 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5.5. Asymmetric α-Benzoyloxylation of 2-Acyl Imidazoles 
5.5.1. Preliminary Results (Scheme 62, p.50) 
Procedure with Photocatalyst: 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (46.0 mg, 200 µmol), benzoyl peroxide 
(96.8 mg, 300 µmol, 75%), NaHCO3 (50.4 mg, 600 µmol), [Ru(bpy)3]Cl2·6H2O (3.00 mg, 4.00 µmol), and 
rac-RhO (5.00 mg, 6.00 µmol). After adding acetonitrile (500 µL), the tube was sealed with a screw-cap. The 
reaction mixture was degassed through the freeze-pump-thaw procedure for three cycles and stirred at rt 
under irradiation with a 13-Watt CFL. The TLC analysis of the reaction mixture revealed a complete 
conversion of imidazole substrate 74ag after 2 h. After evaporating the solvent in vacuum, the residue was 
purified through flash column chromatography on silica gel (n-hexane:EtOAc 3:1) to afford 219ag (50.4 mg, 
144 µmol, 72%) as pale yellow oils. The reaction was repeated in absence of light and finished in 2 h to give 
a similar result, demonstrating that visible light was not necessary for the reaction. 
Procedure without Photocatalyst: 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (46.0 mg, 200 µmol), benzoyl peroxide 
(96.8 mg, 300 µmol, 75%), NaHCO3 (50.4 mg, 600 µmol), Λ-RhO (5.00 mg, 6.00 µmol), and acetonitrile 
(500 µL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the reaction mixture was 
stirred at rt for 2 h in the absence of light. After evaporating the solvent in vacuum, the residue was purified 
through flash column chromatography on silica gel (n-hexane:EtOAc 3:1) to afford 219ag (67.4 mg, 
192 µmol, 96%) with 40% ee as pale yellow oil. The absolute configuration of 219ag was not determined 
1-(4-Methoxyphenyl)-2-(1-methyl-1H-imidazol-2-yl)-2-oxoethyl benzoate (219ag) 
!  
13C-NMR (75.5 MHz, CDCl3): δ 185.5 (O=C), 166.1 (O=CPh), 160.2 (COCH3), 141.0 (N=CNCH3), 133.5 
(CPh), 133.3, 130.2, 130.0, 129.9, 129.7, 128.50, 128.45, 127.4, 126.1, 114.3, 55.4 (OCH3), 36.0 (NCH3); 
[Ru(bpy)3]Cl2.6H2O (2 mol%)
rac-RhO (3 mol%)
NaHCO3 (3 eq.)
13 W CFL, CH3CN, rt, 2 h
O OMe
N
N OBz
219ag
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N
N
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+
211, 1.5 eq.
BPO
OMe
Λ-RhO (3 mol%)
NaHCO3 (3 eq.)
In the absence of light 
CH3CN, rt, 2 h
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HPLC Daicel Chiralpak AD-H column, 25 ºC, 0.5 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(major) 
= 23.9 min, tR(minor) = 29.0 min. 
5.5.2. Optimization of the Reaction Conditions 
Solvent Screening (Table 9 and Table 10, p.51-52) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (23.0 mg, 100 µmol), benzoyl peroxide 
(48.4 mg, 150 µmol, 75%), NaHCO3 (25.2 mg, 300 µmol), Λ-RhO (2.50 mg, 3.00 µmol), and the solvent 
(250 µL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the mixture was stirred at rt 
in absence of light for the given reaction duration. A small amount reaction mixture was taken out and 
diluted with HPLC-grade hexanes. The samples were filtered through a syringe filter and analyzed through 
chiral HPLC to determine the enantiomeric excess of 219ag. The results of the reactions with NaHCO3 as 
base are given in Table 9 (p.51). The results of the reactions in the absence of base are given in Table 10 (p.
51-52).  
Influences of Molar Ratio and Catalysts (Table 11, p.52) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (69.0 mg, 300 µmol), benzoyl peroxide 
(32.3 mg, 100 µmol, 75%), chiral Lewis acid catalyst (3.00 µmol), and THF (250 µL) under nitrogen 
atmosphere. The tube was sealed with a screw-cap and the mixture was stirred at rt in absence of light. A 
small amount reaction mixture was taken out and diluted with HPLC-grade hexanes. The samples were 
filtered through a syringe filter and analyzed through chiral HPLC to determine the enantiomeric excess of 
the product. While the reaction with Λ-RhO (2.50 mg, 3.00 µmol) revealed a complete conversion of 74ag 
after 3 h to give 219ag with 52% ee (entry 1). The reactions with Λ-IrO (2.80 mg, 3.00 µmol) and Λ-IrS 
(2.90 mg, 3.00 µmol) afforded 219ag with 25% ee and 27% ee respectively. Imidazole substrate 74ag was 
not completely consumed after 20 h in both reactions with iridium catalyst (entries 2 and 3). The absolute 
configuration of 219ag was not determined.  
O OMe
N
N
74ag
+
Λ-RhO (3 mol%), NaHCO3 (3 eq.)
In the absence of light
Solvent, rt, t
O OMe
N
N OBz
211, 1.5 eq. 219ag
BPO
O OMe
N
N
74ag, 3 eq.
+
Catalyst (3 mol%)
In the absence of light
THF, rt, t
O OMe
N
N OBz
211, 1 eq. 219ag
BPO
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Influences of Concentration, Temperature, and Additives (Table 12, p.53) 
!  
Entry 2: 
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (23.0 mg, 100 µmol), benzoyl peroxide 
(48.4 mg, 150 µmol, 75%), Λ-RhO (2.50 mg, 3.00 µmol), and toluene (250 µL) under nitrogen atmosphere. 
The tube was sealed with a screw-cap and the mixture was stirred at 0 °C in absence of light for 1.5 h. A 
small amount reaction mixture was taken out and diluted with HPLC-grade hexanes. The sample was filtered 
through a syringe filter and analyzed through HPLC to reveal that 74ag was not completely consumed and 
219ag was formed with 56% ee. The absolute configuration of 219ag was not determined. 
Entry 3: 
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (23.0 mg, 100 µmol), benzoyl peroxide 
(48.4 mg, 150 µmol, 75%), Λ-RhO (2.50 mg, 3.00 µmol), and toluene (1.00 mL) under nitrogen atmosphere. 
The tube was sealed with a screw-cap and the mixture was stirred at rt in absence of light for 1.5 h. A small 
amount reaction mixture was taken out and diluted with HPLC-grade hexanes. The sample was filtered 
through a syringe filter and analyzed through HPLC to reveal that 74ag was not completely consumed and 
219ag was formed with 58% ee. The absolute configuration of 219ag was not determined. 
Entry 4: 
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (23.0 mg, 100 µmol), benzoyl peroxide 
(48.4 mg, 150 µmol, 75%), trifluoroacetic acid (765 nL, 10.0 µmol) Λ-RhO (2.50 mg, 3.00 µmol), and 
toluene (1.00 mL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the mixture was 
stirred at rt in absence of light for 1.5 h. A small amount reaction mixture was taken out and diluted with 
HPLC-grade hexanes. The sample was filtered through a syringe filter and analyzed through HPLC to reveal 
that 74ag was not completely consumed and 219ag was formed with 54% ee. The absolute configuration of 
219ag was not determined. 
Entry 5: 
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (23.0 mg, 100 µmol), benzoyl peroxide 
(48.4 mg, 150 µmol, 75%), hydroxyquinone (1.10 mg, 10.0 µmol), Λ-RhO (2.50 mg, 3.00 µmol) and 1,2-
dimethoxyethane (250 µL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the mixture 
was stirred at rt in absence of light for 1.5 h. A small amount reaction mixture was taken out and diluted with 
HPLC-grade hexanes. The sample was filtered through a syringe filter and analyzed through HPLC to reveal 
that 74ag was completely consumed and 219ag was formed with 52% ee. The absolute configuration of 
219ag was not determined.  
Λ-RhO (3 mol%)
Additive
In the absence of light
Concentration 
Solvent, T, 1.5 h
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Entry 6: 
The procedure from entry 5 was repeated with 2,6-di-tert-butyl-4-methylphenol (2.20 mg, 10.0 µmol) instead 
of hydroxyquinone. The HPLC analysis of the crude reaction mixture revealed that 74ag was completely 
consumed and 219ag was formed with 56% ee. The absolute configuration of 219ag was not determined. 
Influences of Substrate, Catalyst Loading, and Racemization (Scheme 63 and Scheme 64, p.53) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74 (200 µmol), benzoyl peroxide (96.7 mg, 
300 µmol, 75%), RhO (5.00 mg, 3.00 µmol), and DME (500 µL) under nitrogen atmosphere. The tube was 
sealed with a screw-cap and the mixture was stirred at rt in absence of light. After evaporating the solvent in 
vacuum, the residue was purified through flash column chromatography on silica gel (n-hexane:EtOAc 3:1) 
to afford the product 219. 
The reaction with substrate 74aa (34.0 µL, 200 µmol) was performed with the catalyst Δ-RhO to afford the 
product 219aa (54.7 mg, 171 µmol, 85%) with -72% ee. The reaction with substrate 74da (41.4 µL, 200 
µmol) was performed with the catalyst Λ-RhO to afford the product 219da (67.8 mg, 195 µmol, 97%) with 
79% ee (scheme 63, p.53). With Λ-RhO (10.0 mg, 6.00 µmol) as catalyst, the reaction was repeated with 
74da (41.4 µL, 200 µmol). After 1.5 h, HPLC analysis of the crude reaction mixture revealed 82% ee for 
219da. The solvent was evaporated in vacuum after 22 h and the residue was purified through flash column 
chromatography on silica gel to afford 219da (72.1 mg, 207 µmol, >99%) with 52% ee (scheme 64, p.53). 
The absolute configurations of 219aa and 219da were not determined. 
2-(1-Methyl-1H-imidazol-2-yl)-2-oxo-1-phenylethyl benzoate (219da) 
!  
1H-NMR (300 MHz; CDCl3): δ 8.16-8.13 (m, 2H, 2HO=CPh), 7.80-7.76 (m, 2H, 2HPh), 7.60-7.54 (m, 1H, 
1HO=CPh), 7.49-7.34 (m, 6H, 2HO=CPh + 3HPh + O=CCH), 7.22 (d, J = 0.8 Hz, 1H, CHN=C), 7.01 (s, 1H, 
CHNCH3), 3.93 (s, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 185.4 (O=C), 166.0 (O=CPh), 141.1 (N=CNCH3), 134.2 (CPh), 133.4 
(CPh), 130.1 (2CPh), 130.0 (CHN=C), 129.7 (CPh), 128.9 (CHNCH3), 128.8 (2CPh), 128.5 (2CPh), 127.6 (CPh), 
77.5 (O=CCH), 36.0 (NCH3); 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 2.0 mL/min, hexanes:i-PrOH 90:10, isocratic flow, tR(minor) 
= 10.6 min, tR(major) = 11.3 min.  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2-(1-iso-Propyl-1H-imidazol-2-yl)-2-oxo-1-phenylethyl benzoate (219da) 
!  
1H-NMR (300 MHz; CDCl3): δ 8.17-8.13 (m, 2H, 2HO=CPh), 7.78-7.74 (m, 2H, 2HO=CPh), 7.60-7.54 (m, 
1H, HO=CPh), 7.52 (s, 1H, O=CCH), 7.47-7.33 (m, 5H, 3HPh + 2Himidazolyl), 7.25-7.23 (m, 2H, 2HPh), 5.44 (dt, 
J = 13.3, 6.7 Hz, 1H, CHMe2), 1.44 (d, J = 6.7 Hz, 3H, CH3), 1.32 (d, J = 6.7 Hz, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 185.4 (O=C), 166.0 (O=CPh), 140.6 (N=CN-i-Pr), 134.5 (CPh), 133.3 
(CO=CPh), 130.5 (CHN=C), 130.1 (2CPh), 129.8 (CO=CPh), 128.84 (CHN-i-Pr), 128.76 (2CPh), 128.73 
(2CO=CPh), 128.5 (2CO=CPh), 121.8 (CPh), 77.9 (O=CCH), 49.4 (CHMe2), 23.6 (CH3), 23.5 (CH3); 
HRMS(ESI+) calcd. for C21H21N2O3 (M + H)+ 349.1547, found: 349.1547; 
HPLC Daicel Chiralpak AD-H column, 25 ºC, 2.0 mL/min, hexanes:i-PrOH 90:10, isocratic flow, tR(major) 
= 3.6 min, tR(minor) = 4.7 min. 
Reactions with Substrate 74dh In the Absence of Light (Scheme 66, p.54) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74dh (32.5 µL, 200 µmol), benzoyl peroxide 
(96.7 mg, 300 µmol, 75%), Λ-RhO (5.00 mg, 3.00 µmol), base (220 µmol), and DME (500 µL) under 
nitrogen atmosphere. The tube was sealed with a screw-cap and the mixture was stirred at rt in absence of 
light for 17 h. After evaporating the solvent in vacuum, the residue was purified through flash column 
chromatography on silica gel (n-hexane:EtOAc 3:1) to afford a mixture of 74dh and 219dh. The yield of 
219dh was calculated according to the 1H-NMR spectra of the mixture. The reaction with i-Pr2NH (31.0 µL, 
220 µmol) afforded 219dh in 29% yield with 61% ee and the reaction with Na2CO3 (23.4 mg, 220 µmol) 
afforded 219dh in 26% yield with 60% ee. 
1-(1-iso-Propyl-1H-imidazol-2-yl)-1-oxopropan-2-yl benzoate (219dh) 
!  
1H-NMR (300 MHz; CDCl3): δ 8.11-8.08 (m, 2H, 2HPh), 7.57-7.52 (m, 1H, HPh), 7.45-7.40 (m, 2H, 2HPh), 
7.28 (d, J = 1.0 Hz, 1H, Himidazolyl), 7.21 (d, J = 0.9 Hz, 1H, Himidazolyl), 6.39 (q, J = 7.0 Hz, 1H, O=CCH), 
5.50-5.44 (m, 1H, CHMe2), 1.74 (d, J = 7.0 Hz, 3H, O=CCHCH3), 1.42 (d, J = 6.7 Hz, 6H, 2CH3).  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Reactions with Substrate 74dh in the Presence of Light (Scheme 67, p.55) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74dh (16.6 mg, 100 µmol), benzoyl peroxide 
(48.4 mg, 150 µmol, 75%), NaHCO3 (25.4 mg, 300 µmol), [Ru(bpy)3]Cl2·6H2O (1.50 mg, 2.00 µmol), rac-
RhO (2.50 mg, 3.00 µmol), and acetonitrile (250 µL). The tube was sealed with a screw-cap. and the reaction 
mixture was degassed through the freeze-pump-thaw procedure for three cycles. After irradiating with a 13-
Watt CFL at rt for 24 h, the solvent was evaporated under vacuum. The residue was purified through flash 
column chromatography on silica gel (n-hexane:EtOAc 3:1) to afford 220 that contained intact methylene 
group (Figure 22).  
!  
Figure 22: 1H-NMR spectrum of 220 from the reaction illustrated in Scheme 67 (p.55). 
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5.6. Direct α-Arylation of 2-Acyl Imidazoles 
5.6.1. Preliminary Results 
Investigation of Nucleophiles (Scheme 75, p.61) 
!  
To a Schlenk-tube were added 2-acyl imidazole 74ag (138 mg, 600 µmol), diethyl bromomalonate (37.1 µL, 
200 µmol, 92%), nucleophile 114a, 200, 246-249 (600 µmol), Na2HPO4 (31.2 mg, 220 µmol), and rac-IrO 
(5.50 mg, 6.00 µmol). After adding methanol (500 µL), the tube was sealed with a screw-cap. The reaction 
mixture was degassed through the freeze-pump-thaw procedure for three cycles and irradiated with a 13-Watt 
CFL  at rt for 24 h. The TLC analysis revealed that the reactions with the allylsilane 246 (47.6 µL, 300 µmol) 
and the enamine 248 (98.4 µL, 600 µmol) resulted in no conversion of imidazole substrate 74ag. After 
purification through flash column chromatography on silica gel (n-hexane:EtOAc 2:1), the reactions with 2-
(trimethylsiloxy)furan (247, 101 µL, 600 µmol), silyl enol ether 200 (123 µL, 600 µmol), and 1,1-
diphenylethylene (249, 106 µL, 600 µmol) afforded methoxy product 240ag (32.4 mg, 124 µmol, 62%; 
15.8 mg, 60.7 µmol, 30%; 38.5 mg, 148 µmol, 74%). 
2-Methoxy-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-one (240ag) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.51-7.48 (m, 2H, 2Hp-MeO-Ph), 7.12 (s, 1H, CHN=C), 6.98 (s, 1H, 
CHNCH3), 6.85-6.82 (m, 2H, 2Hp-MeO-Ph), 6.11 (s, 1H, O=CCHOCH3), 3.92 (s, 3H, COCH3), 3.74 (s, 3H, 
NCH3), 3.39 (s, 3H, CHOCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 188.4 (C=O), 159.8 (COCH3), 141.9 (N=CN), 129.7 (2Cp-MeO-Ph), 129.6 
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(O=CCH2C), 128.4 (CHN=C), 127.4 (CHNCH3), 114.1 (2Cp-MeO-Ph), 83.2 (O=CCHOCH3), 57.0 
(O=CCHOCH3), 55.3 (OCH3), 36.0 (NCH3); 
HRMS(ESI+) calcd. for C14H17N2O3 (M + H)+ 261.1234, found: 261.1235.  
Reactions with 1H-Indole (Scheme 76, p.61 and Scheme 77, p.62) 
General Procedure 8 
!  
To a Schlenk-tube were added 2-acyl imidazole 74ag, diethyl bromomalonate (93a), 1H-indole (70.3 mg, 
600 µmol), Na2HPO4 (31.2 mg, 220 µmol), and IrO (5.50 mg, 6.00 µmol). After adding solvent (500 µL), the 
tube was sealed with a screw-cap. The reaction mixture was degassed through the freeze-pump-thaw 
procedure for three cycles and irradiated with a 13-Watt CFL at rt. After evaporating the solvent in vacuum, 
the residue was purified through flash column chromatography (n-hexane:ethyl acetate 3:1) to afford the 
arylated product 250aga. The absolute configuration of enantioenriched 250aga was not determined. 
Following general procedure 8, the reaction was performed with 2-acyl imidazole 74ag (138 mg, 600 µmol), 
diethyl bromomalonate (37.1 µL, 200 µmol, 92%), and Λ-IrO (5.50 mg, 6.00 µmol) in methanol (500 µL) to 
afford 250aga (47.3 mg, 137 µmol, 68%) with 20% ee after 14 h photolysis (Scheme 76, p.61).  
Following general procedure 8, the reaction was performed with 2-acyl imidazole 74ag (46.0 mg, 200 µmol), 
diethyl bromomalonate (111 µL, 600 µmol, 92%), and Λ-IrO (5.50 mg, 6.00 µmol) in methanol (500 µL) to 
afford 250aga (43.2 mg, 125 µmol, 63%) with 28% ee after 10 h photolysis (Scheme 76, p.61). 
Following general procedure 8, the reaction was performed with 2-acyl imidazole 74ag (23.0 mg, 100 µmol), 
diethyl bromomalonate (55.6 µL, 300 µmol, 92%), 1H-indole (35.1 mg, 300 µmol), Na2HPO4 (15.6 mg, 
110 µmol), and rac-IrO (2.80 mg, 3.00 µmol) in iso-propanol (250 µL) to afford 250aga (24.9 mg, 
72.1 µmol, 72%) after 40 h photolysis. The conversion of 74ag was not complete according to the TLC 
analysis of the crude reaction mixture (Scheme 77, p.62). 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2-(1H-Indol-3-yl)-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-one (250aga) 
!
1H-NMR (500 MHz; CDCl3): δ 8.19 (s, 1H, NH), 7.56 (dd, J = 7.8, 0.8 Hz, 1H, 1Hindolyl), 7.45-7.42 (m, 2H, 
Hp-MeO-Ph), 7.31 (dt, J = 8.1, 0.8 Hz, 1H, Hindolyl), 7.20 (dd, J = 2.4, 0.5 Hz, 1H, NHCH), 7.18 (d, J = 0.9 Hz, 
1H, CHN=C), 7.14 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H, Hindolyl), 7.04 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H, Hindolyl), 7.01 
(s, 1H, CHNCH3), 6.87 (s, 1H, O=CCH), 6.84-6.81 (m, 2H, Hp-MeO-Ph), 3.98 (s, 3H, NCH3), 3.75 (s, 3H, 
OCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 191.3 (C=O), 158.7 (COCH3), 143.0 (N=CNCH3), 136.4 (Cindolyl), 131.3 
(O=CCHC), 130.2 (2Cp-MeO-Ph), 129.4 (CHN=C), 127.7 (CHNCH3), 127.0 (Cindolyl), 123.6 (Cindolyl), 122.3 
(Cindolyl), 119.7 (Cindolyl), 119.6 (Cindolyl), 114.7 (Cindolyl), 114.0 (2Cp-MeO-Ph), 111.2 (Cindolyl), 55.3 (OCH3); 
HRMS(ESI+) calcd. for C21H20N3O2 (M + H)+ 346.1550, found: 346.1559;  
HPLC Daicel Chiralpak IC column, 25 ºC, 0.5 mL/min, hexanes:i-PrOH 70:30, isocratic flow, tR(major) = 
14.7 min, tR(minor) = 17.1 min. 
5.6.2. Mechanistic Investigations 
General Procedure 9 
!  
To a Schlenk-tube were added 2-acyl imidazole 74ag (46.0 mg, 200 µmol), diethyl bromomalonate (111 µL, 
600 µmol), indole 114 (600 µmol), Na2HPO4 (31.2 mg, 220 µmol), and rac-IrO (5.50 mg, 6.00 µmol). After 
adding methanol (500 µL), the tube was sealed with a screw-cap. The reaction mixture was degassed through 
the freeze-pump-thaw procedure for three cycles and then either irradiated with a 13-Watt CFL at rt or stirred 
at rt in the absence of light. After evaporating the solvent in vacuum, the residue was purified through flash 
column chromatography (n-hexane: ethyl acetate 3:1) to afford the products. 
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Reactions with 2- and 3-Substituted Indoles (Scheme 78, p.63) 
Following general procedure 9, the reaction with 1,2-dimethyl-1H-indole (114b, 87.1 mg, 600 µmol)  and 
rac-IrO (5.50 mg, 6.00 µmol) afforded α-arylated product 250agb (51.3 mg, 137 µmol, 69%) after 14 h 
photolysis. The reaction with 3-methyl-1H-indole (114c, 78.7 mg, 600 µmol) afforded remaining substrate 
74ag (21.2 mg, 92.1 µmol, 54% conv.) and methoxy product 240ag (17.4 mg, 66.8 µmol, 33%) after 14 h 
photolysis, while no α-arylated product was formed. 
2-(1,2-Dimethyl-1H-indol-3-yl)-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-one 
(250agb) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.63 (d, J = 7.9 Hz, 1H, Hindolyl), 7.25-7.22 (m, 3H, 2Hp-MeO-Ph + Hindolyl), 
7.15-7.09 (m, 2H, Hindolyl + CHN=C), 7.02 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, Hindolyl), 6.93 (d, J = 0.5 Hz, 1H, 
CHNCH3), 6.84 (s, 1H, O=CCH), 6.84-6.79 (m, 2H, 2Hp-MeO-Ph), 3.91 (s, 3H, OCH3), 3.76 (s, 3H, 
CHNCH3), 3.65 (s, 3H, CH3CNCH3), 2.51 (s, 3H, CH3CNCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 191.3 (O=C), 158.2 (COCH3), 143.7 (N=CNCH3), 136.9 (Cindolyl), 136.1 
(Cindolyl), 131.9 (Cindolyl), 130.0 (2Cp-MeO-Ph), 129.0 (CHN=C), 127.4 (O=CCHC), 127.2 (CHNCH3), 120.5 
(Cindolyl), 120.4 (Cindolyl), 119.3 (Cindolyl), 113.7 (2Cp-MeO-Ph), 108.6 (Cindolyl), 107.5 (Cindolyl), 55.3 (OCH3), 49.1 
(O=CCH), 36.2 (CHNCH3), 29.7 (CH3CNCH3), 11.0 (CH3CNCH3); 
HRMS(ESI+) calcd. for C23H24N3O2 (M + H)+ 374.1863, found: 374.1874.  
Control Experiment in the Absence of Visible Light (Scheme 79, p.63) 
Following general procedure 9, the reaction was performed with 1H-indole (114a, 70.3 mg, 600 µmol) and 
Λ-IrO (5.50 mg, 6.00 µmol). After stirring at rt in the absence of light for 15 h, 74ag was completely 
consumed and yielded a white solid (62.9 mg), which is a mixture of arylated product 250aga (82% yield, 
33% ee) and methoxy product 240ag (12% yield) according to 1H-NMR spectrum (Figure 23). The absolute 
configuration of enantioenriched product was not determined. 
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 
Figure 23: 1H-NMR spectrum of a mixture of 250aga and 240ag. 
Reaction with Imidazole Substrate 74aa (Scheme 80, p.64) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74aa (16.9 µL, 100 µmol), diethyl bromomalonate 
(55.6 µL, 300 µmol), 1H-indole (35.1 mg, 300 µmol), Na2HPO4 (15.6 mg, 110 µmol), rac-IrO (1.00 mg, 1.00 
µmol), and methanol (250 µL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the 
reaction mixture was stirred at rt for 15 h in absence of light. TLC analysis revealed a complete conversion 
of 74aa. The solvent was evaporated in vacuum and residue was purified through flash column 
chromatography on silica gel (n-hexane:EtOAc 3:2) to afford brominated product 251aa (11.0 mg, 39%) and 
a mixture (6.70 mg) of arylated product 250aaa (10%) and methoxy product 240aa (16%) (Figure 24). 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2-Bromo-1-(1-methyl-1H-imidazol-2-yl)-2-phenylethan-1-one (251aa) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.68-7.64 (m, 2H, 2HPh), 7.37-7.29 (m, 3H, 3HPh), 7.20 (d, J = 0.9 Hz, 1H, 
CHN=C), 7.09 (s, 1H, CHNCH3), 6.99 (s, 1H, O=CCHBr), 3.99 (s, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 183.5 (O=C), 140.5 (N=CNCH3), 135.8 (O=CCHC), 129.8 (CHN=C), 
129.6 (2CPh), 129.0 (CHNCH3), 128.8 (2CPh), 128.5 (CPh), 49.3 (O=CCH), 36.4 (NCH3); 
HRMS(ESI+) calcd. for C12H11BrN2ONa (M + Na)+ 300.9947, found: 300.9973.  
!  
Figure 24: 1H-NMR spectrum of a mixture of 250aaa and 240aa. 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Mechanism Investigation through Stepwise Addition of 1H-indole (Scheme 81, p.64) 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (46.0 mg, 200 µmol), diethyl bromomalonate 
(111 µL, 600 µmol), Na2HPO4 (31.2 mg, 220 µmol), rac-IrO (5.50 mg, 6.00 µmol), and iso-propanol 
(500 µL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the reaction mixture was 
stirred at rt for 48 h in absence of light. TLC analysis revealed an incomplete conversion of 74ag and the 
formation of brominated product 251ag (Figure 25, spot 1). 1H-indole (70.2 mg, 600 µmol) was then added 
and the reaction mixture was stirred for 12 h. TLC analysis revealed that brominated product 251ag was 
consumed and arylated product 250aga was formed (spot 2). A complete conversion of 74ag could not be 
achieved, when the mixture was stirred for further 24 h (spot 3). 
 
Figure 25: TLC analysis of the reaction from scheme 81 (p.64).  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5.6.3. Optimization of the Reaction Conditions 
General Procedure 10 
 
To a Schlenk-tube were added 2-acyl imidazole substrate 74 (200 µmol), 3,3-dibromopetane-2,4-dione (252, 
81.7 µL, 600 µmol), 1H-indole (70.3 mg, 600 µmol), base (220 µmol), catalyst (6.00 µmol), and solvent (500 
µL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the reaction mixture was stirred at 
rt for the given duration in the absence of light. The solvent was evaporated in vacuum and the residue was 
purified through flash column chromatography on silica gel (n-hexane:EtOAc) to afford the product 250 or 
251.  
Evaluation of 3,3-Dibromopetane-2,4-dione (252) as Brominating Reagent with different 2-Acyl 
Imidazoles (Table 14, p.66) 
Following general procedure 10, the reaction was performed with 2-acyl imidazole substrate 74ag (46.0 mg, 
200 µmol), Na2HPO4 (31.2 mg, 220 µmol), and rac-IrO (5.50 mg, 6.00 µmol) in iso-propanol (500 µL). The 
TLC analysis of the crude reaction mixture revealed a complete conversion of imidazole substrate 74ag after 
15 h and the purification afforded arylated product 250aga (59.6 mg, 173 µmol, 86%) as white solid (entry 
1). 
Following general procedure 10, the reaction was performed with 2-acyl imidazole substrate 74aa (33.8 µL, 
200 µmol), Na2HPO4 (31.2 mg, 220 µmol), rac-IrO (5.50 mg, 6.00 µmol), and AgOTf (56.5 mg, 220 µmol) 
in iso-propanol (500 µL). The TLC analysis of the crude reaction mixture revealed a complete conversion of 
imidazole substrate 74aa after 17 h and the purification afforded arylated product 250aaa (32.2 mg, 
102 µmol, 86%) as pale brown solid (entry 2).  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2-(1H-Indol-3-yl)-1-(1-methyl-1H-imidazol-2-yl)-2-phenylethan-1-one (250aaa) 
!  
1H-NMR (300 MHz; CDCl3): δ 8.14 (s, br, 1H, NH), 7.58 (dd, J = 7.9, 0.4 Hz, 1H, Hindolyl), 7.54-7.51 (m, 
2H, 2Hindolyl), 7.33-7.26 (m, 3H, 3HPh), 7.24-7.12 (m, 4H, 2HPh + Hindolyl + CHN=C), 7.07-7.01 (m, 2H, 
Hindolyl + CHNCH3), 6.95 (s, 1H, O=CCH), 3.98 (s, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 191.1 (O=C), 143.1 (N=CNCH3), 139.3 (O=CCHC), 136.4 (Cindolyl),  129.5 
(CHN=C), 129.2 (2CPh), 128.6 (2CPh), 127.8 (CHNCH3), 127.1 (Cindolyl), 127.0 (CPh), 123.7 (Cindolyl), 122.3 
(Cindolyl), 119.8 (Cindolyl), 119.6 (Cindolyl), 114.6 (Cindolyl), 111.2 (Cindolyl), 49.7 (O=CCH), 36.5 (NCH3); 
HRMS(ESI+) calcd. for C20H16N3O (M)+ 314.1288, found: 314.1291. 
Following general procedure 10, the reaction was performed with 2-acyl imidazole substrate 74bh (40.0 mg, 
200 µmol), Na2HPO4 (31.2 mg, 220 µmol), rac-IrO (5.50 mg, 6.00 µmol), and AgOTf (56.5 mg, 220 µmol) 
in iso-propanol (500 µL). The TLC analysis of the crude reaction mixture revealed a complete conversion of 
the imidazole substrate 74bh after 17 h and the purification afforded brominated product 251bh (55.5 mg, 
199 µmol, 99%) as yellow oil (entry 3). 
2-Bromo-1-(1-phenyl-1H-imidazol-2-yl)propan-1-one (231bh) 
!  
1H-NMR (300 MHz; CDCl3): δ 7.49-7.45 (m, 3H, 3HPh), 7.33-7.29 (m, 3H, 2HPh + CHNPh), 7.25 (d, J = 
1.0 Hz, 1H, CHN=C), 5.87 (q, J = 6.8 Hz, 1H, O=CCH), 1.80 (d, J = 6.8 Hz, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 184.3 (O=C), 140.8 (N=CNPh), 137.9 (CPh), 130.0 (CHN=C), 129.3 
(2CPh), 129.1 (CPh), 127.9 (CHNPh), 125.6 (2CPh), 43.4 (O=CCH), 19.7 (CH3).  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Solvent Screening with RhO as Catalyst (Scheme 83, p.67) 
!  
Following general procedure 10, the reactions were performed with 2-acyl imidazole substrate 74ag 
(46.0 mg, 200 µmol), Na2HPO4 (31.2 mg, 220 µmol), and rac-RhO (5.00 mg, 6.00 µmol). The reactions 
were worked up after 18 h. The reaction in iso-propanol (500 µL) afforded arylated product 250aga 
(41.0 mg, 119 µmol, 59%) as white solid. The reaction in THF (500 µL) afforded 250aga (52.2 mg, 151 
µmol) in 76% yield. The reaction in DMF (500 µL) afforded 250aga (19.0 mg, 55.0 µmol) in 28% yield. 
Base Screening (Table 15, p.67) 
!  
Following general procedure 10, the reactions were performed with 2-acyl imidazole substrate 74ag 
(92.0 mg, 400 µmol), dibromide 252 (163 µL, 1.20 mmol), 1H-indole (141 mg, 1.20 mmol), and rac-RhO 
(10.0 mg, 12.0 µmol) in THF (1.00 mL). The reactions were worked up after 18 h. The reaction with Cs2CO3 
(143 mg, 440 µmol) afforded arylated product 250aga (93.7 mg, 271 µmol) in 67% yield (entry 2). The 
reaction with 2,6-lutidine (51.2 µL, 440 µmol) afforded 250aga (123 mg, 356 µmol) in 89% yield (entry 3). 
The reaction with 2,2,6,6-tetramethylpiperidine (74.3 µL, 440 µmol) afforded 250aga (60.2 mg, 174 µmol) 
in 43% yield (entry 4). The reaction with triethylamine (61.3 µL, 440 µmol) afforded 250aga (57.4 mg, 
166 µmol) in 42% yield (entry 5). 
74ag, 1 eq., 0.4 M           114a, 3 eq.                                                                 250aga
N
O
N
rac-RhO (3 mol%),
Na2HPO4 (1.1 eq.)
In the absence of light
Solvent, rt, 18 h
Me
OMe
+
252 (3 eq.)
N
O
N
Me
OMe
NH
O O
Br Br
N
H
74ag, 1 eq., 0.4 M           114a, 3 eq.                                                           250aga
N
O
N
rac-RhO (3 mol%),
Base  (1.1 eq.)
In the absence of light
THF, rt, 18 h
Me
OMe
+ 252 (3 eq.)
N
O
N
Me
OMe
NH
O O
Br Br
N
H
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5.6.4. Evaluation of the Arene Scope (Scheme 84, p.68) 
General Procedure 11 
!  
To a Schlenk-tube were added 2-acyl imidazole substrate 74ag (92.0 mg, 400 µmol), dibromide 252 (163 µL, 
1.20 mmol), arene (1.20 or 2.40 mmol), 2,6-lutidine (51.2 µL, 440 µmol), rac-RhO (10.0 mg, 12.0 µmol), 
and THF (1.00 mL) under nitrogen atmosphere. The tube was sealed with a screw-cap and the reaction 
mixture was stirred at rt for the given duration in absence of light. The solvent was evaporated under vacuum 
and the residue was purified through flash column chromatography on silica gel (n-hexane:EtOAc) to afford 
the product. 
2-(1,2-Dimethyl-1H-indol-3-yl)-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-one 
(250agb) 
!  
Following general procedure 11, the reaction was performed with 2-acyl imidazole substrate 74ag (92.0 mg, 
400 µmol) and 1,2-dimethyl-1H-indole (174 mg, 1.20 mmol) to afford arylated product 250agb (131 mg, 
351 µmol, 81%) after 20 h. The NMR data are consistent with the afore-presented data (p.122). 
2-(4-Methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(6-methyl-1H-indol-3-yl)ethan-1-one (250agd) 
!  
Following general procedure 11, the reaction was performed with 2-acyl imidazole substrate 74ag (92.0 mg, 
400 µmol) and 6-methyl-1H-indole (157 mg, 1.20 mmol) to afford arylated product 250agd (104 mg, 
289 µmol, 72%) after 25 h.  
N
O
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Me
OMe
74ag, 1 eq., 0.4 M          3 or 6 eq.
+
N
O
N
Me
OMe
ArH
H Ar
rac-RhO (3 mol%)
2,6-lutidine (1.1 eq.)
In the absence of light
THF, rt, t
252 (3 eq.)
O O
Br Br
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1H-NMR (300 MHz; CDCl3): δ 8.22 (s, br, 1H, NH), 7.46-7.41 (m, 3H, 2Hp-MeO-Ph + 1Hindolyl), 7.17 (d, J = 
0.9 Hz, 1H, CHN=C), 7.07-7.05 (m, 2H, 2Hindolyl), 6.97 (s, 1H, CHNCH3), 6.90-6.82 (m, 4H, 2Hp-MeO-Ph + 
1Hindolyl + O=CCH), 3.95 (s, 3H, OCH3), 3.75 (s, 3H, NCH3), 2.41 (s, 3H, CH3); 
13C-NMR (75.5 MHz; CDCl3): δ 191.4 (O=C), 158.6 (COCH3), 143.0 (N=CNCH3), 136.9 (Cindolyl), 131.9 
(Cindolyl), 131.4 (O=CCHC), 130.2 (2Cp-MeO-Ph), 129.3 (CHN=C), 127.7 (CHNCH3), 124.8 (Cindolyl), 123.1 
(Cindolyl), 121.4 (Cindolyl), 119.2 (Cindolyl), 114.3 (Cindolyl), 114.0 (2Cp-MeO-Ph), 111.2 (Cindolyl), 55.3 (OCH3), 49.0 
(O=CCH), 36.3 (NCH3), 21.7 (CH3); 
HRMS(ESI-) calcd. for C22H20N3O2 (M - H)-, 358.1550, found: 358.1553. 
2-(5-(Benzyloxy)-1H-indol-3-yl)-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-one 
(250age) 
!  
Following general procedure 11, the reaction was performed with 2-acyl imidazole substrate 74ag (92.0 mg, 
400 µmol) and 5-(benzyloxy)-1H-indole (268 mg, 1.20 mmol) to afford arylated product 250age (115 mg, 
255 µmol, 64%) after 24 h. 
1H-NMR (300 MHz; CDCl3): δ 8.11 (s, 1H, NH), 7.43-7.28 (m, 7H, 2Hp-MeO-Ph + 5HPh), 7.20-7.17 (m, 3H, 
2Hindolyl + CHN=C), 7.11 (d, J = 2.3 Hz, 1H, Hindolyl), 7.00 (s, 1H, CHNCH3), 6.89-6.82 (m, 4H, 2Hp-MeO-Ph + 
1Hindolyl + O=CCH ), 5.00 (s, 2H, CH2), 3.95 (s, 3H, OCH3), 3.76 (s, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 191.1 (O=C), 158.7 (COCH3), 153.3 (COBn), 142.9 (N=CNCH3), 137.9 
(Cindolyl), 131.8 (Cindolyl), 131.2 (O=CCHC), 130.2 (2Cp-MeO-Ph), 129.2 (CHN=C), 128.6 (CPh), 128.5 (2CPh), 
127.8 (2CPh), 127.7 (CPh), 127.4 (CHNCH3), 124.5 (Cindolyl), 114.4 (Cindolyl), 114.1 (2Cp-MeO-Ph), 113.2 
(Cindolyl), 111.9 (Cindolyl), 103.1 (Cindolyl), 70.9 (OCH2Ph), 55.3 (OCH3), 49.0 (O=CCH), 36.5 (NCH3); 
2-(4-Methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(5-nitro-1H-indol-3-yl)ethan-1-one (250agf) 
!  
Following general procedure 11, the reaction was performed with the 2-acyl imidazole substrate 74ag (92.0 
mg, 400 µmol) and 5-nitro-1H-indole (195 mg, 1.20 mmol) to afford arylated product 250agf (113 mg, 
289 µmol, 72%) after 20 h. 
1H-NMR (300 MHz; CDCl3): δ 9.20 (s, br, 1H, NH), 8.47 (d, J = 2.1 Hz, 1H, Hindolyl), 7.95 (dd, J = 9.0, 
2.2 Hz, 1H, Hindolyl), 7.42-7.38 (m, 2H, 2Hp-MeO-Ph), 7.28 (d, J = 2.1 Hz, 1H, Hindolyl), 7.23 (d, J = 9.0 Hz, 1H, 
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Hindolyl), 7.19 (d, J = 0.8 Hz, 1H, CHN=C), 7.06 (s, 1H, CHNCH3), 6.85 (s, 1H, O=CCH), 6.84-6.80 (m, 2H, 
2Hp-MeO-Ph), 3.98 (s, 3H, OCH3), 3.73 (s, 3H, NCH3); 
13C-NMR (75.5 MHz; CDCl3): δ 190.5 (O=C), 158.9 (COCH3), 142.6 (N=CNCH3), 141.6 (Cindolyl), 139.5 
(Cindolyl), 130.4 (Cindolyl), 130.1(2Cp-MeO-Ph), 129.6 (Cindolyl), 128.2 (CHN=C), 126.9 (CHNCH3), 126.3 
(O=CCHC), 117.8 (Cindolyl), 117.3 (Cindolyl), 116.8 (Cindolyl), 114.3 (2Cp-MeO-Ph), 111.3 (Cindolyl), 55.3 (OCH3), 
48.6 (O=CCH), 36.4 (NCH3).  
2-(4-(Dimethylamino)-2-methoxyphenyl)-2-(4-methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)ethan-1-
one (253) 
!  
Following general procedure 11, the reaction was performed with 2-acyl imidazole substrate 74ag (92.0 mg, 
400 µmol) and 3-methoxy-N,N-dimethylaniline (352 µL, 2.40 mmol) to afford arylated product 253 
(78.8 mg, 208 µmol, 52%) after 24 h. 
1H-NMR (300 MHz; CDCl3): δ 7.31-7.28 (m, 2H, 2Hp-MeO-Ph), 7.11 (d, J = 0.9 Hz, 1H, CHN=C), 6.95 (s, 
1H, CHNCH3), 6.90-6.81 (m, 3H, 2Hp-MeO-Ph + HAr), 6.67 (s, 1H, O=CCH), 6.29 (td, J = 8.5, 2.4 Hz, 2H, 
2HAr), 3.97 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.75 (s, 3H, NCH3), 2.93 (s, 6H, N(CH3)2); 
13C-NMR (75.5 MHz; CDCl3): δ 192.2 (O=C), 158.6 (COCH3), 157.8 (COCH3), 150.7(CN(CH3)2), 143.3 
(N=CNCH3), 130.9 (2Cp-MeO-Ph), 130.6 (O=CCHC), 130.0 (CHN=C), 129.2 (CHNCH3), 126.8 (CAr), 118.4 
(CAr), 114.1 (2Cp-MeO-Ph), 105.1 (CAr), 97.2 (CAr), 55.8 (OCH3), 55.3 (OCH3), 51.2 (O=CCH), 41.2 
(N(CH3)2), 36.3 (NCH3). 
2-(4-Methoxyphenyl)-1-(1-methyl-1H-imidazol-2-yl)-2-(1H-pyrrol-3-yl)ethan-1-one (254) 
!  
Following general procedure 11, the reaction was performed with 2-acyl imidazole substrate 74ag (92.0 mg, 
400 µmol) and 1H-pyrrole (167 µL, 2.40 mmol) to afford the arylated product 254 (52.4 mg, 177 µmol, 44%) 
after 23 h. 
1H-NMR (300 MHz; CDCl3): δ 9.13 (s, br, 1H, NH), 7.36-7.33 (m, 2H, 2Hp-MeO-Ph), 7.20 (s, 1H, CHN=C), 
7.04 (s, 1H, CHNCH3), 6.85-6.82 (m, 2H, 2Hp-MeO-Ph), 6.75 (s, 1H, O=CCH), 6.56 (s, 1H, Hpyrrole), 6.14 (dd, 
J = 5.2, 2.3 Hz, 2H, 2Hpyrrole), 3.97 (s, 3H, OCH3), 3.76 (s, 3H, NCH3); 
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13C-NMR (75.5 MHz; CDCl3): δ 190.4 (O=C), 158.8 (COCH3), 142.7 (N=CNCH3), 131.1 (O=CCHC), 
129.8 (2Cp-MeO-Ph), 129.6 (Cpyrrole), 128.6 (CHN=C), 128.0 (CHNCH3), 117.8 (Cpyrrole), 114.1 (2Cp-MeO-Ph), 
108.4 (Cpyrrole), 107.7 (Cpyrrole), 55.4 (OCH3), 50.5 (O=CCH), 36.5 (NCH3).
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7.1. NMR-Spectra 
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1H-NMR spectrum of compound 265 (300 MHz, CDCl3) 
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13C-NMR spectrum of compound 265 (75.5 MHz, CDCl3) 
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1H-NMR spectrum of compound 268 (300 MHz, CD2Cl2) 
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Chapter 7. Appendices
!  
1H-NMR spectrum of compound 35 (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of compound 35 (75.5 MHz, CD2Cl2) 
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Chapter 7. Appendices
!  
1H-NMR spectrum of compound Λ-(S)-270 (300 MHz, CD2Cl2) 
!  
1H-NMR spectrum of compound Δ-(S)-270 (300 MHz, CD2Cl2) 
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Chapter 7. Appendices
!  
1H-NMR spectrum of compound Λ-L-37 (300 MHz, CD2Cl2)
!  
1H-NMR spectrum of compound Λ-(S)-39 (300 MHz, CD2Cl2) 
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Chapter 7. Appendices
!  
1H-NMR spectrum of compound Δ-(S)-39 (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of compound Δ-(S)-39 (75.5 MHz, CD2Cl2) 
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Chapter 7. Appendices
!  
1H-NMR spectrum of compound 60 (IrO) (300 MHz, CD2Cl2)
!  
13C-NMR spectrum of compound 60 (IrO) (75.5 MHz, CD2Cl2) 
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!  
1H-NMR spectrum of compound Λ-64 (IrS) (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of compound Λ-64 (IrS) (75.5 MHz, CD2Cl2) 
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!  
1H-NMR spectrum of compound Λ-70 (RhO) (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of compound Λ-70 (RhO) (75.5 MHz, CD2Cl2) 
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!  
1H-NMR spectrum of compound 71 (RhS) (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of compound 71 (RhS) (75.5 MHz, CD2Cl2) 
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Chapter 7. Appendices
!  
1H-NMR spectrum of 271 (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of 271 (75.5 MHz, CD2Cl2) 
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!  
1H-NMR spectrum of 91 (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of 91 (75.5 MHz, CD2Cl2) 
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!  
1H-NMR spectrum of 89.PF6 (300 MHz, CD2Cl2) 
!  
13C-NMR spectrum of 89.PF6 (75.5 MHz, CD2Cl2) 
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!  
1H-NMR spectrum of compound 272b (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 272b (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 272c (300 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273a (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273a (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273b (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273b (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273c (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273c (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273d (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273d (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273e (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273e (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273f (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273f (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273g (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 273g (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 273h (300 MHz, CDCl3) 
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!  
1H-NMR spectrum compound 74aa (300 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74ag (300 MHz, CDCl3) 
3
3
2.062.06
1.011.01
11
5.785.78
0
01122334455667788ppmppm-20.618
3.
98
1
4.
46
9
7.
06
0
7.
06
2
7.
22
2
7.
22
5
7.
23
8
7.
24
8
7.
25
1
7.
27
1
7.
27
7
7.
29
7
7.
29
9
7.
30
3
7.
31
6
7.
32
3
7.
32
6
7.
33
8
7.
34
5
7.
34
9
7.
35
5
7.
36
9
7.
37
3
7.
37
7
7.
38
3
3.09
3.09
3.043.04
2.042.04
2.012.01
11
0.9760.976
2.022.02
0
01122334455667788ppmppm-20.614
3.
76
1
3.
93
8
4.
35
4
6.
82
4
6.
83
4
6.
84
1
6.
85
6
6.
86
3
6.
87
3
7.
01
2
7.
16
1
7.
16
4
7.
23
5
7.
24
5
7.
25
2
7.
26
7
7.
27
4
7.
28
4
!165
O
74aa
N
N
O
74ag
N
N
OMe
Chapter 7. Appendices
!  
13C-NMR spectrum of compound 74ag (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74ba (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74ba (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74ca (300 MHz, CDCl3) 
0 02020404060608080100100120120140140160160180180200200ppmppm- 38.823
45
.7
17
76
.7
36
77
.1
60
77
.5
84
12
5.
96
4
12
6.
88
5
12
7.
53
3
12
8.
54
0
12
8.
79
4
12
9.
03
1
12
9.
86
7
13
0.
05
6
13
4.
50
3
13
8.
39
7
14
2.
91
7
18
8.
55
6
3.04
3.04
2.042.04
1.991.99
88
1.01.09
0
01122334455667788ppmppm-20.614
1.
86
1
4.
33
7
4.
38
8
4.
43
8
4.
48
9
7.
03
6
7.
04
1
7.
05
2
7.
05
6
7.
06
2
7.
17
3
7.
17
7
7.
19
6
7.
20
2
7.
21
7
7.
22
0
7.
22
4
7.
23
7
7.
23
9
7.
24
3
7.
24
6
7.
25
7
7.
26
5
7.
26
8
7.
27
3
7.
29
2
7.
29
6
7.
32
8
7.
33
1
!167
O
74ba
N
N
O
74ca
N
N
Chapter 7. Appendices
!  
13C-NMR spectrum of compound 74ca (75.5 MHz, CDCl3) 
!
1H-NMR spectrum of compound 74cb (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74cb (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74cc (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74cc (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74cd (300 MHz, CDCl3) 
0 02020404060608080100100120120140140160160180180200200ppm-238.823
17
.1
77
44
.8
20
76
.7
37
77
.1
60
77
.5
83
12
0.
96
9
12
6.
32
7
12
6.
69
0
12
7.
07
7
12
9.
19
8
13
0.
19
0
13
0.
84
5
13
1.
59
5
13
1.
73
8
13
3.
46
7
13
4.
50
3
13
7.
80
6
14
3.
12
6
18
7.
84
0
3
3
2
11
11
33
11
22
22
0
01122334455667788ppmppm-20.614
1.
90
4
4.
47
7
4.
52
8
4.
56
8
4.
61
9
7.
07
1
7.
07
4
7.
09
6
7.
09
9
7.
13
4
7.
13
8
7.
22
3
7.
22
7
7.
22
8
7.
24
7
7.
24
8
7.
25
2
7.
26
0
7.
27
0
7.
27
6
7.
27
7
7.
28
9
7.
32
5
7.
32
9
7.
35
0
7.
37
6
7.
37
9
7.
44
9
7.
45
6
7.
46
3
7.
47
9
7.
48
6
7.
49
3
8.
11
2
8.
12
0
8.
12
7
8.
14
3
8.
14
9
8.
15
7
!170
O
74cc
N
N
Br
O
74cd
N
N
NO2
Chapter 7. Appendices
!  
13C-NMR spectrum of compound 74cd (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74ce (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74ce (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74cf (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74cf (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 74da (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74da (75.5 MHz, CDCl3)
!  
1H-NMR spectrum of compound 74dh (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 74dh (75.5 MHz, CDCl3)
!  
1H-NMR spectrum of compound 95b (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 95b (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 252 (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 252 (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189aaa (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 189aaa (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189baa (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 189baa (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189caa (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 189caa (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189cba (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 189cba (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189cca (300 MHz, CDCl3) 
20 20404060608080100100120120140140160160180180200200ppm-238.823
16
.6
41
17
.3
84
20
.5
58
20
.8
32
21
.4
92
49
.4
37
49
.5
69
76
.7
36
77
.1
60
77
.5
84
12
5.
44
0
12
5.
50
5
12
6.
19
0
12
6.
67
5
12
6.
83
8
12
7.
22
5
12
8.
95
8
12
8.
98
3
12
9.
09
4
12
9.
40
7
12
9.
45
7
13
0.
65
8
13
0.
69
8
13
0.
85
7
13
0.
97
1
13
4.
35
8
13
4.
92
8
13
6.
05
7
13
6.
10
4
13
7.
55
0
13
7.
59
8
13
8.
91
8
13
9.
00
4
14
2.
36
3
18
7.
07
1
1.7
1.7
1.51.5
1.01.0
1.01.0
1.01.0
0.50.5
1.01.0
6.76.7
2.02.0
1
122334455667788ppmppm-20.614
1.
63
9
2.
03
4
2.
71
3
2.
73
9
2.
76
3
2.
76
9
2.
78
4
2.
79
1
2.
79
5
2.
81
2
2.
81
9
2.
84
6
2.
89
0
2.
90
5
2.
91
4
2.
92
1
2.
94
7
2.
97
1
2.
97
7
3.
00
3
5.
41
5
5.
44
1
5.
46
7
6.
89
8
6.
92
3
6.
92
4
7.
08
4
7.
17
6
7.
17
9
7.
20
4
7.
22
1
7.
25
0
7.
26
0
7.
30
2
7.
30
5
7.
31
4
7.
34
0
7.
34
4
7.
36
9
7.
37
3
7.
39
9
7.
43
7
7.
44
5
7.
45
2
7.
46
7
7.
47
3
7.
48
2
!181
O
N
N CN
189cba
O
N
N CN
189cca
Br
Chapter 7. Appendices
!  
13C-NMR spectrum of compound 189cca (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189cda (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 189cda (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189cfa (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 189cfa (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 189cab: major diastereomer (300 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 189cab: minor diastereomer (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 189cab: mixture of diastereomers (75.5 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 219ag (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 219aa (300 MHz, CDCl3) 
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Chapter 7. Appendices
!  
13C-NMR spectrum of compound 219aa (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 219da (300 MHz, CDCl3) 
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!  
13C-NMR spectrum of compound 219da (75.5 MHz, CDCl3) 
!  
1H-NMR spectrum of compound 219dh (300 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 240ag (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 240ag (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 250aga (500 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 250aga (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 250agb (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 250agb (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 251aa (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 251aa (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 250aaa (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 250aaa (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 251bh (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 251bh (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 250agd (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 250agd (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 250age (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 250age (75.5 MHz, CDCl3) 
3.1
3.1
2.92.9
1.91.9
4.24.2
1.11.1
1.11.1
3.03.0
7.47.4
1.01.0
3
34455667788ppmppm-20.618
3.
75
8
3.
95
3
4.
99
8
5.
29
1
6.
81
5
6.
82
9
6.
83
5
6.
84
2
6.
85
2
6.
86
0
6.
88
1
6.
88
9
7.
00
4
7.
10
3
7.
11
0
7.
17
2
7.
17
5
7.
19
9
7.
26
0
7.
27
5
7.
28
7
7.
29
7
7.
30
5
7.
31
0
7.
31
6
7.
32
4
7.
34
3
7.
34
8
7.
36
4
7.
37
1
7.
37
6
7.
40
3
7.
43
1
8.
10
7
0 02020404060608080100100120120140140160160180180200200ppm-238.871
36
.4
64
48
.9
71
55
.3
48
70
.9
49
76
.7
37
77
.1
60
77
.5
83
10
3.
11
5
11
1.
90
3
11
3.
23
9
11
4.
06
4
11
4.
36
5
12
4.
51
2
12
7.
41
4
12
7.
69
9
12
7.
76
5
12
8.
53
6
12
8.
59
1
12
9.
15
1
13
0.
22
6
13
1.
20
5
13
1.
82
0
13
7.
85
3
14
2.
93
3
15
3.
34
3
15
8.
70
8
19
1.
13
6
!196
N
O
N
Me
OMe
NH
250age
OBn
N
O
N
Me
OMe
NH
250age
OBn
Chapter 7. Appendices
!  
1H-NMR spectrum of compound 250agf (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 250agf (75.5 MHz, CDCl3) 
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!  
1H-NMR spectrum of compound 253 (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 253 (75.5 MHz, CDCl3) 
6
6
66
33
22
11
33
11
11
22
0
01122334455667788ppmppm-20.618
2.
92
8
3.
75
0
3.
76
8
3.
97
2
6.
26
3
6.
27
1
6.
29
1
6.
29
9
6.
32
0
6.
32
7
6.
66
6
6.
81
1
6.
81
8
6.
82
2
6.
82
7
6.
82
8
6.
83
7
6.
84
4
6.
85
9
6.
86
6
6.
87
3
6.
90
1
6.
94
9
6.
95
0
7.
11
3
7.
11
5
7.
26
3
7.
28
1
7.
30
3
7.
31
0
0 02020404060608080100100120120140140160160180180200200ppmppm- 38.871
36
.2
58
36
.3
01
41
.2
36
51
.2
43
55
.3
19
55
.7
55
76
.7
37
77
.1
60
77
.5
83
97
.1
54
10
5.
07
5
11
4.
06
3
12
6.
77
6
12
9.
17
0
13
0.
00
6
13
0.
57
9
13
0.
86
7
13
0.
91
9
14
3.
32
6
15
0.
70
6
15
7.
76
1
15
8.
60
6
19
2.
18
3
!198
N
O
N
Me
OMe
253
OMe
NMe2
N
O
N
Me
OMe
253
OMe
NMe2
Chapter 7. Appendices
!  
1H-NMR spectrum of compound 254 (300 MHz, CDCl3) 
!  
13C-NMR spectrum of compound 254 (75.5 MHz, CDCl3) 
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7.2. HPLC-Traces 
!
!  
HPLC chromatogram of compound rac-189aaa 
!  
!  
HPLC chromatogram of compound (R)-189aaa with 77% ee (Table 4, entry 7, p.37) 
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!
!  
HPLC chromatogram of compound rac-189baa 
!  
!  
HPLC chromatogram of (R)-189baa with 70% ee (Table 6, entry 3, p.40)  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!  
!  
HPLC chromatogram of compound rac-189caa 
!  
!  
HPLC chromatogram of compound (R)-189caa with 80% ee (Table 6, entry 7, p.40) 
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!
!  
HPLC chromatogram of compound (R)-189caa with 84% ee (Table 6, entry 8, p.40) 
!
!  
HPLC chromatogram of compound (R)-189caa with 94% ee (Table 6, entry 9, p.40) 
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!
!  
HPLC chromatogram of compound rac-189cba (Table 7, entry 1, p.41) 
!  
!  
HPLC chromatogram of compound (S)-189cba with 95% ee (Table 7, entry 1, p.41) 
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!  
!  
HPLC chromatogram of compound rac-189cca (Table 7, entry 2, p.41) 
!  
!  
HPLC chromatogram of compound (S)-189cca with 88% ee (Table 7, entry 2, p.41) 
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!  
!  
HPLC chromatogram of compound rac-189cda (Table 7, entry 3, p.41) 
!  
!  
HPLC chromatogram of compound (S)-189cda with 1% ee (Table 7, entry 3, p.41) 
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!
!  
HPLC chromatogram of compound rac-189cea (Table 7, entry 4, p.41) 
!  
!  
HPLC chromatogram of compound (S)-189cea with 84% ee (Table 7, entry 4, p.41) 
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!  
!  
HPLC chromatogram of compound rac-189cfa (Table 7, entry 5, p.41) 
!
!  
HPLC chromatogram of compound (S)-189cfa with 96% ee (Table 7, entry 5, p.41) 
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!  
!  
HPLC chromatogram of compound rac-189cab major diastereomer (Scheme 49, p.41) 
!  
!  
HPLC chromatogram of compound (S)-189cab major diastereomer with 98% ee (Scheme 50, p.42)  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!  
!  
HPLC chromatogram of compound rac-189cab minor diastereomer (Scheme 49, p.41) 
!  
!  
HPLC chromatogram of compound (S)-189cab minor diastereomer with 98% ee (Scheme 50, p.42)  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!  
!  
HPLC chromatogram of compound rac-219ag 
!  
!  
HPLC chromatogram of enantioenriched compound 219ag with 40% ee (Scheme 62, p.50)  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!  
!  
HPLC chromatogram of compound rac-219aa 
!  
!  
HPLC chromatogram of enantioenriched compound 219aa with 72% ee (Scheme 63, p.53)  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!  
!  
HPLC chromatogram of compound rac-219da 
!  
!  
HPLC chromatogram of enantioenriched compound 219da with 79% ee (Scheme 63, p.53) 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!  
!  
HPLC chromatogram of compound rac-250aga 
!  
!  
HPLC chromatogram of enantioenriched compound 250aga with 20% ee (Scheme 76, p.61)  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!  
!  
HPLC chromatogram of enantioenriched compound 250aga with 28% ee (Scheme 76, p.61)  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7.3. Crystallographic Data 
(S)-3-(4-Bromophenyl)-4-oxo-4-(1-(o-tolyl)-1H-imidazol-2-yl)butanenitrile (189cca) 
!  
Crystal data and structure refinement 
Crystal data
Identification code ZuoE-183e
Habitus, color plate, colorless
Crystal size 0.61 × 0.14 × 0.03 mm3
Crystal group P212121
Unit cell dimensions a = 9.7170(4) Å 
b = 12.4043(5) Å 
c = 15.5021(7) Å
α = 90º. 
β = 90º. 
γ = 90º.
Volume 1868.51(14) Å3
Z 4
Cell determination 9896 peaks with Theta 2.5 to 27.4º.
Empirical formula C20H16BrN3O
!216
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Moiety formula C20H16BrN3O
Density (calculated) 1.402 Mg/m3
Absorption coefficient 2.212 mm-1
F(000) 800
Data collection
Diffractometer type Bruker D8 QUEST area Detektor
Wavelength 0.71073 Å
Temperature 115(2) K
Theta range for data collection 2.474 to 27.524º.
Index Ranges -12<=h<=10, -16<=k<=16, 
-18<=l<=20
Data collection software APEX3 (Bruker AXS Inc., 2015)
Cell refinement software SAINT V8.35A (Bruker AXS Inc., 
2015)
Data reduction software SAINT V8.35A (Bruker AXS Inc., 
2015)
Solution and refinement
Reflections collected 41914
Independent reflections 4301 [R(int) = 0.0363]
Completeness to theta = 25.242º 100 %
Observed reflections 4085[I > 2(I)]
Reflections used for refinements 4301
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 0.94 and 0.65
Fleck parameter (absolute struct.) -0.010(3)
Largest diff. peak and hole 0.854 and -0.429 e.Å-3
Solution Direct Methode
Refinement Full-matrix least-squares on F2
Treatment of hydrogen atoms Calculated positions, constr. ref.
Programs used XT V2014/1 (Bruker AXS Inc., 
2014) 
SHELXL-2014/7 (Sheldrick, 2014) 
DIAMOND (Crystal Impact) 
ShelXle (Hübschle, Sheldrick, 
Dittrich, 2011)
Data / restrains / parameters 4301 / 798 / 330
Goodness-of-fit on F2 1.108
R index (all data) wR2 = 0.0753
R index conventional [I>2sigma(I)] R1 = 0.0277
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Atomic coordinates and equivalent isotropic displacement parameters (Å2) 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor 
x y z U(eq) Occupancy
Br1 0.59880(3) 0.78969(3) 0.48369(2) 0.02524(10) 1
C1 0.5178(3) 0.2527(3) 0.5839(2) 0.0228(7) 1
O1 0.3953(3) 0.2377(2) 0.57658(14) 0.0285(5) 1
C2 0.6074(3) 0.2921(2) 0.50991(18) 0.0204(5) 1
C3 0.5616(3) 0.2413(3) 0.4238(2) 0.0225(7) 1
C4 0.5849(4) 0.1241(3) 0.4245(2) 0.0308(8) 1
N5 0.6044(4) 0.0342(3) 0.4279(3) 0.0522(10) 1
C11 0.6022(3) 0.4139(2) 0.50498(18) 0.0198(6) 1
C12 0.7236(3) 0.4728(3) 0.5105(3) 0.0288(7) 1
C13 0.7230(3) 0.5845(3) 0.5042(3) 0.0308(9) 1
C14 0.5996(4) 0.6369(2) 0.4929(2) 0.0226(6) 1
C15 0.4765(3) 0.5810(3) 0.4877(3) 0.0278(7) 1
C16 0.4791(3) 0.4690(3) 0.4939(2) 0.0265(7) 1
C6 0.5881(9) 0.2230(8) 0.6642(5) 0.033(2) 0.65
N7 0.5240(6) 0.1885(8) 0.7379(4) 0.0488(18) 0.65
C8 0.6246(8) 0.1749(12) 0.7970(6) 0.071(3) 0.65
C9 0.7456(8) 0.1974(11) 0.7582(6) 0.066(3) 0.65
N10 0.7233(9) 0.2269(8) 0.6748(5) 0.047(2) 0.65
C17 0.3816(6) 0.1698(7) 0.7536(4) 0.0427(14) 0.65
C18 0.2920(7) 0.2542(6) 0.7811(4) 0.0392(14) 0.65
C19 0.1577(7) 0.2228(8) 0.8002(6) 0.0323(17) 0.65
C20 0.1141(7) 0.1148(6) 0.7896(4) 0.0435(15) 0.65
C21 0.2011(8) 0.0382(7) 0.7619(5) 0.0578(19) 0.65
C22 0.3372(12) 0.0579(10) 0.7421(8) 0.061(3) 0.65
C23 0.3344(18) 0.3665(12) 0.773(2) 0.078(2) 0.65
C6A 0.5899(17) 0.2600(11) 0.6673(10) 0.023(3) 0.35
N7A 0.5241(10) 0.2495(11) 0.7449(7) 0.037(2) 0.35
C8A 0.6254(13) 0.2473(14) 0.8058(8) 0.045(3) 0.35
C9A 0.7454(12) 0.2589(12) 0.7649(8) 0.033(3) 0.35
N10A 0.7241(15) 0.2702(9) 0.6787(9) 0.025(3) 0.35
C17A 0.3770(12) 0.2669(12) 0.7622(9) 0.054(3) 0.35
C18A 0.2963(14) 0.1805(12) 0.7779(10) 0.052(3) 0.35
C19A 0.1548(19) 0.1861(18) 0.7958(18) 0.054(4) 0.35
C20A 0.1069(16) 0.2956(13) 0.8018(9) 0.056(3) 0.35
C21A 0.1852(17) 0.3846(15) 0.7837(13) 0.073(4) 0.35
C22A 0.329(3) 0.384(2) 0.778(4) 0.078(2) 0.35
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Bond lengths [Å] and angles [º] 
C23A 0.361(2) 0.0798(18) 0.7668(13) 0.056(5) 0.35
Br1-C14 1.900(3) C17-C18 1.427(10)
C1-O1 1.209(4) C17-C22 1.465(15)
C1-C6 1.467(9) C18-C19 1.393(8)
C1-C6A 1.473(16) C18-C23 1.458(17)
C1-C2 1.521(4) C19-C20 1.416(11)
C2-C11 1.514(4) C19-H19 0.9500
C2-C3 1.542(4) C20-C21 1.342(11)
C2-H2 1.0000 C20-H20 0.9500
C3-C4 1.472(5) C21-C22 1.379(14)
C3-H3A 0.9900 C21-H21 0.9500
C3-H3B 0.9900 C22-H22 0.9500
C4-N5 1.132(5) C23-H23A 0.9800
C11-C16 1.388(4) C23-H23B 0.9800
C11-C12 1.390(4) C23-H23C 0.9800
C12-C13 1.389(5) C6A-N10A 1.322(15)
C12-H12 0.9500 C6A-N7A 1.369(15)
C13-C14 1.375(5) N7A-C8A 1.364(14)
C13-H13 0.9500 N7A-C17A 1.471(14)
C14-C15 1.385(5) C8A-C9A 1.335(15)
C15-C16 1.393(5) C8A-H8A 0.9500
C15-H15 0.9500 C9A-N10A 1.360(14)
C16-H16 0.9500 C9A-H9A 0.9500
C6-N10 1.325(9) C17A-C18A 1.350(17)
C6-N7 1.370(8) C17A-C22A 1.55(2)
N7-C8 1.351(9) C18A-C19A 1.404(18)
N7-C17 1.424(8) C18A-C23A 1.41(2)
C8-C9 1.350(10) C19A-C20A 1.44(2)
C8-H8 0.9500 C19A-H19A 0.9500
C9-N10 1.361(10) C20A-C21A 1.370(18)
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C9-H9 0.9500 C20A-H20A 0.9500
C21A-C22A 1.40(3) C23A-H23D 0.9800
C21A-H21A 0.9500 C23A-H23E 0.9800
C22A-H22A 0.9500 C23A-H23F 0.9800
O1-C1-C6 119.9(4) C15-C14-Br1 119.5(3)
O1-C1-C6A 124.0(7) C14-C15-C16 118.7(3)
O1-C1-C2 122.8(3) C14-C15-H15 120.6
C6-C1-C2 117.0(4) C16-C15-H15 120.6
C6A-C1-C2 111.7(6) C11-C16-C15 121.0(3)
C11-C2-C1 109.8(2) C11-C16-H16 119.5
C11-C2-C3 110.7(2) C15-C16-H16 119.5
C1-C2-C3 110.9(2) N10-C6-N7 111.0(7)
C11-C2-H2 108.4 N10-C6-C1 123.9(7)
C1-C2-H2 108.4 N7-C6-C1 125.1(7)
C3-C2-H2 108.4 C8-N7-C6 106.0(6)
C4-C3-C2 110.6(3) C8-N7-C17 124.6(6)
C4-C3-H3A 109.5 C6-N7-C17 129.4(6)
C2-C3-H3A 109.5 C9-C8-N7 107.6(7)
C4-C3-H3B 109.5 C9-C8-H8 126.2
C2-C3-H3B 109.5 N7-C8-H8 126.2
H3A-C3-H3B 108.1 C8-C9-N10 109.9(7)
N5-C4-C3 177.6(4) C8-C9-H9 125.0
C16-C11-C12 118.7(3) N10-C9-H9 125.0
C16-C11-C2 121.8(3) C6-N10-C9 105.4(7)
C12-C11-C2 119.5(3) N7-C17-C18 121.7(7)
C13-C12-C11 121.1(3) N7-C17-C22 114.8(8)
C13-C12-H12 119.5 C18-C17-C22 123.5(7)
C11-C12-H12 119.5 C19-C18-C17 115.5(7)
C14-C13-C12 119.0(3) C19-C18-C23 123.4(9)
C14-C13-H13 120.5 C17-C18-C23 120.2(9)
C12-C13-H13 120.5 C18-C19-C20 121.3(8)
C13-C14-C15 121.6(3) C18-C19-H19 119.3
C13-C14-Br1 119.0(3) C20-C19-H19 119.3
C21-C20-C19 121.3(7) N10A-C9A-H9A 124.9!220
Chapter 7. Appendices
Symmetry transformations used to generate equivalent atoms  
C21-C20-C19 121.3(7) N10A-C9A-H9A 124.9
C21-C20-H20 119.4 C6A-N10A-C9A 105.8(12)
C19-C20-H20 119.4 C18A-C17A-N7A 118.8(13)
C20-C21-C22 123.3(9) C18A-C17A-C22A 122.8(16)
C20-C21-H21 118.3 N7A-C17A-C22A 117.4(15)
C22-C21-H21 118.3 C17A-C18A-C19A 124.4(15)
C21-C22-C17 115.0(10) C17A-C18A-C23A 114.9(15)
C21-C22-H22 122.5 C19A-C18A-C23A 120.4(16)
C17-C22-H22 122.5 C18A-C19A-C20A 112.1(17)
C18-C23-H23A 109.5 C18A-C19A-H19A 123.9
C18-C23-H23B 109.5 C20A-C19A-H19A 123.9
H23A-C23-H23B 109.5 C21A-C20A-C19A 124.6(15)
C18-C23-H23C 109.5 C21A-C20A-H20A 117.7
H23A-C23-H23C 109.5 C19A-C20A-H20A 117.7
H23B-C23-H23C 109.5 C20A-C21A-C22A 124.4(19)
N10A-C6A-N7A 110.6(13) C20A-C21A-H21A 117.8
N10A-C6A-C1 126.3(12) C22A-C21A-H21A 117.8
N7A-C6A-C1 122.9(12) C21A-C22A-C17A 108(2)
C8A-N7A-C6A 105.9(11) C21A-C22A-H22A 125.9
C8A-N7A-C17A 125.3(11) C17A-C22A-H22A 125.9
C6A-N7A-C17A 126.9(12) C18A-C23A-H23D 109.5
C9A-C8A-N7A 107.4(10) C18A-C23A-H23E 109.5
C9A-C8A-H8A 126.3 H23D-C23A-H23E 109.5
N7A-C8A-H8A 126.3 C18A-C23A-H23F 109.5
C8A-C9A-N10A 110.2(11) H23D-C23A-H23F 109.5
C8A-C9A-H9A 124.9 H23E-C23A-H23F 109.5
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Anisotropic displacement parameters (Å2) 
The anisotropic displacement factor exponent takes the form: -2π2[h2 a*2 U11 + … + 2 h k a* b* U12] 
U11 U22 U33 U23 U13 U12
Br1 0.02392(15) 0.02417(15) 0.02763(16) -0.00387(14) -0.00031(14) 0.00062(15)
C1 0.0165(15) 0.0316(16) 0.0204(15) -0.0003(13) -0.0018(12) 0.0002(12)
O1 0.0179(10) 0.0440(14) 0.0237(11) 0.0054(9) -0.0019(10) -0.0046(10)
C2 0.0137(11) 0.0272(14) 0.0203(13) 0.0002(14) 0.0009(12) 0.0028(14)
C3 0.0219(16) 0.0250(16) 0.0206(15) -0.0014(12) 0.0025(12) -0.0016(11)
C4 0.0240(17) 0.0314(19) 0.0370(19) -0.0072(15) 0.0010(15) -0.0011(15)
N5 0.046(2) 0.0302(18) 0.081(3) -0.0099(17) -0.004(2) -0.0009(17)
C11 0.0153(12) 0.0267(14) 0.0175(15) -0.0029(11) 0.0005(12) -0.0008(12)
C12 0.0133(13) 0.0289(16) 0.044(2) -0.0063(16) -0.0053(14) 0.0018(12)
C13 0.0186(15) 0.0273(16) 0.047(2) -0.0079(15) -0.0046(14) -0.0026(13)
C14 0.0232(14) 0.0214(13) 0.0232(16) -0.0054(12) 0.0002(14) -0.0002(14)
C15 0.0155(14) 0.0306(16) 0.0372(18) 0.0011(15) 0.0007(14) 0.0037(12)
C16 0.0142(15) 0.0288(16) 0.036(2) 0.0018(14) 0.0006(13) -0.0029(11)
C6 0.020(2) 0.059(6) 0.020(3) 0.010(4) 0.0011(19) 0.001(4)
N7 0.024(2) 0.100(5) 0.022(3) 0.020(3) 0.0010(19) 0.001(3)
C8 0.043(4) 0.136(7) 0.034(3) 0.030(4) -0.006(3) 0.000(4)
C9 0.035(3) 0.122(7) 0.042(4) 0.025(5) -0.010(3) -0.003(4)
N10 0.023(2) 0.086(6) 0.031(3) 0.012(4) -0.006(2) -0.003(4)
C17 0.025(3) 0.082(4) 0.021(3) 0.024(3) 0.005(2) 0.000(2)
C18 0.020(3) 0.076(4) 0.022(3) 0.007(3) 0.004(2) -0.011(3)
C19 0.025(3) 0.055(4) 0.018(3) 0.008(3) 0.003(2) -0.005(3)
C20 0.033(3) 0.059(3) 0.039(3) 0.022(3) 0.007(3) -0.012(3)
C21 0.049(3) 0.066(4) 0.059(4) 0.030(3) 0.017(3) 0.001(3)
C22 0.043(4) 0.077(5) 0.061(6) 0.020(4) 0.001(4) 0.002(3)
C23 0.061(3) 0.086(4) 0.087(5) 0.008(5) 0.006(3) -0.007(3)
C6A 0.023(4) 0.028(7) 0.018(4) 0.005(4) -0.001(3) 0.003(4)
N7A 0.026(4) 0.063(6) 0.023(4) 0.003(4) 0.000(3) -0.002(4)
C8A 0.032(5) 0.080(8) 0.022(4) 0.007(5) -0.004(3) 0.002(5)
C9A 0.025(4) 0.050(6) 0.024(4) 0.006(4) -0.005(3) 0.003(4)
N10A 0.019(4) 0.034(6) 0.022(4) 0.005(4) -0.003(3) 0.001(4)
C17A 0.040(4) 0.086(5) 0.036(5) 0.001(5) -0.001(4) 0.000(4)
C18A  0.042(5) 0.079(5) 0.033(6) 0.008(5) 0.003(5) 0.006(4)
C19A  0.046(6) 0.075(7) 0.041(8) 0.007(7) 0.011(5) 0.007(5)
C20A  0.049(5) 0.075(6) 0.043(6) 0.011(5) 0.004(5) 0.005(5)
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C21A 0.059(5) 0.084(6) 0.075(8) 0.010(6) 0.005(6) 0.004(5)
C22A  0.061(3) 0.086(4) 0.087(5) 0.008(5) 0.006(3) -0.007(3)
C23A  0.048(9) 0.082(7) 0.037(9) -0.015(7) -0.005(6) 0.012(6)
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7.4. List of Synthesized Compounds 
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!  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!  
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7.5. Abbreviations and Symbols 
Ac acetyl
acac acetylacetonato
AcO acetate
Ar aryl
aq. aqueous
BArF tetrakis[(3,5-trifluoromethyl)phenyl]borate
β-CD β-cyclodextrin
BHT 2,6-di-tert-butyl-4-methylphenol
Bn benzyl
Boc tert-butyloxycarbonyl
BPO benzoyl peroxide
bpy 2,2’-bipyridine
bpz 2,2’-pyrazine
Bu butyl
BzO benzoyl
cal calorie
calcd. calculated
CAN ceric ammonium nitrate
cat. catalyst
Cbz carboxybenzyl
CFL compact fluorescent lamp
conv. conversion
COSY correlation spectroscopy
D dextrorotatory
d day(s)
d doublet
DMA dimethylacetamide
DME 1,2-dimethoxyethane
DMF N,N’-dimethylformamide
DMSO dimethyl sulfoxide
DNA deoxyribonucleic acid
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dr diastereomeric ratio
dtbbpy 4,4’-di-tert-butyl-2,2’-bipyridine
E electrophile(s)
EDA electron donor acceptor
EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
EDG electron-donating group
ee enantiomeric excess
en ethylene-1,2-diamine
eq. equivalent(s)
er enantiomeric ratio
ET triplet energy
Et ethyl
ESI electrospray ionization
EWG electron-withdrawing group
fac facial
FG functional group(s)
h hour(s)
hex hexyl
HMPA hexamethylphosphoramide
HPLC high performance liquid chromatography
HQ hydroxyquinone
HRMS high resolution mass spectrometry
i iso
ISC intersystem crossing
L levorotatory
λ wave length
LDA lithium diisopropylamide
LED light-emitting diode
m meta
m multiplet
M molar(concentration)
Me methyl
menbpy 4,4’-di(1R,2S,5R)-(−)-menthoxycarbonyl-2,2’-bipyridine
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MLCT metal-to-ligand charge transfer
MS mass spectrometry
n normal
n.d. not determined
NHC N-heterocyclic carbene
nm nanometer
NMP N-methyl-2-pyrrolidone
NMR nuclear magnetic resonance spectroscopy
Nu-H/Nu nucleophile(s)
o ortho
ODN 2,4-dinitrophenylsulfonyloxy
OLED organic light-emitting diode
p para
Ph phenyl
phen 1,10-phenanthroline
ppy 2-phenylpyridine
Pr propyl
PS photosensitizer
PyBOX pyridine-2,6-bis(oxazoline)
rac racemic
rt room temperature
SCE standard calomel electrode
SET single electron transfer
SOMO single occupied molecular orbital
T temperature
t tertiary
t duration
TBHP tert-butyl hydroperoxide
TBS tert-butyldimethylsilyl
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxyl, free radical
TFA trifluoroacetic acid
Tf trifluoromethanesulfonyl
TfOH trifluoromethanesulfonic acid
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THF tetrahydrofuran
TLC thin layer chromatography
TMS trimethylsilyl
TRISPHAT tris[tetrachlorobenzene-1,2-bis(olato)] phosphate(V)
Ts para-toluenesulfonyl
TsOH para-toluenesulfonic acid
UV ultraviolet
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